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Characterization of NPRC and Its Binding Partners 
Abdel A. Alli 
ABSTRACT 
 The C type natriuretic peptide receptor (NPRC), also known as NPR3 is a widely 
expressed single transmembrane-spanning protein.  NPRC functions as a homodimer at 
the cell surface for the metabolic clearance of a broad range of natriuretic peptides from 
circulation.  The intracellular domain of NPRC is coupled to inhibitory G proteins and is 
involved in mediating signal transduction.  In order to further elucidate the role of NPRC 
in signal transduction, a proteomic approach was taken to identify putative protein 
binding partners for NPRC in different cell-types.  An interrogation of the molecular 
association between NPRC and its identified protein binding partner(s) was carried out in 
different cell types to identify the specific interacting domains.  The physiological role of 
the association between NPRC and its protein binding partner(s) were investigated in 
situ.  Furthermore, NPRC is subject to post translation modifications, including 
glycosylation and phosphorylation.  Although evidence suggests NPRC is phosphorylated 
on serine residues, the specific amino acid residues that are phosphorylated and the 
kinases responsible for their phosphorylation has yet to be determined.  A recombinant 
GST-NPRC fusion protein, polyclonal NPRC antibody, kinase prediction algorithm, and 
several phosphospecific and substrate motif antibodies were utilized to characterize the 
phosphorylation state of NPRC in vitro.      
 
 
 
 
 
Introduction 
 
Natriuretic Peptides 
 
Natriuretic peptides (NPs) are a family of hormones, which include atrial 
natriuretic peptide (ANP), B-type natriuretic peptide (BNP), C-type natriuretic peptide 
(CNP), dendroaspis natriuretic peptide (DNP), and urodilatin [1, 2].  ANP, BNP, CNP, 
and DNP each contain a conserved 17-amino acid ring structure (Figure 1).  Upon 
secretion, proANP (amino acids 1-126) is cleaved by the serine protease corin [3] into an 
N-terminus fragment (amino acids 1-98) and a C-terminus fragment (amino acids 99-
126) in equimolar amounts [4].  Long-acting natriuretic peptide (LANP) (amino acids 1-
30), vessel dilator (VDL) (amino acids 31–67), and kaliuretic peptide (KP) (amino acids 
79–98) originate from the N-terminus, while ANP (amino acids 99–126) originates from 
the C-terminus of the prohormone [5, 6]. Upon secretion proBNP (amino acids 1-108) is 
cleaved by furin [7], into an N-terminus fragment (amino acids 1-76) and a C-terminus 
fragment (amino acids 77-108) [7].  A paradigm for the synthesis and processing of ANP 
[5] and BNP [8] is shown in Figure 2.   
Although they are also produced in other tissues, ANP is primarily secreted by 
atrial myocytes, while BNP is secreted by both the atria and ventricles of the heart [9, 
10].  ANP is released from the secretory granules in response to an increase in wall 
stretch and/or pressure [11], or in response to various factors including catecholamines, 
glucocorticoids, angiotensin II, and endothelin [12].  For example, endothelin-1 (ET-1) 
was shown to induce ANP secretion in ventricular cardiomyocytes through an 
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intracellular signaling pathway mediated by the ETA receptor involving the production of 
cAMP and the activation of an nifedipine-sensitive calcium channel [13].  Rebsamen et 
al. also demonstrated that the mechanism in which ET-1 induced ANP secretion involved 
calcium influx instead of calcium release from intracellular stores [13].   
ANP and BNP play an important physiological role in promoting natriuresis and 
diuresis, inhibiting renin and aldosterone release, and directly influence blood pressure 
and body fluid homeostasis [14-16].  NPs have been shown to inhibit adenylyl cyclase 
and decrease cAMP levels in various tissues [17], suppress vascular smooth muscle cell 
growth [18], inhibit DNA synthesis in cardiac fibroblasts [19], and inhibit cell 
proliferation in several different cell types through the generation of cyclic guanosine 
monophosphate (cGMP) [20-23].  NPs have been shown to induce apoptosis in cardiac 
myocytes [24] and in endothelial cells (EC) [25].  NPs were shown to affect the 
electrophysiology of the heart [26, 27] and central nervous system [28, 29], and muscle 
relaxation in the gastrointestinal system [30, 31].   
CNP, which lacks the carboxyl-terminal tail, is not known to be natriuretic, 
although it does possess vasorelaxant activity [32, 33].  CNP complements the endocrine 
actions of ANP and BNP to lower blood volume and pressure, and has a paracrine role in 
the regulation of vascular tone [33].  CNP is abundantly produced in the vascular 
endothelium, and because it does not circulate in large amounts as does ANP and BNP, it 
is thought to function locally in an autocrine/paracrine way [33].  CNP induces 
vasodilatation though activation of the B type natriuretic peptide receptor (NPRB) or the 
C type natriuretic peptide receptor (NPRC) and hyperpolarization of vascular smooth 
muscle [34].  Evidence has shown that the responses of CNP mediated through NPRB 
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result in stimulation of EC, but attenuation of smooth muscle cells [35, 36].  CNP has 
been shown to be an important regulator of endochondral ossification and a major 
phenotype of CNP-deficient mice is dwarfism, as demonstrated by shortened long bones 
[37, 38].  Several groups have demonstrated that CNP stimulates bone growth primarly 
through increased proliferation, mineralization, and extracellular matrix synthesis [37, 39, 
40].  Also, Agoston et al. demonstrated the ability of CNP to stimulate endochondral 
bone growth through expansion of the hypertrophic zone of the growth plate [41].   NPs 
are efficiently removed from the circulation by binding to natriuretic peptide clearance 
receptor NPRC [42] or by hydrolysis by the enzyme neprilysin or neutral endopeptidase 
(NEP) [43]. 
Several distinct phenotypes have been observed for various NPs or NPRs using 
mouse models, as indicated in Table 1.  The overexpression of ANP [44] or NPRA [45] 
induces a dose-dependent decrease in arterial blood pressure.  The deletion of ANP [46] 
or NPRA [47, 48] in mice leads to cardiac hypertrophy and sudden death.  The deletion 
of CNP or NPRB in mice leads to severe dwarfism [37], while deletion of NPRC results 
in skeletal overgrowth [49].  
 Plasma concentrations of ANP and BNP may be considered useful biomarkers of 
cardiac function [50, 51], since their concentrations increase in response to volume and 
pressure overload of the heart [11, 52-56].  Accordingly, ANP and BNP secretion is 
significantly elevated during cardiac failure and their plasma concentrations are 
proportional to the severity of the condition [52-56].  Resistance to the natural effects of 
NPs occurs in cardiac failure, especially in patients with the most advanced disease, but 
short-term infusions in patients have beneficial effects [57, 58].   
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 NPs are also capable of regulating various digestive functions.  Sabbatini et al. 
showed ANP and CNP play a role in stimulating pancreatic fluid and protein secretion in 
a dose-dependent manner when administered intravenously in rats [59].  The activation of 
NPRC was shown to mediate specific effects of ANP and CNP in the digestive system.  
CNP was shown to increase amylase secretion in response to NPRC activation and 
subsequent stimulation of phospholipase C (PLC) in pancreatic acinar cells [60].  At low 
doses, ANP was found to stimulate bicarbonate, decrease chloride output, and enhance 
secretin-induced pancreatic secretion in pancreatic duct cells [61].  At high doses, ANP 
was found to decrease secretin-induced pancreatic secretion through inhibition of 
adenylyl cyclase activity [61].  ANP and CNP were shown to inhibit spontaneous and 
sodium dehydrocholate induced bile secretion upon administration into rats [62].  
Moreover, ANP was shown to play a role in the regulation of gastric acid secretion 
through a vagal pathway and also through a paracrine/autocrine pathway [63].  ANP was 
found to increase gastric acid secretion in rats through a vagal-dependent mechanism 
when administered into rat’s intracerebroventricularly [64].  However, ANP 
demonstrated a biphasic effect when administered into rats intravenously, as low doses of 
ANP enhances vagally stimulated gastric secretion and high doses of ANP decreases 
vagally stimulated gastric secretion [65].  Also, a feedback mechanism has been 
suggested between ANP and somatostatin.  In rat antrum and fundus, ANP was found to 
stimulates somatostatin secretion through the activation of NPRA, while somatostatin 
inhibits ANP secretion [66, 67]. 
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Natriuretic Peptide Receptors  
One class of natriuretic peptide receptors (NPRs) constitutes the guanylyl cyclase-
coupled receptors NPRA and NPRB [68-75].  NPRA preferentially binds ANP and BNP 
(ANP>BNP>>CNP), while NPRB is more selective for CNP (CNP>>ANP>BNP) [76-
78].  The topology of NPRA and NPRB include a large extracellular domain (ECD), a 
single transmembrane domain (TMD), and an intracellular domain (ICD) consisting of 
kinase-homology regulatory domain (KHD), and a guanylyl cyclase domain (GCD) [79] 
(Figure 3).  At the basal state, the KHD interacts with the GCD to suppress its activity 
and upon ligand binding guanylyl cyclase activity is elevated, resulting in the conversion 
of guanosine triphosphate (GTP) to cGMP [79].  Various desentizating agents and 
conditions have been reported to inhibit the guanylyl cyclase-coupled receptors by 
decreasing their phosphorylation state [80], as phosphorylation is required for their 
activation [81].                  
The other class of NPRs constitutes the non-guanylyl cyclase-coupled receptor 
NPRC.  The topology of NPRC consists of a large ECD of ~440 amino acids, a single 
TMD, and a short 37 amino acid ICD [82].  NPRC exists as monomers and disulfide-
linked homodimers with a relative molecular mass of approximately 66 kDa and 130 
kDa, respectively [82].  Structural analysis of NPRC by truncation and site-directed 
mutagenesis studies, followed by binding assays provided evidence that the monomeric 
form of NPRC is capable of binding NPs with high affinity [83].  Two isoforms, of 67 
and 77 kDa, have been identified and both have been reported to form disulfide-linked 
homodimers and have high affinities for ANP and the NPRC selective agonist, ANP 
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analog des-[Glu18Ser19Gly20Leu21Gly22]-ANF-(4-23)-NH2  (cANF)  [84].  The location of the 
genes coding for the NPRs is described in Table 3.  
NPRC is the most promiscuous of the NPRs and the stoichiometry of the ligand-
receptor complex is 1:2 [85].  NPRC has much broader specificity and also binds small 
peptide analogs [86].  NPRC is widely expressed in a wide range of cells and tissues and 
represents the majority of the population of NPRs in vivo [82].  NPRC protein expression 
has been reported in human breast adenocarcinoma cells [87], human pancreatic 
adenocarcinoma cells [88], human renal carcinoma cells [89], human prostate carcinoma 
cells [90], human medullary thyroid carcinoma cells [91], human glioblastoma cells [92], 
human colon adenocarcinoma cells [93], human melanoma cells [94], human ovarian 
adenocarcinoma (HTB-161) cells, human angiosarcoma cells [95], human small cell lung 
carcinoma (SHP77) cells [96, 97], rat A-10 VSMCs [98], normal rat gastric mucosa 
(RGM1) cells [99], rat aortic smooth muscle (RASM) cells [99], pancreatic alpha cells 
[100], human aortic smooth muscle cells (AoSMCs) [99], mouse 3T3-L1 preadipotytes 
and adipoctyes [99].  A summary of the expression profile for the NPRs in various cell 
lines is shown in Table 2.    
 The primary function of NPRC is the metabolic clearance of NPs from circulation 
[82].  Upon ligand binding, the NPRC-ligand complex undergoes endocytosis via 
clathrin-coated pits, which is thought to be dependent on the integrity of the cytoplasmic 
domain of NPRC [101].  The complex then dissociates intracellularly in endosomes, 
followed by hydrolysis of ligand in lysomes and rapid recycling of receptor back to the 
cell surface [102].  NPRC locally modulates the physiological effects of the NP system 
by regulating the availability of NPs at their target organs [49].  Another mechanism for 
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the metabolic clearance of NPs from circulation is mediated by NEP.  Several groups 
have investigated effects of simultaneously blocking each or both the NPRC and NEP NP 
degradative pathways in normal animals.  Rademaker et al. [103], Chiu et al. [104], and 
Kukkonen et al. [105] reported the NPRC and NEP systems have an additive effect for 
the clearance of NPs from circulation.  Charles, C et al. [106] and Wegner et al. [107] 
demonstrated the NPRC and NEP systems can work in concert or synergistically to 
modulate the clearance of NPs from circulation.     
The extracellular ligand binding domain of NPRC contains several glycosylation 
sites [108]. The crystal structures of NPRC bound and unbound to ligand suggest 
glycosylation plays a role in the structural stabilization of the receptor and an indirect role 
in binding activity [109].      
NPRC expression has been demonstrated to be affected under various conditions 
and by a variety of factors.  Sarzani et al. demonstated fasting inhibits natriuretic peptides 
clearance receptor expression in rat adipose tissue [110].  Chabrier et al. reported a 
decrease in NPR density in response to angiotensin II (Ang II) in rat vascular smooth 
muscle cells (VSMCs) [111].  Similarly, Yasimoto et al. showed Ang II treatment 
decreased NPRC mRNA levels in cultured rat aortic smooth muscle cells, while NPRA 
and NPRB were not affected [112].  Boumati et al. showed endothelin (ET-1) treatment 
attenuated NPRC protein expression in A-10 SMCs [113]. Kishimoto et al. demonstrated 
that norepinephrine or isoproterenol downregulates NPRC density mediated by the 
activation of the β-adrenergic receptor, as the effect was blocked only by a β-selective 
adrenergic antagonist and not by α1 or α2 or β1 adrenergic antagonists in rat VSMCs 
[114].  Agui et al. demonstrated the differential regulation of NPR in response to 
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transforming growth factor-β1 (TGF-β1) treatment of murine thymic stromal cells, as 
NPRC expression was augmented and NPRA and NPRB expression was attenuated 
[115].  However, Sun et al. found that platelet-derived growth factor BB (PDGF-BB) and 
fibroblast growth factor (FGF-1 and FGF-2) treatments downregulated NPRC mRNA in 
pulmonary arterial smooth muscle cells [116].  Itoh et al. showed dehydration causes 
decrease in NPRA, NPRB, and NPRC mRNA expression in rat glomeruli, as the effect 
was proposed to be attributed to a lower circulating levels of ANP [117].  Ardaillou et al. 
demonstrated glucocorticoids upregulate NPRC protein expression in cultured human 
mesangial cells [118].  Lu et al. reported vasonatrin peptide can decrease the expression 
of NPRC in cardiac fibroblasts and myocytes under both air-control and hypoxic 
condition, and the effect is mediated by an increase in intracellular cGMP [119].  Several 
groups have demonstrated NPRC expression is regulated by ANP itself.  Hirata et al. 
reported downregulation of ANP receptors in VSMCs in response to ANP exposure 
[120].  Arejian et al. showed nitric oxide attenuates the expression of natriuretic peptide 
receptor C in rat aortic vascular smooth muscle cells [121].  Gower et al. showed 
prostaglandin E(2) (PGE(2) and transforming growth factor (TGF) can decrease NPRC 
mRNA and protein expression in RGM1 cells [122].  Multiple groups have shown that 
acute and chronic hypoxia cause the downregulation of NPRC gene expression and 
binding in rat lung without affecting other NPRs [123-125].  Sun et al. demonstrated that 
NPRC mRNA expression is downregulated in the lungs of hypoxia-adapted mice [125] 
and rats [124] in response to increased circulating levels of ANP, while NPRA and NPRB 
mRNA levels were not affected. This group later demonstrated that dietary salt 
supplementation is able to downregulate NPRC mRNA levels in the kidneys of wild-type 
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mice and mice with insertion inactivation of the ANP gene independently of endogenous 
ANP levels, but had no effect on NPRA or NPRB mRNA levels [126].  These findings 
were consistent with findings from Nagase et al. who demonstrated that NPRC gene 
expression was selectively attenuated in the kidney by chronic salt loading in Dahl salt-
sensitive and salt-resistant rats, whereas expression of NPRA and NPRB expression was 
not affected [127].     
The regulation of NPRC in disease has also been documented.  Luk et al. showed 
NPRC is downregulated in chronic renal failure rat glomeruli, and is the result of ANF-
stimulated cGMP responses [128].  Yoshimoto et al. demonstrated NPRC mRNA 
expression is downregulated in the aorta from stroke prone spontaneously hypertensive 
rats, while NPRA mRNA expression was upregulated [112].  Similarly, NPRC mRNA 
expression was found to be downregulated in the aorta [129], as well as in the lung, renal 
cortex of DOCA-salt hypertensive rats,while ANP levels were elevated [124]. 
 NPRC is an atypical G protein coupled receptor (GPCR), because it lacks the 
seven transmembrane spanning domains that is a hallmark of traditional serpentine or 
heptahelical GPCRs [130]. NPRC is coupled to the inhibitory G protein, Gi [31, 82].  
NPRC was shown to be negatively coupled to adenylyl cyclase in cultured atrial and 
ventricular cardiocytes [131-133]. The cytoplasmic domain of rat NPRC was shown to 
contain Gi activator sequences that inhibit adenylyl cyclase activity [134, 135].  NPRC is 
coupled to adenylyl cyclase inhibition via α subunits [134] and PLC-β3 activation via βγ 
subunits of Gi1 and Gi2 [31].  The ability of NPRC to inhibit adenylyl cyclase has been 
suggested to contribute to the attenuation of PGE2-production of lipopolysaccharide-
activated macrophages and reduces COX-2-protein and -mRNA levels [136], astrocyte 
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proliferation [137], and production and release of endothelin from EC [138].  Johnson et 
al. and Kanwal et al. demonstrated NPRC mediates inhibition of adenylyl cyclase and 
neurotransmission through cANF in nerve growth factor-treated PC12 cells [139, 140].    
 Mouawad et al. has shown a possible cross-talk that may exist between the 
adenylyl cyclase pathway and the PLC pathway in A-10 VSMCs, as the NPRC induced 
inhibition of adenylyl cyclase and decreased levels of cAMP contributes to NPRC 
mediated stimulation of PI turnover [141].  They also showed that the cANF (4-23) 
induced increased in IP3 production was further increased by the cAMP inhibitor 
dideoxyadenosine (DDA) and was inhibited by the cAMP inducing agent forskolin (FSK) 
[141].   
 NPRC has also been implicated in the modulation of other signaling pathways.  
Murthy et al. has shown NPRC activation by cANF(4-23) can result in the activation of 
constitutive nitric oxide synthase (NOS) via Giα1 and Giα2 in gastrointestinal smooth 
muscle [30].  Prins et al. has demonstrated cANF (4-23) can inhibit platelet-derived 
growth factor (PDGF) and endothelin-3 stimulated mitogen-activated protein kinase 
(MAPK) activity in astrocytes [142].  Furthermore, NPRC binding to CNP or cANF has 
been shown to inhibit L-type Ca2+ current (ICa,L) without modulating other voltage-gated 
Ca2+ currents in mouse atrial, ventricular, and sinoatrial node myocytes [26, 143].   
 The coupling of NPRC to various signaling pathways has provided a mechanism 
for additional roles of NPRC.  For example, several reports have shown NPRC mediates 
ANP-inhibition of vascular smooth muscle cell proliferation [144] and endothelial cell 
proliferation [145].  In another report, NPRC was found to mediate cANF induced 
antiproliferative effects in multiple different neuroblastoma cell lines [146].  Also, the 
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cAMP inhibition mediated by NPRC has been shown to modulate endothelial cell 
permeability in coronary EC [147].   NPRC was suggested to be implicated in vascular 
remodeling and angiogenesis, as cANF was found to inhibit ET and hypoxia-stimulated 
vascular endothelial cell growth factor (VEGF) transcription and production in VSMCs 
[148].        
 The complete absence of NPRC in mice by homologous recombination results in 
skeletal abnormalities, characterized by hunched backs, dome-shaped skulls, decreased 
weight, and elongated femurs, tibias, metatarsal, digital bones, vertebral bodies, and body 
length [149].  Jaubert et al. reported that three mutations involve the Npr3 gene encoding 
for NPRC, as well as an NPRC knockout results in a mouse skeletal-overgrowth 
phenotype, thus implicating a role for NPs in bone growth [149].  The three mutations 
reported to be within the extracellular domain of NPRC included an lgj2J allele displaying 
a C toT transition at position 283, resulting in a stop codon; a stri allele showing a C to A 
transversion at position 502, leading to an asparagines to histidine substitution; an lgj 
allele exhibiting an in-frame 36-bp deletion between position 195 and 232, causing a 
truncated protein by 12 amino acids [149].     
   
 
β-arrestins 
The arrestin family consist of cone arrestin [150], visual arrestin [151], β arrestin 
1 [152], and β arrestin 2 [153].  Cone arrestin and visual arrestin are almost exclusively 
expressed in the retina and regulate photoreceptor function, whereas the β-arrestins are 
virtually ubiquitously expressed and regulate most GPCRs, or seven membrane spanning 
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receptors (7MSRs) [154-157].  The β-arrestins bind to agonist-activated cell surface 
GPCRs phosphorylated by G protein-coupled receptor kinases (GRKs) and mediate their 
homologous desensitization and internalization [158, 159].  The GRK family consists of 
seven different genes and the seven GRK members are divided into three subfamilies 
[160].  The first subfamily of GRKs consist of GRK1 and -7, the second subfamily of 
GRKs consist of the pleckstrin homology domain-containing GRK2 and -3, and the third 
subfamily of GRKs consist of constitutively membrane bound GRK4, -5, and -6 [161].  
Upon GPCR stimulation and activation by agonist, GRKs phosphorylate GPCRs on 
serine and threonine residues within the carboxyl-terminal tail and/or the third 
cytoplasmic loop [130, 162-165].  GPCR phosphorylation by GRKs significantly 
enhances the affinity of the receptor for arrestins, but it is the binding of the β-arrestins to 
the GPCR that leads to the actual homologous desensitization [154, 166, 167].  In 
contrast to homologous desensitization mediated by GRK phosphorylation and β-arrestin 
binding, heterologous desensitization of GPCRs is not dependent on agonist occupancy 
and instead is mediated by phosphorylation within the cytoplasmic loops and C-terminal 
tail domains of GPCRs by second-messenger-dependent protein kinases, including 
protein kinase A and protein kinase C [168].     
In addition to their role in desensitization of GPCRs, β arrestins act as adapter 
proteins to target GPCRs to clathrin-coated pits for endocytosis [154].  The ability of β-
arrestins to function as adapter proteins to target GPCRs to components of the clathrin-
dependent endocytic machinery is attributed to two motifs within the β-arrestins.  The 
first motif involves the binding of an LIEF sequence located between residues 374 and 
377 of β-arrestin 2 [169], to a region between amino acid residues 89 and 100 of the N 
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terminal domain of the clathrin heavy chain.  The other motif involves the binding of β-
arrestins to the β2 adaptin subunit of the heterotetrameric AP-2 adaptor complex through 
an RxR sequence located between amino acid residues 394 to 396 of β-arrestin 2 [170]. 
The endocytic function of β-arrestin 1 and 2 are differentially regulated.  The endocytic 
function of β-arrestin 1 is mediated by ERK1 and ERK2 phosphorylation [171], while the 
endocytic function of β-arrestin 2 is mediated by ubiquitination catalyzed by the E3 
ubiquitin ligase Mdm2 in response to agonist binding of the GPCR [172].  The 
deubiquitinating enzyme ubiquitin-specific protease 33 (USP33) was found to bind to 
beta-arrestins, resulting in deubiquitination of beta-arrestins [173].  The USP33 and 
Mdm2 function reciprocally and allow for beta-arrestin complex stability or lability, 
respectively [173].  This process of sequestration contributes to the attenuation of GPCR 
signaling and resensitization and downregulation of the GPCR [154].  Receptor 
downregulation involves a decrease in the density of cell surface receptors and is a slow 
process that occurs over a period of hours to days [154, 157].  In contrast, receptor 
desensitization involves a temporary loss of receptor responsiveness to agonist and is a 
rapid process that begins within seconds of agonist binding [154, 157].  Receptor 
resensitization requires dephosphorylation of the receptor and the dissociation of the 
ligand [154].  Multiple studies support the requirement for receptor internalization for 
resensitization of many GPCRs [174, 175].               
Furthermore, the β-arrestins can confer enzymatic activities upon GPCRs by 
binding directly to signal transduction associated proteins including Src family kinases 
and components of the MAP kinase and ERK1/2 signaling cascades [154].  The binding 
of β-arrestin to Src is mediated by interaction between the proline-rich PXXP motifs of 
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amino acid residues 88-91 and 121-124 of the N terminal domain of β-arrestin 1 and the 
Src homology (SH) 3 domain of the kinase [154].  One role of the β-arrestin-Src complex 
is to modulate GPCR endocytosis.  The three major classes of MAP kinases of 
mammalian cells include the ERKs, which play a role in the control of the G0-G1 cell 
cycle, and the JNKs and p38/HOG1, which play a role in the regulation of growth arrest 
and apoptosis [154].  Activated MAP kinases phosphorylate various cytoplasmic, 
membrane, and nuclear substrates.  The ability of β-arrestins to serve as scaffolds for 
MAP kinases allows for the targeting of MAP kinases to specific subcellular locations, 
increased signaling efficiency, and the dampening of cross talk between MAP kinase 
cascades [154].  Accordingly, the β-arrestins have significant implications for cellular 
processes such as chemotaxis and apoptosis [176].          
 
G proteins 
 Guanine nucleotide regulatory proteins (G-proteins) are a family of GTP-binding 
proteins that are involved in second messenger signaling cascades [177].  G proteins may 
refer to two different families of proteins, the Ras subfamily of small GTPases (small G-
proteins) and the heterotrimeric G-proteins (large G-proteins).  Small GTPases are 
homologous to the α subunit of heterotrimeric G-proteins [178].  The G-protein is active 
when bound to GTP and inactive when bound to GDP.  The cognate G-protein is 
activated upon activation of guanine nucleotide exchange factors (GEFs) [179-183], and 
inactivated upon activation of GTPase activating proteins (GAPs) [184-188].  Guanosine 
nucleotide dissociation inhibitors (GDI) [189] keep small GTPases in the inactive state.  
Heterotrimeric G-proteins consist of α, β, and γ subunits [190-194].  There are three 
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distinct forms of Gαi from different genes, and four forms of Gαs from splicing of a 
single gene [194].  In the resting state, Gα is bound to GDP and associates with Gβγ 
[192].  The GDP bound heterotrimer is coupled to surface receptors, which increases the 
receptors affinity for ligand [192].  Upon ligand binding, the activated receptor acts as a 
guanine nucleotide exchange factor by activating the heterotrimer and increasing the rate 
of GDP to GTP exchange on Gα [192].  The exchange triggers dissociation of Gα from 
Gβγ and the receptor [192].  GαGTP and Gβγ then activate different signaling pathways 
and effector proteins including adenylyl cyclase [195-197] and PLC [195, 198-200].  
Upon disassociation between ligand and receptor, intrinsic GTPase activity of Gα 
hydrolyzes the GTP to GDP and the inactive GDP bound Gα associates with Gβγ to 
begin a new cycle.   
Bacterial toxins are useful tools for identifying and investigating the role of G 
proteins.  Pertussis toxin and cholera toxin are known to covalently modify the α subunits 
of G proteins by ADP-ribosylating specific amino acid residues [201].  Pertussis toxin 
attenuates the effect of Gi [202, 203], while cholera toxin irreversibly activates the Gs 
protein resulting in stimulation of adenylyl cyclase [202, 204].  The role of various G 
proteins in mediating adenylyl cyclase and phospholipase C signal transduction is shown 
in Figure 4.     
 
Adenylyl cyclase  
There are at least nine isoforms of membrane associated adenylyl cyclase (AC) 
and one isoform of soluble AC [205] that currently exist, and each is characterized by 
distinct biochemical properties and tissue distribution.  The AC isoforms are subdivided 
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into five distinct families based on their amino acid sequence similarity and functional 
characteristics [205-207].  The Ca2+ CaM-sensitive forms include AC1, AC3, and AC8 
[205-207].  The Gβγ stimulatory forms include AC2, AC4, and AC7 [205-207].  The 
Ca2+ and Gαi sensitive isoforms include AC5 and AC6 [205-207].  The most divergent 
membrane bound AC isoform is AC9 and is highly insensitive to the diterpene forskolin 
[205-207]. The overall most divergent AC isoform is the soluble AC isoform and it 
maintains similarities to the cyclases found in cyanobacteria [205]. The ACs hydrolyzes 
ATP to produce pyrophosphate and the second messenger cyclic AMP (cAMP) [206, 
207](Figure 5).  Elevated levels of pyrophosphate can force AC into a product-bound 
conformation and inhibit the activity of AC [206, 207].  AC consists of six 
transmembrane segments and two catalytic domains that extend into the cytoplasm [206, 
207].  With the exception of the soluble AC isoform, all other AC isoforms are inhibited 
by adenosine analogs, or P-site inhibitors [208].  P-site inhibitors inhibit AC activity 
without competing with ATP binding [208], but instead by binding to a conformation of 
the enzyme that closely resembles the product bound state, or posttransition state [209].  
While all membrane bound AC isoforms are expressed in excitable tissues, such as 
neurons and muscle, AC1 and AC3 are expressed exclusively in the brain [210] and the 
soluble form of AC is ubiquitously expressed with high levels in sperm cells [211].  Each 
AC isoform is activated by alpha subunits of G proteins and some have been found to be 
activated by various other molecules including forskolin.  Non-physiological 
concentrations of Ca2+in the mM range inhibit all AC isoforms, but AC5 and AC6 are 
inhibited by concentrations of Ca2+ in the µM range from capacitative entry [212] 
epinephrine, glucagon, prostaglandin, prostaglandin E2 (PGE2), adenosine are known to 
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activate AC through membrane-bound receptors.  Unlike the membrane bound AC 
isoforms, the soluble AC isoform is unresponsive to hormones, G proteins, and forskolin 
and its biochemical activity is dependent on the divalent cation Mn2+ [211].  Furthermore, 
the soluble AC isoform displays approximately a 10-fold lower affinity for substrate 
[213] than the membrane associated AC isoforms [214].  The intracellular domain of G 
protein coupled receptors interact with the GDP bound heterotrimeric G proteins, 
resulting in the displacement of bound GDP by GTP and the dissociation of the GTP 
bound G α subunit and the G βγ dimer [206, 207].  The GTP bound Gαs family stimulates 
AC, while the GTP-bound Gαi family inhibits AC [206, 207].  
 
AHNAK1/Desmoyokin 
 AHNAK, meaning giant in Hebrew or also referred to as Desmoyokin [215] is a 
large phosphoprotein of approximately 700 kDa [216].  A second AHNAK1-like protein 
located on chromosome 14q32, AHNAK2, has been identified [217].  The amino terminal 
domain of AHNAK2 is predicted to contain a PDZ domain [217].  AHNAK1 is encoded 
by a single exon located on human chromosome 11q12 [218].  AHNAK1 is composed of 
three distinct structural domains:  a short amino terminus domain of 251 amino acids, a 
large central domain of 4,392 amino acids characterized by 39 highly conserved 
repeating units each of 126 amino acids, and a large carboxy terminus domain of 1000 
amino acids [216].  
AHNAK1 expression increases in the Go stage of the cell cycle, as quiescent cells 
contain higher levels of AHNAK1 protein.  Among various human cell lines, Shtivelman 
et al. reported AHNAK1 downregulation in neuroblastoma cells, Burkitt lymphomas, and 
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small cell lung carcinomas [216].  Gentil et al. observed AHANK1 is widely expressed in 
smooth muscle cells, skeletal muscle, myoepithelium, and myofibroblasts [219].  
However, Gentil et al. did not observe significant AHNAK1 staining in cells having 
secretory functions such as the glandular epithelium of the mammary gland, the salivary 
gland, the stomach, the prostate, or the exocrine and endocrine pancreas [219].    
Kingsley et al. reported AHNAK1 expression in extraembronic tissue, mesenchymal cells 
of the branchial artery, and nasal epithelia and skin [220] .  Salim et al. found AHNAK1 
expression in developing and adult rat peripheral nervous system [221].  AHNAK1 
expression was found in small and medium-sized neurons and satellite cells of dorsal root 
ganglia and Schwaan cells [221].  Matza et al. found strong AHNAK1 expression in 
CD4+ T cells and less expression in thymocytes [222].         
  The carboxy terminal domain of AHNAK1 was found to contain nuclear 
localization sequences and a nuclear export signal [223].  The subcellular localization of 
AHNAK1 is cell type dependent, as AHNAK1 has been described to be restricted 
predominantly to cell nuclei and Golgi apparatuses of nonepithelial cells and cytoplasmic 
or plasma membrane-associated in epithelial cells [216] or upon PKC activation or 
increase in extracellular calcium [224].  Sussman et al. reported phosphorylation of 
AHNAK1 by PKB contributes its nuclear exclusion in epithelial cells, and that AHNAK1 
translocates from the cytosol to the cytosolic side of the plasma membrane during the 
formation of cell-cell contact and epithelial polarity development [225].  Benaud et al. 
reported that the translocation is regulated by Ca2+ dependent cell-cell adhesion and is a 
reversible process [226].  Hashimoto et al. reported AHNAK1 translocates from the 
cytosol to the plasma membrane in response to increased extracellular calcium in 
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keratinocytes [224].  AHNAK1 demonstrated a predominantly nuclear distribution in low 
calcium medium and both a nuclear and cytoplasmic distribution in normal calcium 
medium [224].      
AHNAK1 has been implicated in several different cell type specific functions 
including neuroblast differentiation [216], tumorigenesis [227], epidermal cell adhesion 
[228], Ca2+ homeostasis regulation [229], regulated exocytosis [230], skeletal muscle 
regeneration [231], regulation of cell membrane cytoarchitecture [226], maintaining 
blood brain barrier properties [232], regulation of L-type calcium channels [233, 234],  
modulation of DNA ligase IV-mediated double-stranded ligation [235], T cell calcium 
signaling [222, 236], and activation of phopholipase C γ1 in the presence of Tau or 
arachidonic acid (AA) [237-239].  Matza et al. proposed AHNAK1 helps regulate 
membrane localization of L-type calcium channels during T cell activation [236].  
Benaud et al. showed down-regulation of AHNAK1 affects the cell membrane 
cytoarchitecture of epithelial cells [226].  In addition, AHNAK1 was found to be widely 
distributed in EC with blood-brain barrier properties and was found to co-localize to the 
TG protein ZO-1 [232].  These findings suggest a role for AHNAK1 in the regulation of 
cell adhesion and permeability.  Since paracellular permeability and intramembrane 
diffusion of various components between the apical and basolateral membranes of 
epithelial cells is attributed to TJs, the expression and role of AHANK1 in establishing 
such junctions have been investigated [219].  AHNAK1 has also been identified as a 
novel autoantigen in systemic lupus erythematosus [240].  Skoldberg et al. has shown 
AHNAK1 contains distinct cleavage sites for granzyme B and caspase-3 [240].  Since a 
hallmark of many autoantigens in systemic autoimmune disease is the efficient cleavage 
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by granzyme B to produce fragments distinct from those produced during other forms of 
apoptosis, AHNAK1 was suggested to be a target of the immune system in autoimmune 
disease.     
AHNAK1 has been shown to associate with several different proteins including 
the calcium and zinc-binding protein S100b [229], the regulatory β2 subunit of L-type 
calcium channels [233], G-actin [241], PLC [237], and PKC [239].  The carboxyl-
terminal domain AHNAK1 has also been found to associate with a type of vesicles called 
enlargosomes, a new population of calcium regulated vesicles capable of fast exocytosis 
[230, 231].  
Phospho analysis revealed AHNAK1 is phosphorylated on serine and threonine 
residues, and subsequent studies showed it is a substrate of PKA, PKB, and PKC in vitro.  
AHNAK1 was reported to consist of eight potential in vitro phosphorylation sites for 
PKA [233], six potential in vitro phosphorylation sites for PKC [234], and seven 
potential in vitro phosphorylation sites for casein kinase II [234].  Phosphorylation of 
AHNAK1 is important for its subcellular localization and function.  AHNAK1 
phosphorylation decreases when cells are made quiescent.  Phosphorylation of serine 
5535 of AHNAK1 by PKB results in nuclear exclusion in MDCK and HeLa cells [225].  
The binding affinity between the C1 domain of AHNAK1 and the β2 subunit of L-type 
calcium channels decreases by approximately 50% upon PKA phosphorylation [233].   
 
Arachidonic Acid 
 Arachidonic acid (AA) is a polyunsaturated fatty acid with four double bonds, in 
which by iself or its metabolites serves multiple roles in living cells [242].  AA and its 
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metabolites (e.g. eicosanoids) function as modulators to suppress inflammation [243].  
The concentration of AA in resting cell is generally described as being low [244].  AA is 
amphipathic in nature, as its hydrophobic tail can remain in a lipid bilayer, while its polar 
carboxyl group can emerge into the extracellular aqueous environment [244].  
Additionally, the amphipathic nature of AA allows it to readily bind to proteins such as 
serum albumin [245].  Fatty acid binding proteins (FABPs) [246] and fatty acid transport 
proteins (FATPs) [247-251] allow for cellular uptake of AA.   Liberated AA is 
metabolized by the cyclooxygenase (COX), lipoxygenase (LO), and cytochrome P450 
monooxygenase (CYP) enzymatic pathways [252, 253].  The COX pathway converts AA 
into prostaglandins (PGs) and is clinical relevant since it is the main target for non-
steroidal anti-inflammatory drugs (NSAIDs) [254].  Three COX isoforms exist [255], 
where COX-1 is virtually ubiquitiously expressed in most tissues and COX-2 is thought 
to be an inducible isoform upregulated by inflammatory stimuli [254, 256-260].  The LO 
pathway converts AA into leukotrienes (LT), and the lipoxygenases demonstrate 
regiospecificity during interaction with substrates [261].  Accordingly, the LOs have been 
designated as arachidonate 5-, 8, 12-, 15-lipoxygenase (5-LOX, 8-LOX, 12-LOX, and 
15-LOX) [244, 262, 263].  In EC, the CYP pathway metabolizes arachidonic acid to four 
regioisomeric epoxyeicosatrienoic acids, which are then rapidly hydrolyzed to 
dihydroxyeicosatrienoic acids [264, 265].  Many of the bioactivities of AA is from its 
conversion to bioactive products such as prostaglandins by oxygenases [242].  The 
extracellular release of AA allows for the exchange of AA between cells and certain cell 
types further release AA in response to exogenous AA.  AA is known to regulate 
transcription factors, including the activation of peroxisome-activated receptors (PPARs) 
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[242].  The hydrolysis of phospholipids by phospholipase A2 (PLA2) is the primary 
pathway leading to AA production [266, 267].  Activation of PLA2 is tightly regulated at 
both the transcriptional and posttranslational levels.  The secretory (sPLA2), cytosolic 
Ca2+ dependent (cPLA2), and cytosolic Ca2+ independent (iPLA2) are three types of 
PLA2s [266].  The sPLA2 enzymes have a molecular mass of between 13-19 kDa and 
lack specificity for arachidonate containing phospholipids [268].  The sPLA2 enzymes are 
stored in the secretory granules and released upon the activation of cells, and can increase 
the activity of cPLA2 in cell types including EC.  Several EC functions, including 
migration, proliferation, viability, barrier maintenance, adherence, and generation of 
bioactive mediators are affected by AA metabolites [243].  The cPLA2 enzymes have a 
molecular mass of greater than 60 kDa and preferentially hydrolyze arachidonate 
containing phospholipids [269].  The cPLA2 enzymes are constitutively expressed in 
most cells and tissues.  The iPLA2 enzymes have a molecular mass of approximately 85 
kDa and are not selective for arachidonate containing phospholipids [270].  Stimulation 
of cells with pro-inflammatory cytokines and growth factors results in increased 
expression of cPLA2 and sPLA2 [266]. AACOCF3, a trifluoromethyl ketone analog of 
AA, is a potent inhibitor of cPLA2 [271].  Alternatively, AA can be released from 
membrane phospholipids form hydrolysis of DAG catalyzed by two DAG-lipase [272]. 
A few reports have provided evidence for a positive correlation between the 
amount of AA in adipose tissue and the risk of ischemic heart disease (IHD) [273].  
Furthermore, AA concentrations in adipose tissue have been found to be positively 
correlated with body mass index, which is a risk factor for myocardial infarction [273].     
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Phospholipase C 
 PLCβ, PLCγ, PLCδ, and PLCε are four main subfamilies of PLC [238].  There 
are four members of the PLCβ subfamily, and each are activated by α or βγ subunits of 
the heterotrimeric G-proteins in response to agonist binding [198, 238].  PLCβ1 exist as 
alternatively spliced variants β1a and β1b and each show differential tissue distribution 
and expression [238].  PLCβ2 is highly expressed in cells of hematopoeitic origin and is 
implicated in leukocyte signaling and host defenses [238].  PLCβ3 is widely expressed 
with high levels in granule cells and the pituitary gland [238].  PLCβ4 exist as 
alternatively splice variants with the PLCβ4b variant having a unique 10 residue peptide 
instead of the 162 amino acid carboxy-terminal [238].  PLCβ3 is the only β isoform that 
is essential as homologous disruption of the PLCβ3 gene is lethal for mice early in 
development [238].  However, null mutations of the other β isoforms each result in a 
phenotype representative of the specialized role of that specific isoform [238].  There are 
two members of the PLCγ subfamily, and each contains two types of SH domains and is 
believed to be regulated by tyrosine phosphorylation following binding to either growth 
factor activated receptor kinases or to cytosolic tyrosine kinases of the src family [238].  
Alternatively, lipid-derived second messengers have been shown to activate this isozyme 
[238].  There are four members of the PLCε subfamily and they are activated by Ras and 
Rho GTPases and contains both guanine nucleotide exchange factor (GEF) and RA (Ras 
associating) domains [238].  PLC hydrolyzes phosphatidylinositol 4,5-biphosphate (PIP2) 
to generate the water soluble inositol 1,4,5-triphosphate (IP3), which is released into the 
cytosol and the hydrophobic DAG, which is released into the membrane [238].  IP3 
triggers calcium release from intracellular calcium stores through binding to IP3 
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receptors, while DAG is known to activate PKC [238, 274].  Both IP3 and DAG are 
important second messengers in various signaling pathways (Figure 6).  Moreover, 
activation of PLC is a key event in cellular signal transduction involved in cell growth, 
metabolism, secretion, and proliferation [238] 
 
Calcium Signaling 
Calcium is a ubiquitous and universal second messenger that plays an important 
role in the regulation of a wide range of cellular processes [275].  As a second messenger 
calcium is known to influence cell growth and proliferation [276-283], differentiation 
[284-287], survival and death [288-291].  Cells posses the necessary machinery to 
regulate both [Ca2+]e and [Ca2+]i with accuracy and precision by directional Ca2+ 
transport across the plasma membrane and across membranes of intracellular organelles 
(e.g. endoplasmic reticulum).   
The second messenger function of Ca2+ extends beyond inside the cell, as many 
cells express cell surface sensors for Ca2+.  The best characterized Ca2+ sensor is the 
extracellular-Ca2+ sensing receptor (CaR), a GPCR that is able to respond to divalent and 
trivalent metal ions including Ca2+, Mg2+, Zn2+ and Gd3+, extracellular amino acids, and 
various polycations [292].  ACaR is abundantly expressed in epithelial cells, glial cells, 
and central and peripheral neurons [293].  CaR couples to various intracellular signal 
transduction cascades upon activation by ligand [294-297].  CAR is coupled to Gαq/Gα11 
to stimulate intracellular PLC/IP3/Ca2+ signaling, and through PTX-sensitive Gαi to 
interrupt cAMP production [292, 298].  CaR is also linked to AA production activation of 
the MAP kinase pathways [292].  Ca2+ may act as paracrine messenger via CaR, since 
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CaRs of neighboring cells are able to respond to changes in [Ca2+]e as a consequence of 
[Ca2+]I signaling.  Moreover, Ca2+ may act as an autocrine messenger, as export of Ca2+ 
following intracellular Ca2+ spiking upon activation of CaR has been reported.  Several 
other membrane proteins have been reported to respond to [Ca2+]e.  The metabotropic 
glutamate receptors (mGluRs), a G-protein coupled receptor that is sensitive to [Ca2+]e is 
expressed predominantly in the central nervous system [299]. Hemichannels of adjacent 
cells that form gap junctions have been reported to be highly responsive to small 
decreases in [Ca2+]e [300].  Ion channels, including the ASIC1a/ASIC1b, proton-gated 
cation channels are responsive to fluctuations in [Ca2+]e [301]. 
 An increase in [Ca2+]I may occur from an influx of extracellular calcium via 
channels in the plasma membrane or from depletion of intracellular calcium stores.  In 
non-excitable cells, a biphasic increase in [Ca2+]I may occur from store-operated calcium 
entry (SOC) (also known as capacitative calcium entry) as calcium store depletion 
triggers an influx of extracellular calcium [293].  SOC helps to replenish intracellular 
calcium stores and activate various physiological processes [293].   
 
Adipogenesis 
Adipose tissue is a type of specialized connective tissue that is composed of 
several cell types including fibroblasts, macrophages, EC, and adipocytes [302].  White 
and brown adipocytes derive from fibroblastic precursor cells and constitute the two 
forms of adipose tissue found in mammals [303].  Brown adipose tissue, which acquires 
its color from vascularization and densely packed mitochondria, is believed to function as 
a defense against cold and protection against obesity, but the physiological significance 
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of brown adipose tissue has been less characterized than white adipose tissue [302].  
Adipose tissue store energy in the form of triglycerides and secretes a variety of 
hormones termed adipokines [302].  Adipokines such as adiponectin, leptin, interleukin 6 
(IL-6), tumor necrosis factor  (TNF- ), adipsin, visfatin, and leptin are involved in the 
regulation of energy metabolism [302].  The dysfunction of adipokine production may 
contribute to the pathogenesis of diseases associated with energy metabolism including 
insulin resistance and type 2 diabetes [302].   
The function of adipose tissue is disregulated in obesity [304], which has been 
linked with an increase risk of various diseases including cancer, heart disease, 
hypertension, stroke, and diabetes [305].  Since obesity is characterized by an excess of 
adipose tissue, pharmacological approaches to modulate adipogenesis, the development 
of adipocytes from preadipocytes is an attractive solution to this disorder.  However, the 
medical benefits from the direct reduction of adipogenesis is not yet clearly understood.  
For example, stimulators of adipogenesis are used clinically to reduce hyperglycemia in 
patients with type 2 diabetes [302].  Also, it would seem increasing brown fat 
adipogenesis would be beneficial.               
Adipogenesis involves a cascade of events leading to the development of 
adipocytes from preadipocytes.  The core constituents of the initial cascade include the 
CCAAT/enhancer-binding protein β (C/EBPβ) and C/EBPδ transcription factors [306].  
The core constituents of the second cascade include the peroxisome proliferator-activator 
receptor γ (PPARγ) and C/EBPα transcription factors [306].  The C/EBP family members 
belong to the basic-leucine zipper class of transcription factors [306].  The PPARγ is a 
member of the nuclear receptor family and exist as two protein isoforms from alternative 
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splicing at the 5’ end of the gene [307].  The PPARγ2 isoform contains 30 additional 
amino acids at the amino terminus and is highly specific for fat cells [308].  PPARγ is 
activated upon binding of ligands to its carboxy terminal domain ligand binding domain 
[307].  In a model by Rosen and Spiegelman, C/EBPβ and C/EBPδ induces the 
expression of PPARγ, which in turn activates C/EBPα [302].  PPARγ and C/EBPα are 
believed to act synergistically to activate differentiation gene expression [307, 309].  
Furthermore, the ADD1/SREBP1 transcription factor has been linked to the activation of 
PPARγ by inducing its expression and promoting the production of endogenous PPARγ 
ligand [307].   
In comparison with other cell lineages, the differentiation of preadipocytes into 
mature adipocytes in vitro closely mimics and recapitulates many of the key features of 
adipogenesis in vivo.  These features include cell growth cessation, morphological 
changes, lipid accumulation, and sensitivity to various hormones including insulin [302].  
Several extracellular and intracellular signals, including various hormones growth factors 
have been shown to influence preadipocyte determination, preadipocyte growth, and 
terminal differentiation.  Insulin is known to induce differentiation and increase lipid 
accumulation, although preadipocytes express low, if any levels of insulin receptors 
[302].  Accordingly, the effect of insulin on differentiation was found to be the result of 
cross-activation of the insulin-like growth factor 1 (IGF-1) receptor [302].  Activation of 
preadipocyte IGF-1 receptors by IFG-1 or pharmacological doses of insulin results in the 
activation of several distinct transduction pathways, including ras and akt, which activate 
adipogenesis via unknown effectors [302].  Furthermore, glucocorticoids are known to 
induce adipocyte differentiation [306].  Glucocorticoids can be administered in the form 
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of dexamethasone and activate the glucocorticoid receptor, which belongs to the same 
superfamily as PPARγ [118, 306].  Glucocorticoids have been shown to reduce 
expression of the negative regulator of adipogenesis, preadipocyte factor-1 (pref-1) [302].  
Inhibition of adipogenesis involves the activation of MAPK by various cytokines, 
including TNF-α and IL-1 and growth factors, including PDGF, FGF, and EGF.  MAPK 
phosphorylates PPARγ leading to repression of differentiation [302]. 
 
Protein Kinases and Phosphatases 
Protein phosphorylation plays an important role in many physiological processes 
and is often disregulated in various pathological conditions.  A protein kinase is 
responsible for the transfer of terminal phosphate of ATP to a hydroxyl group on a 
protein, while a protein phosphatase is responsible for removal of the phosphate by 
hydrolysis.  Protein kinases and phosphatases have been implicaed in various diseases 
and are major drug targets [310].     
The cAMP-dependent protein kinase, or protein kinase A (PKA) is a 
serine/threonine kinase that is composed of two catalytic subunits and a regulatory 
subunit dimer [311].  The kinase is rendered inactive when the two catalytic subunits 
associate with the regulatory subunit to form a tetrameric complex [311].  The kinase 
becomes active when the intracellular signaling molecule cAMP binds to the regulatory 
subunit and facilitates dissociation of the complex [311].  The two forms of the 
heterotetrameric PKA holoenzyme are the type I (RIα and RIβ dimer) and type II (RIIα 
and RIIβ dimer) PKA holoenzymes [312].  Type I PKA is predominantly cytoplasmic, 
while type II is known to associate with various cellular structures and organelles [313].  
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The localization of PKA and other signaling enzymes is dependent on its interaction with 
A-kinase anchoring proteins (AKAPs) [314].  The AKAPs play an important role in the 
coordination of signaling complexes by connecting upstream activators with downstream 
targets [314]. 
PKB, also known as Akt, is a serine/threonine kinase that is activated in the 
phosphoinositide-3 kinase (PI3K)-dependent pathway [315].  PKB exist as α, β, γ 
isoforms, each of which are encoded by separate genes [315].  PKB possesses a 
Pleckstrin homology domain (PHD), which binds to phosphoinositides with high affinity.  
PKB has been implicated in cell survival, cell cycle, metabolism, and angiogenesis and 
tumor development.  The PH domain leucine-rich repeat protein phosphatase (PHLPP) is 
the phosphatase responsible for dephosphorylating the hydrophobic motif of PKB [316].   
PKB serves a protective role against apoptosis in response to mitochondrial damage, as 
its activation has been found to reduce ischemia-reperfusion and hypoxia/reoxygenation-
induced apoptosis in neuronal cells and in cardiomyocytes by inhibiting the release of 
cytochrome c the activation of caspase-3 and caspase-9 [317, 318].      
The PKC family consists of 10 isozymes that are organized into three subclasses 
according to their second messenger mode of regulation [319].  The conventional PKC 
isozymes, α, β1/β2, and γ respond to DAG and Ca2+ [319] .  The novel isozymes, δ, ε, η, θ 
respond only to DAG [319].  The atypical isozymes ι, λ, ξ respond to neither to Ca2+ nor 
DAG [319].  A given PKC isozyme can directly oppose the function of another isozyme.  
For example, PKC δ is known to be proapoptotic and anti-proliferative, while PKC ε is 
known to be anti-apoptotic and proliferative [319].  All members of the PKC family have 
a conserved C-terminal kinase core and an N-terminal regulatory moiety [319-321].  The 
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regulatory moiety is responsible for maintaining the enzyme in an autoinhibited state in 
the absence of a second messenger, targeting the enzyme to specific cellular sites, and 
mediating protein-protein interactions [319-321].  PKC translocates from the cytosol to 
the plasma membrane in response to the generation and subsequent binding of the lipid 
second messengers, Ca2+ and DAG [319-321].  Increases in intracellular concentrations 
of these second messengers results in activation of PKC, while decreases in these second 
messengers results in inactivation of PKC [319-321].  The C1, C2 and C-terminal tail of 
PKC help to mediate protein-protein interactions.  PKC can interact with various binding 
partners to target it to different signaling pathways [319-321].  Receptors for activated C-
kinase (RACKs), which serve as adaptors for various proteins are responsible for binding 
to the C2 domain of activated PKC and regulating its activity [319].  Activated PKC that 
is in the open conformation is susceptible to phosphatases, proteolysis, and degradation 
[319].  Dephosphorylation at the activation loop, turn motif, and hydrophobic motif 
renders PKC inactive [321].  Chronic activation of PKC by treatment with phorbol esters 
and bryostatins results in the loss in enzymatic activity and down-regulation of the 
enzyme [321].  Maturation of PKC is dependent on phosphorylation at the activation 
loop, allows for autophosphorylation at the C-terminus, correctly positions residues 
required for catalysis, and reveals access to the substrate binding site [321].         
 
Cell-cell junctions 
 The formation and integrity of cell-cell contacts is important for establishing and 
maintaining the permeability barrier property of endothelial and epithelial cells [322].  
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Cell-cell contacts between epithelial cells are attributed to the junctional complex, which 
contains gap junctions, desmosomes, adherens junctions (AJs), and TJs [322, 323].   
 Gap junctions metabolically and electrically couple neighboring cells together by 
allowing the passage of second messengers, ions, and small molecules between 
cytoplasms of adjacent cells [324].  Gap junctions are formed by two unrelated families 
of proteins, the connexins and the pannexins [324].  Connexin proteins are similar in 
structure as they contain four transmembrane domains that are connected by two 
extracellular loops and form the wall or pore of the channels [324].  The connexin 
proteins are also composed of cytoplasmic N and C terminal domains and a cytoplasmic 
loop that links the second and third transmembrane domains [324].     
Desmosomes help hold epithelial cells together and provide anchoring sites for 
intermediate filaments [325].  Desmosomal cell-cell attachment is mediated by the 
transmembrane glycoproteins of the cadherin superfamily, desmoglein and desmocollin 
[326, 327], in which three known tissue specific isoforms exist for each protein [328].  
The cytoplasmic domains of desmoglein and desmocollin connect to intermediate 
filaments through desmosomal proteins such as plakoglobin, while the extracellular 
domains connect with their counterparts in adjacent cells [327, 328].  The cell type 
specific intermediate filament (IF) proteins are arranged into several different sequence 
homology classes [329].  Classes I and II represent the acidic and basic cytokeratins, 
respectively [329].  Class III include vimentin, desmin, glial fibrillary acidic protein, and 
peripherin [329].  Class IV include α-internexin and neurofilament triplet proteins, and 
nestin [329].  Class V include the nuclear lamins [329].     
31
AJs play an important role in maintaining endothelial and epithelial paracellular 
permeability [330].  In addition AJs promote cell-cell communication and transfer signals 
between cells that regulate cell shape and polarity, mediate contact inhibition of cell 
growth, and increase resistance to apoptosis [330].  The two major protein complexes that 
exist at AJs of epithelial cells include the cadherin-catenin complex and the nectin-afadin 
complex [331, 332].  The cadherin-catenin complex is composed of the Ca2+ dependent 
adhesion E-cadherin molecule and the armadillo repeat domain containing family of 
proteins, p120ctn and β/γ-catenin [331, 332].  The nectin-afadin complex is composed of 
the Ca2+ independent nectin molecule and the PDZ afadin protein [331, 332].  AJs may 
signal by binding to growth factor receptors and modulate their downstream pathways 
and internalization, recruit transcriptional co-factors, and activate signaling mediators 
[331, 332].  Furthermore, AJs play a vital role during development and appear to be 
dynamic structures during morphogenesis and in resting cells [331, 332].   
 TJs functions as a permeability barrier and separates the apical and basolateral 
membrane domains [333]. The biosynthesis of TGs is affected by various signal 
transduction pathways.  Proteins including G proteins, PLC, calmodulin and second 
messengers including Ca2+ and cAMP are important for the assembly of TJs [323].  Three 
major classes of integral membrane proteins exist at TJs of epithelial and EC.  The first 
class consist of tricellulin, claudins, and occludin all of which contain cytoplasmic N-
terminal and C-terminal domains, two extracellular loops, and four transmembrane 
domains [323, 333].  Claudins constitute the TJ intercellular strands and mediate calcium 
independent cell-cell adhesion  [323, 333].  Claudins directly interact with peripheral 
PDZ domain containing zonula occluden (ZO) proteins, including ZO-1, ZO-2, and ZO-3 
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[323, 333].  The ZOs belong to the membrane associated guanylylkinase (MAGUK) 
family of proteins, which contain a core structure of at least one PDZ domain, a SH3 
domain, and a guanylylkinase (GUK) domain [334].  In addition to being present at the 
TJs of epithelial and EC, ZOs are also present in nonepithelial cells such as astrocytes, 
fibroblasts, and Schwann cells [335].  Mammalian ZOPs consist of ZO-1, ZO-2, and ZO-
3 proteins.  ZO-1, a 220 kDa protein and is highly homologous to ZO-2, a 160-kDa 
protein, and two proteins were found to co-precipitate in epithelial cells [333, 335, 336].  
However, the C-terminus of ZO-1 and ZO-2 diverges at the C-terminus and ZO-2 
contains an alternatively spliced region, the β-motif [333, 337].  As previously 
mentioned, the AHNAK1 protein was shown to co-localize with ZO-1 in EC with blood-
brain properties [232].  ZO-3, a 130-kDa protein, which was originally described as p130, 
shows high homology to ZO-1 and ZO-2 but contains a unique proline-rich region [333, 
334].  ZO-3 directly interacts with ZO-1 and the cytoplasmic domain of occludin, but not 
ZO-2 [333, 334].  Occludin may serve a role in the regulation of various signaling 
cascades attributed to the formation of TJs.  At the TJ occludin directly interacts with the 
ZO-1, ZO-2, and ZO-3 proteins [333].  Occludin indirectly interacts with the actin 
cytoskeleton and junctional adhesion molecules (JAMs) by interacting with ZO proteins 
[333].  JAMs contain a single transmembrane domain, a cytoplasmic tail, and an 
extracellular domain, which contain two Ig-like motifs [333].  The second class consists 
of Ig-SF members and include JAM-A, CAR, CLMP, ESAM, and JAM4, all of which 
contain two Ig-like domains [323, 333].  The third class consists of a homologue of the 
Drosophila Crumbs proteins, Crumbs3 (CRB3), which contains a short extracellular 
domain and a short cytoplasmic domain  [323, 333].  In addition to interacting with 
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claudins, occludin, and junctional adhesion molecule the ZOPs also associate with 
various cytoplasmic proteins of less defined function [333, 338-340]. 
 
RGM1 
The rat gastric mucosal (RGM1) cell line (Figure 7C), established by Dr. H. 
Matsui at the Institute of Physical and Chemical Science (RIKEN) Cell Bank and 
Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan are 
nontransformed and immortalized gastric surface epithelial cells [341].  RGM1 cells were 
found to be an excellent model to investigate gastric epithelial restoration in vitro [342]. 
 
3T3-L1 
 The establishment of the 3T3-L1 mouse cell line from a continuous strain of 3T3 
cells by Green and colleagues is a commonly used model to study adipocyte physiology 
[343-345].  Undifferentiated, or 3T3-L1 preadipocytes have a fibroblast-like morphology 
(Figure 7D), but can be differentiated to have an adipocyte-like phenotype and 
morphology with the signet ring appearance of adipose cells.  3T3-L1 adipocytes 
recapitulate many of the endocrine and metabolic functions of mature adipocytes in vivo 
[343-345].  Differentiated 3T3-L1 cells (Figure 7D) are sensitive to lipogenic and 
lipolytic hormones and drugs, including insulin, epinephrine, and isoproterenol [343].  
3T3-L1 cells can be spontaneously converted into adipocytes when maintained in culture 
with fetal bovine serum alone [345].  Alternative means of triggering spontaneous 
differentiation of fibroblasts into adipocytes include the expression of constitutively 
active Akt kinase [346], bisphenol A treatment.  The most effective method to induce 
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differentiation is to treat confluent cultures of 3T3-L1 cells with a combination of insulin, 
DEX, and MIX [347].   
  
AoSMC 
 Vascular smooth muscle cells (VSMCs) are important for providing structural 
support .  VSMCs are characterized by the expression of various smooth muscle isoforms 
of structural genes involved in contraction, including smooth muscle myosin heavy 
chains (smMHCs), smooth muscle calponin (smCalponin), smooth muscle α-actin (smα-
actin), smooth muscle myosin light chain kinase (smMLCK), and α-tropomyosin [348, 
349].  The proliferation, differentiation or change in regulation of VSMCs may contribute 
to the pathogenesis of atherosclerosis, restenosis and diabetic angiopathy [350].  Human 
aortic vascular smooth muscle cells (AoSMCs) are shown in Figure 7E. 
 
Recombinant Proteins 
 Manufactured proteins are useful for various biomedical applications including 
small molecule drug discovery and the production of therapeutic proteins and vaccines 
[351].  A renewable source of protein is also useful for other applications such as 
antibody generation and purification [352], protein structure determination [353], protein-
protein interactions studies [354], and post-translational modifications studies.  Recent 
advancements leading to the better understanding of transcription, translation, and protein 
folding in Escherichia coli (E. coli) has made it the system of choice for recombinant 
protein production.   
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Production of recombinant proteins involves subcloning the gene of interest into 
an expression vector that is under the control of an inducible promoter.  High-throughput 
purification of human proteins from bacteria has been accomplished [355].  Advantages 
of using a bacterial system for protein production include rapid growth, high protein 
yields, practicality, and lower cost compared to mammalian, insect, or yeast cultures.  
Shortcomings of using a bacterial system for protein production include the lack of 
specialized post-translational modifications, the absence of eukaryotic chaperones, the 
lack of specific co-factors, the inability of the protein to form complexes or associations 
with other proteins, and the failure of the protein to be targeted to subcellular locations.  
One or a combination of these limitations may contribute to protein aggregation and/or 
protein mis-folding.  Furthermore, membrane proteins such as receptors often pose 
difficulties in the expression and purification of bacterial systems because of their 
hydrophobicity [356, 357].  A number of different approaches to manipulate various 
expression parameters are commonly used to circumvent these problems.  For example, 
reducing the cultivation temperature, reducing the amount of expression inducer, and the 
co- expression of various chaperones are common strategies to minimize protein 
misfolding [358].  A typical approach to enhancing the solubility of the overexpressed 
protein in the host bacteria is the incorporation of a solubility enhancing tag such as 
maltose binding protein (MBP), thioredoxin (Trx), and GST [355, 359, 360].  Additional 
advantages of inclusion of a fusion tag include the larger size fusion protein containing a 
greater number of potentially immunogenic epitopes for antibody generation [361], a 
means of purification, and the ability to immobilize the fusion protein in various assays.                          
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 The overexpression of foreign proteins in bacteria usually results in the 
production of insoluble aggregates termed inclusion bodies (IBs).  IBs are the result of an 
unbalanced equilibrium between solubilization and in vivo protein aggregation [362].  
The formation of inclusion body proteins are often thought to be biologically inactive and 
therefore discarded.  However, multiple reports have suggested that aggregation of 
bacterial inclusion bodies does not imply biologically inactivation of proteins [363, 364].  
In fact, the incorporation of the overexpressed foreign protein into bacterial inclusion 
bodies has been described to be advantageous for several reasons [360].  The 
recombinant protein may be protected from proteolysis within the inclusion bodies, 
enriched in the inclusion bodies, and may not be lethal to the host cell when 
overexpressed.  There have been numerous reports of refolding of various proteins 
including enzymes and receptors form bacterial inclusion bodies.  Kiefer et al. reported 
efficient refolding of GST-GPCR-His fusion proteins from bacterial inclusion bodies 
[365].  The procedure involved solubilization of the inclusion body fusion protein 
complex, transfer into a neutral detergent, thombin cleavage of the GST, and purification 
on a nitrilotriacetic acid column [365].  Frangioni and Neel reported efficient recovery of 
enzymatically active nontransmembrane tyrosine phosphatase GST fusion proteins from 
bacterial inclusion bodies [366].  The procedure involved solubilizing the fusion proteins 
with an empirically determined molar ratio of the ionic detergent N-laurylsarcosine 
(sarkosyl) and the non-ionic detergent Trition X-100 and purification over glutathione 
agarose beads.   In one report, the complexity of  inclusion body aggregates were 
analyzed and separated into subclasses based on their mass [367].  The aggregates of 
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lower complexity were found to be more efficiently recovered in the presence of 
molecular chaperones.   
 The main disadvantages of using a bacterial system for overexpressing a foreign 
protein of interest include the loss of posttranslational modifications and protein folding.  
The distinct differences in protein processing between bacterial and eukaryotic systems 
contribute to the lack of conservation of posttranslational modifications and protein 
folding of eukaryotic proteins when overexpressed in a bacterial system.  Membrane 
proteins are overexpressed in the cytoplasmic membrane of bacteria, while they are 
overexpressed in the endoplasmic reticulum membrane of eukaryotes [368].  Also, the 
rate of polypeptide elongation and the rate of protein folding are considerably higher in 
prokaryotes than in eukaryotes, which may contribute to protein misfolding [368].  
Differences in lipid composition and lack of chaperone proteins between prokaryotic and 
eukaryotic systems may also contribute to protein misfolding [368].  Glycosylation is 
often required for correct folding of eukaryotic membrane proteins, but bacterial cells 
such as E. coli do not have the ability to glycosylate proteins [368].  The lack of 
chaperone proteins, glycosylation machinery, differences in lipid compositions, and the 
lack chaperone proteins does not eliminate bacterial cells from being used as a host for 
the production of functional eukaryotic membrane proteins [368].  If desired, it is 
possible to utilize active kinases to posttranslational modify the protein in vitro after 
expression and purification from bacterial cells.  Similarly, it is possible the target protein 
may spontaneously adopt its native confirmation after being expressed and purified from 
the bacterial cells, since its structure is largely determined by its amino acid sequence.  In 
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other cases, artificial membranes may be used to induce folding of certain membrane 
proteins overexpressed in bacterial cells.          
 
Table 1.  Natriuretic Peptides and their receptors in disease 
Genotype Phenotype Reference  
ANP/BNP ++  Arterial hypotension   [44] 
ANP -/-  Salt-sensitive hypertension,   [46] 
pulmonary hypertension 
BNP -/-  Cardiac fibrosis    [46] 
CNP -/-  Dwarfism    [37] 
NPRA ++  Arterial hypotension   [45] 
NPRA -/-  Cardiac hypertrophy and fibrosis, [47, 48]  
 salt-resistant hypertension 
NPRB -/-  Seizure attacks, infertility  [37] 
NPRC -/-  Hypotension, skeletal deformations [49] 
 
Phenotypes seen in mouse models.   ++ represents overexpression, -/- represents deletion 
 
 
 
Table 2.  Protein expression of natriuretic peptide receptors in various cell lines 
Cell line Assay NPRA NPRB NPRC 
NIH 3T3  WB   +  +  ++ 
3T3-L1   WB/IHC  +  +  ++ 
RGM1   WB/IHC  -  -  +++ 
A-10   WB   +++  +  +++ 
AoSMC  WB/IHC  +++  +++  ++ 
HeLa   WB/IHC  ++  +++  +++ 
PANC   WB   ++  ++  ++ 
HEK 293  WB   +  +  ++ 
αTC1   WB   +  +  ++ 
AR42J   WB   +  +  + 
BON   WB   +  +  + 
HCT-15  WB   +  +  ++ 
HCC-1428  WB   +  +  + 
HPAC   WB   +  +  + 
KATO III  WB   +  +  + 
Min6   WB   +  +  ++ 
MS1VEGF  WB   +  +  + 
NCI-N87  WB   +  +  + 
SHP-77   WB   +  +  ++ 
 
+ represents low, ++ represents moderate, and +++ represents high immunoreactivity using 
polyclonal anti-NPRA, NPRB, or NPRC antibodies.  
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Table 3.  Location of the gene coding for the NPRs 
   Mouse Rat Human 
NPRA  3 47.6 cM  2q34  1q21-q22 
NPRB  4 21.5 cM  5q22  9p21-p12 
NPRC  15 6.7 cM  2q16  5p14-p13 
 
 
 
 
 
 
 
Central Hypothesis:  NPRC is an atypical G protein coupled receptor that associates with  
 various proteins, and plays an important role in signal transduction. 
 
Specific Aim #1:  To identify novel NPRC protein binding partners in various cell lines. 
 
Specific Aim #2:  To confirm the molecular association and identify the specific  
 interacting domains between NPRC and arrestins and AHNAK1 
 
Specific Aim #3:  To determine the role of NPRC in AHNAK1 mediated calcium  
 signaling 
 
Specific Aim #4:  To characterize the phosphorylation state of NPRC 
 
Specific Aim #5:  To identify novel or putative roles of AHNAK1   
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Figure 1. Amino acid structure of the natriuretic peptides. ANP
(28 amino acids), BNP (32 amino acids), CNP (22 amino acids),
and DNP (38 amino acids) share a similar 17-amino acid
disulfide ring structure
COOH
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CFigure 2.  Paradigm of natriuretic peptide synthesis and release 
A:   ANP;  B:  BNP;  C:  CNP
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Figure 3. Topology of the natriuretic peptide receptors
(NPRs). NPRA, NPRB, and NPRC are single
transmembrane spanning receptors and each contains a large
extracellular ligand binding domain (LBD). NPRA and –B
contain a kinase homology domain (KHD), hinge region
(HR), and a guanylyl cyclase domain (GCD). NPRC is
devoid of the KHD, HR, and GCD. Instead, NPRC contains
a short 37 amino acid (a.a.) intracellular domain.
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Figure 4. Diagram showing the role of G proteins in signal
transduction. Receptors signaling through Gq activate PLC
enzymes resulting in the hydrolysis of phosphatidylinositol-4,5-
bisphosphate (PIP ) generating diacylglycerol (DAG) and2 ,
inositol-1,4,5-triphosphate (IP3). IP3 binds to receptors of
intracellular stores and Ca2+ is released. The second messengers
Ca2+ and DAG bind to and activate PKC. Receptors signaling
through Gi inhibit adenylyl cyclase, resulting in decreased levels
of cAMP, and decreased activity of PKA. Receptors signaling
through Gs activate adenylyl cyclase resulting in increased levels,
of cAMP, and increased activity of PKA.
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Figure 5.  Reactions catalyzed by (A) adenylyl cyclase and (B) 
phospholipase C
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Figure 6. Role of the second messengers IP3, DAG, and Ca2+
in the phosphatidylinositol system. After hormone binds to a
specific receptor, the receptor-hormone complex catalyzes
GTP-GDP exchange on Gq, and activates it. Active Gq
activates PLC, which then cleaves phosphatidyl-inositol 4,5-
bisphosphate to IP3 and DAG. IP3 binds to specific receptors
2on the endoplasmic reticulum, releasing sequestered Ca +. DAG
and Ca2+ activates PKC at the plasma membrane PKC
phosphorylates proteins to produce cellular responses to the
hormone.
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Figure 7. Phase-contrast
microscopy of the cell lines
used in the various studies of
NPRC. (A) A-10 cells were
purchased from the ATCC
and culured in DMEM high
glucose supplemented with 10
% FBS and maintained at 37
°C, 5% CO2 in a humidified
incubator. (B) HeLa cells
were purchased from the
ATCC and cultured in DMEM
high glucose media
supplemented with 10% FBS
and maintained at 37 °C 5%,
CO2 in a humidified
incubator. (C) RGM1 cells
were obtained from Dr.
Hirofumi Matsui and cultured
in DMEM/Ham’s F-12 growth
media supplemented with
10% FBS and maintained at
37 °C, 5% CO2 in a
humidified incubator. (D)
3T3-L1 cells were purchased
from the ATCC and cultured
in DMEM high glucose media
supplemented with 10%
newborn calf serum and
maintained at 37 °C 10% CO2,
in a humidified incubator. (E)
hAoSMC were purchased
from Lonza and cultured in in
smooth muscle growth media
supplemented with insulin,
hFGF-gentamicin/
amphotericin-B, FBS, hEFG
and maintained at 37 °C, 5%
CO2 in a humidified incubator.
For panels A-D, subconfluent
cells are shown in the left
panels and confluent cells are
shown in the right panels.
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Chapter 1: Development of a Polyclonal Antibody (JAH84) For Investigations of NPRC 
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Background  
Currently, there are very few commercially available antibodies for NPRC.  The 
few commercial antibodies against NPRC that are available demonstrate limited species 
cross-reactivity, high background, and poor applicability.  The only antibody that has 
been validated for cross-reactivity between multiple species and for use in multiple 
immunoassays including immunoprecipitation, immunoblotting, and 
immunohistochemistry is a polyclonal antibody established several years ago by 
Fujishige et al. [369].  Antibodies are useful tools to probe for protein expression, 
regulation, post-translational modification, interaction, and function.  Therefore, there 
was an urgent need to create an antibody against NPRC that was readily available and 
would crossreact with different species and could be used to perform different 
immunoassays in order to allow for various studies of NPRC.     
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Materials and Methods 
Reagents and antibodies 
All cell culture plasticware was purchased from Nalge Nunc (Rochester, NY).  
Precast gels (7.5% resolving with 4% stacking), 10X Tris-buffered saline (TBS), 
Laemmli sample buffer, Precision plus protein dual color standards, and horseradish 
peroxidase conjugated goat anti-rabbit secondary antibody were purchased from Bio-Rad 
(Hercules, CA).  Colloidal coomassie blue stain was purchased from Genomic Solutions, 
Inc. (Ann Arbor, MI).  10X phosphate buffered saline (PBS) was purchased from Fisher 
Scientific (Fair Lawn, NJ).  Protein G agarose was purchased from Upstate 
Biotechnologies (Lake Placid, NY).  Mammalian protein extraction reagent (M-PER), 
Halt Protease and Phosphatase Inhibitor, Super Signal West Pico Chemiluminescent 
Substrate, BCA (bicinchoninic acid) protein assays reagents, and Restore Western blot 
stripping buffer were purchased from Pierce (Rockford, IL).  Anti-NPRC antibody 
directed against the 37 COOH-terminal amino acids of rat NPRC was kindly provided by 
Dr. K. Omori (Kansai Medical University, Osaka, Japan) [369].  β-actin antibody and 
anti-mouse secondary antibody were purchased from Sigma (St. Louis, MO).  Hybond-C 
extra nitrocellulose membranes and Hyperfilm ECL were purchased from Amersham 
Biosciences (Piscataway, NJ).  Ponceau Red solution was purchased from Sigma.  All 
other chemicals were purchased from Sigma unless otherwise noted.  Texas Red/ FITC-
streptavidin, anti-rabbit/anti-mouse biotinylated secondary antibodies, and Vectashield 
mounting medium with or without 4’,6’-diamidino-2-phenylindole hydrochloride (DAPI) 
were purchased from Vector Laboratories (Burlingame, CA). 
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Cell Lines and Cell Culture 
Human aortic vascular smooth muscle cells (AoSMC) were purchased from 
Lonza (Walkersville, MD) and were cultured in smooth muscle cell basal medium 
(SmBM) (Lonza) supplemented with SmGM-2 SingleQuots (Lonza).  All other cell lines 
were purchased from the American type culture collection (ATCC) (Manassas, VA).  
SHP77 cells were cultured in RPMI 1640.  NIH 3T3, HEK293, CCL13, PANC, and 
HeLa cells were cultured in high glucose Dulbecco’s modified Eagle’s medium (DMEM) 
(Gibco Invitrogen; Grand Island, NY).  RGM1 cells were cultured in DMEM/F12 
Medium (Gibco).  With the exception of SmBM, all other media were supplemented with 
1X antibiotic/antimycotic (Gibco) and 10% fetal bovine serum (Atlanta Biologicals; 
Norcross, Atlanta).  All cell lines were maintained at 37°C in a 5% CO2 humidified 
atmosphere.  Only low passaged cells of less than 25 passages were used for experiments.   
 
Polyclonal Antibody Production 
 A synthetic peptide corresponding to the last 26 amino acids of the cytoplasmic 
domain of human NPRC was used as the immunogen.  The first amino acid of this 
peptide, a threonine, was replaced with a cysteine and the peptide was conjugated to 
Keyhole Limpet Hemocyanin (KLH).  White New Zealand rabbits were immunized with 
the conjugated synthetic peptide (BIO-SYNTHESIS, INC.; Lewisville, TX). 
        
SDS-PAGE and Immunoblotting  
Proteins were harvested from cells cultured in 100 mm tissue culture dishes by 
scraping and collecting the lysate in the presence of M-PER.  Proteins were harvested 
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from 50 mg pieces of tissue by moderate homogenization in the presence of tissue protein 
extraction reagent M-PER.  All protein lysates were supplemented with Halt Protease and 
Phosphatase Inhibitors.  Protein was quantified using BCA reagents and 25 μg of protein 
from cell or tissue lysate prepared in Laemmli sample buffer was loaded onto a 7.5% 
gradient polyacrylamide precast gel and subjected to SDS-PAGE for 4 hrs.  Proteins were 
electrically transferred onto nitrocellulose membranes at 100 V in Towbin buffer for 75 
minutes.  In order to confirm the transfer of proteins, membranes were stained with 
Ponceau red solution.  The membranes were destained by washing with 1X TBS and then 
blocked in 5% (w/v) nonfat milk in 1X TBS at room temperature (RT) for 1 hr.  
Membranes were washed with 1X TBS and then incubated with anti-NPRC (JAH84; 
1:1000 dilution) polyclonal antibody in 5% BSA in TBS at RT for 2 hrs.  Membranes 
were washed and then incubated with horseradish peroxidase conjugated goat anti-rabbit 
secondary antibody (1:3000 dilution) in blocking solution (5% (w/v) nonfat milk in 1X 
TBS) at RT for 1 hr.  Membranes were washed with 1X TBS and immunoreactive bands 
were detected by SuperSignal West Pico chemiluminescent substrate and developed 
using Hyperfilm-ECL.  As an internal control membranes were stripped using Restore 
Western blot stripping buffer and reprobed with anti-β-actin (1:1000 dilution) and anti-
mouse secondary antibody (1:25000 dilution).  Precision plus protein dual color standards 
were used as molecular weight markers.     
 
Immunohistochemistry of Paraffin-embedded Tissue Samples 
Paraffin embedded tissues were sectioned and mounted on Superfrost Plus (+) 
glass slides.  The slides were subject to deparaffinization, hydration, and antigen 
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retrieval.  The slides were subject to three exchanges of xylene, two exchanges of 100% 
ethanol, two exchanges of 95% ethanol, and a single exchange of 80% ethanol, 70% 
ethanol, 60% ethanol, and reagent grade water for 5 min durations.  The slides were then 
subject to a series of four microwave sessions in 10 mM citrate buffer (pH 6.0) for 5 min 
durations.  The slides were rinsed with reagent grade water for 10 min and then rinsed 
with 1X PBS for 10 min.  The slides were blocked in 8% filtered normal goat serum in 
1X PBS at RT for 30 min.  The slides were then incubated with anti-NPRC (JAH84; 
1:250) polyclonal antibody in blocking solution at RT for 90 min.  The slides were 
washed in 1X PBS and then incubated with anti-rabbit biotinylated secondary antibody 
(Vector Laboratories; Burlingame, CA) diluted in PBS and filtered normal goat serum at 
RT for 30 min.  The slides were wahed in 1X PBS and then incubated with FITC-
conjugated streptavidin (Vector Laboratories) (1:50 dilution) in 1X PBS at RT for 30 
min.  The  slides were washed, coversliped, and mounted with mounting media 
containing DAPI in Vectashield medium.        
 
Immunofluorescence of Cultured Cells 
AoSMC, SHP77, HEK293, CCL13, PANC, and HeLa cells were cultured on type 
1 collagen coated chamber slides.  At 70% confluency, cells were washed with PBS, and 
then fixed at -20 °C for 5 minutes in MeOH/Acetone (1:1).  Fixed cells were washed with 
PBS, and then blocked and stained as follows.  Slides were incubated at RT for 30 
minutes in blocking solution (8% filtered normal goat serum diluted in PBS), and then 
incubated at RT for 90 minutes with a polyclonal primary antibody (diluted in blocking 
solution).  Slides were washed and incubated at RT for 30 minutes with anti-rabbit 
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biotinylated secondary antibody.  Slides were washed and incubated at RT for 30 minutes 
in the dark in a solution of Texas Red-conjugated streptavidin (diluted in PBS).  Slides 
were incubated at RT for 30 minutes in a second blocking solution (8% filtered normal 
horse serum diluted in PBS) and then incubated at RT for 90 minutes with a monoclonal 
primary antibody (diluted in blocking solution).  Slides were washed and incubated at RT 
for 30 minutes with anti-mouse biotinylated secondary antibody.  Slides were washed and 
incubated at RT for 30 minutes in the dark in a solution of FITC-conjugated streptavidin 
(diluted in PBS).  Finally, slides were washed and coverslips were applied with mounting 
media containing DAPI in Vectashield medium. 
 
Immunoprecipitation  
Proteins were harvested from 100 mm tissue culture dishes as described above.  
After quantification by the BCA assay, 200 μg of protein was incubated with 4 μl of anti-
NPRC (JAH84) polyclonal antibody with end-over-end mixing at 4 ˚C for 2 hrs.  The 
resulting complexes were incubated with 40 μl of prewashed 50% protein G agarose 
slurry with end-over-end mixing at 4 ˚C for 4 hrs.  The immunocomplex was washed four 
times with ice cold PBS and bound proteins were eluted by boiling for 5 minutes in 
Laemmli sample buffer.  Eluted proteins were analyzed by SDS-PAGE and Coomassie 
blue staining.  
 
MS 
Gel bands were excised from Coomassie stained gels.  The gel bands were 
subjected to in-gel tryptic digestion, liquid extraction of the gel fragments, followed by 
54
LC-MS/MS on an LTQ mass spectrometer (Thermo Electron Corporation, Waltham, 
MA) with an LC packing ultimate dual gradient nano-LC system (Dionex, Sunnyvale, 
CA)  (Proteomics Department at the Moffitt Cancer Center, Tampa FL).  The Mascot 
algorithm (Matrix Science, London UK) was used to search the collected data against the 
nonredundant rodentia database at the national center for biotechnology information 
(NCBInr). 
 
Transient Transfection of FLAG-NPRC 
FLAG-NPRC was transfected into COS7 cells using Lipofectamine reagents 
(Invitrogen; Carlsbad, CA) according to the manufactures instructions.  Briefly, cells 
were seeded in 100 mm dishes and the cells were transfected after reaching 70% 
confluency.  The Lipofectamine diluted in OptiMEM medium was added dropwise to the 
plasmid DNA (10 µg/dish) diluted in OptiMEM medium and the complex was briefly 
incubated at room temperature before adding it dropwise to the cells.  Cells were 
maintained in complete growth medium and cultured for at least 48 hours before 
harvesting the cells for protein.        
 
Statistics 
Results are expressed as the mean ± SEM.  Statistical significance was set at 
p <0.05.  Student's paired t test was used to compare data from two groups.   
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Results 
Polyclonal Antibody Production 
 Multiple sequence alignments of the intracellar domain of NPRC reveals high 
homology between various different species (Figure 8).  Multiple polyclonal antibodies 
were created against NPRC (JAH84 and JAH85) (Figure 9), and each appeared to 
recognize different epitopes of the target antigen and have different crossreactivities 
among different species (Figure 9).  JAH84 and JAH85 each demonstrated a titer of 
1:12,800 and the IgG concentration of each was approximately 2.5 mg/mL after 
purification and after the addition of sodium azide.     
 
Monitoring transient transfection of Flag-NPRC to confirm specificity of JAH84  
To demonstrate specificity of JAH84, the transfection efficiency of FLAG-NPRC 
was determined by immunoblotting with JAH84 and analyzing the immunoreactive bands 
by densitometry.  COS7 cells were transfected with a FLAG-NPRC construct and the 
transfection efficiency was assessed by immunoblot and densitometric analysis using 
JAH84 or established anti-NPRC antibody.  The presence of an immunoreactive band at 
66 kDa corresponding to mock transfection, and at least a three-fold increase in a band at 
the same molecular weight, but corresponding to FLAG-NPRC was observed after 
probing with JAH84 (Figure 10).  In addition to evaluating the ability of JAH84 to be 
used in Western blotting, it was evaluated to be used in immunoprecipitation studies 
(Figure 11).  Several putative NPRC binding partners were pulled down with JAH84 
(Figure 11).  These proteins are identified in the next Chapter.          
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JAH84 confirms NPRC is the most widely and abundantly expressed NPR subtype 
 Several normal and abnormal cell lines, corresponding to various tissue origins of 
mouse, rat, and human species were screened for NPR protein expression by Western 
blot analysis and/or immunoflourescence.  While using rabbit polyclonal antibodies 
against NPRA, NPRB, or NPRC, NPRC is shown to be the most widely and highly 
expressed NPR subtype across several different cell lines of various species (Table 2).  
Western blots, performed using JAH84 show NPRC is expressed in mouse heart, lung, 
kidney, liver, and pancreas (Figure 12A) and expressed in cell lines corresponding to 
human aortic vascular muscle derived cells, small cell lung carcinoma cancer-derived 
cells, embryonic kidney derived cells, hepatocyte-derived liver cells, and pancreatic 
ductal adenocarcinoma cancer-derived cells (Figure 12B).     
 
JAH84 is applicable for immunohistochemistry analysis       
 Since antibodies are assay specific in addition to being species specific, the ability 
of JAH84 to be used in various different immunoassays was investigated.  In addition to 
being able to crossreact with NPRC proteins from various different species by Western 
blot analysis and pull-down putative NPRC binding partners by immunoprecipitation, 
JAH84 was able to detect NPRC protein in RGM1 cells by immunofluorescence (Figure 
13). 
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Discussion 
Initial attempts to produce a monoclonal antibody to NPRC were unsuccessful.  
However, multiple polyclonal antibodies to NPRC were produced and assessed for 
applicability, sensitivity, specificity, and crossreactivity.  Of these antibodies, JAH84 
detected NPRC protein by multiple immunoassays, was sensitive and specific, and cross-
reacted with multiple species.     
Polyclonal antibodies generally cost less to produce and have a much faster 
overall turnaround time for production than monoclonal antibodies.  Although polyclonal 
antibodies may be less specific, and are limited in quantity by the lifespan and size of the 
host animal, they have a wider range of potential applications than do monoclonal 
antibodies.  One advantage of using a polyclonal antibody instead of a monoclonal 
antibody in an immunoassay such as immunoprecipitation is a polyclonal antibody is 
more likely to recognize multiple epitopes of the antigen with varying affinities.  It is 
favorable to have an antibody recognize multiple epitopes while attempting to capture 
protein binding partners by immunoprecipitation.  If the antibody is capable of 
recognizing multiple epitopes it may be possible to capture a protein-protein interaction if 
one or more of the antigenic epitopes are masked by the binding sites between the 
proteins of interest.   Another advantage of using a polyclonal antibody in a typical 
immunoassay such as immunoblotting for screening cell lines or tissues for protein 
expression is there is a greater likelihood the protein of interest will be detected if it is 
readily susceptible to proteolysis or is posttranslationally modified.  Polyclonal 
antibodies are generally not homogenous in nature as are monoclonal antibodies, and 
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because they can recognize different epitopes of the antigen, slight changes of the protein 
are generally tolerated.    
 The unique cytoplasmic domain of NPRC as an immunogen was targeted because 
of the high degree of homology of the extracellular and transmembrane domains between 
NPRA, NPRB, and NPRC.  Since it is possible to predict antigenic determinants of a 
protein largely from its amino acid sequence, the entire cytoplasmic domain of NPRC 
was analyzed prior to designing the immunogen.  The cytoplasmic domain was found to 
be antigenic enough to use as an immunogen, based on various immunogenic 
determinants.  
The double bands that are present in immunoblots corresponding to some of the 
various tissue or cell lysates, indicates the JAH84 antibody detects total NPRC protein, 
including both unmodified and posttranslationally modified forms.  NPRC has been 
reported to be phosphorylated on serine residues [370], although the specific residues that 
are phosphorylated and the kinases that are responsible for phosphorylating them have 
not yet been identified.  The double bands at 66 kDa that were observed in some 
immunoblots and immunoprecipitation experiments may be attributed to NPRC 
phosphoryation, since only a single band is sometimes observed in the absence of 
phosphatase inhibitors.  Moreover, the multiple bands that were observed in Western 
blots could also be attributed to other postranlational modifications such as glycosylation.        
 The undiluted JAH84 antibody with supplemented with a bacteriostat, 0.05% 
sodium azide, to preserve its integrity.  Several different buffers were tested for dilution 
of JAH84 for immunoblotting, and determined optimal dilutions for immunoblotting, 
immunohistochemistry, and immunoprecipitation.   A typical attribute of polyclonal 
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antibodies is high background.  Antibodies that produce high background in 
immunoassays such as immunohistochemistry and immunoblotting after blocking with a 
common agent may require affinity purification prior to use.  JAH84 presented little 
background in immunostaining of cells and tissues and only a few nonspecific bands in 
immunoblotting.  There was no need to affinity purify our JAH84 antibody prior to its 
use in various immunoassays.       
 Antibodies are indispensable tools that are commonly used in several different 
applications in biological research.  As an alternative to detecting NPRC expression by 
Northern blotting, in situ hybridization, and PCR, the antibody presented in this report, 
JAH84, may be used as a valuable tool to confirm NPRC protein expression by various 
immunoassays.  JAH84 offers several attractive advantages including high sensitivity, 
high specificity, cross-reactivity between multiple species, low background, minimal 
optimization, and applicability for discovery or confirmatory purposes.    
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Figure 8. Sequence alignment of the intracellular domain of NPRC
from various species. Shaded areas indicate highly conserved
amino acid residues. The source of each of the partial sequences
shown for NPRC can be traced from the accession numbers given
on the left.
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Figure 9. Western blot analysis showing cross-reactivity
of various polyclonal antibodies against NPRC. The
immunoreactive band at 75 kDa in panel A, was further
identified as NPRC, as the band was excised and subject to
t t l i f t i id tifi ti Thmass spec rome ry ana ys s or pro e n en ca on. e
top bands in panes A, B, and C may be nonspecific.
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Figure 10. Western blot and densitometric
analysis of flag-NPRC using JAH84
ib d i i bl (A)ant o y. Representat ve mmuno ot
and densitometric analysis (B) of FLAG-
NPRC 72 hours after transient transfection
of COS7 cells. The immunoblot for actin
demonstrates equal loading.
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Figure 11. Coomassie blue stained gel (grayscale) after
immunoprecipitation of NPRC with JAH84. From left to
right (Molecular Weight Markers (MWMs), RGM1 Whole
Cell Lysate (WCL), Immunoprecipitation (IP) with JAH84,
Control (protein G agarose beads alone). Six putative
NPRC binding proteins are indicated by arrows.
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Figure 12. Western blot analysis of endogenous
NPRC t i i i JAH84 tib dpro e n express on us ng an o y.
Representative immunoblots showning endogenous
NPRC protein expression in various mouse tissues
(A) and in various human cell lines (B).
Corresponding immunoblots for actin demonstrate
equal loading. POSITIVE refers to whole cell lysate
positive control.
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Figure 13. Immunofluorescence of RGM1 cells using JAH84.
A: Negative control showing no appreciable positive staining in
the absence of specific antibody. B: Nuclear staining of (A)
with DAPI C: Strong positive staining is observed when using
JAH84 at a dilution of 1:250 D: Nuclear staining of (C) with.
DAPI.
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Chapter 2: Protein Binding Partners of NPRC 
67
Background 
 NPRC may no longer be considered a biologically silent receptor with the only 
purpose being the clearance of NPs from circulation.  As mentioned earlier, there have 
been several reports from different groups that have provided evidence of NPRC 
modulating signaling pathways through Gαi.  In order to futher investigate the role of 
NPRC in mediating signaling transduction through Gαi or independent of Gαi, a 
proteomic approach was taken to identify novel protein binding partners for NPRC in 
various cell types.  The identification of these novel protein-protein associations were 
confirmed by different methods.  The molecular associations were characterized in vitro 
before investigating their functional significance in situ, using various cell lines that 
express endogenos NPRC, as mentioned earlier.       
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Materials and Methods 
Reagents and antibodies 
In addition to the reagents and antibodies mentioned in the previous chapter, the 
following reagents and antibodies were purchased or acquired as described.  JAH84 
antibody was from our laboratory [371], β-arrestin polyclonal antibody was kindly 
provided by Dr. R.J. Lefkowitz (Howard Hughes Medical Institute and Duke University 
Medical Center, Durham, North Carolina), polyclonal AHNAK1 antibody was kindly 
provided by Dr. Hannelore Haase (Max Delbrück Center, Berlin, Germany), monoclonal 
AHNAK1 antibody was purchased from Abnova (Taipei City, Taiwan), β-actin antibody 
was purchased from Sigma (St. Louis, MO).  Hybond-C extra nitrocellulose membranes 
and Hyperfilm ECL were purchased from Amersham Biosciences (Piscataway, NJ).  All 
other chemicals were purchased from Sigma unless otherwise noted.  Collagen Type 1 
cellware culture slides were purchased from BD Biosciences (Bedford, MA).    
 
Cell Lines and Cell Culture 
 In addition to various cell lines mentioned in the previous chapter, the rat gastric 
mucosa cell line (RGM1) was acquired from Dr. Hirofumi Matsui (Riken, Japan) and 
cultured in a 1:1 mixture of Dulbecco's Modified Eagle's Medium and Ham's Nutrient F-
12 (DMEM/F12) supplemented with 10% Fetal Bovine Serum (FBS; Atlanta Biologicals) 
and 100 U/ml penicillin, 100 µg/ml streptomycin, and 25 ng/ml fungizone (GIBCO 
Invitrogen; Grand Island, NY).  Cells were grown to confluent monolayers in 100 mm 
tissue culture dishes or chamber slides at 37°C in a humidified incubator with an 
atmosphere of 5% CO2. 
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Immunoprecipitation 
Two hundred μg of total protein cell lysate was incubated with a 1:250 dilution of 
anti-β-arrestin polyclonal antibody, anti-NPRC polyclonal antibody (OMORI or JAH84 
as indicated) or anti-AHNAK1 polyclonal antibody at 4 ˚C for 2-4 hrs with end-over-end 
mixing.  Complexes were incubated with a 1:10 dilution of prewashed 50% protein G 
agarose slurry at 4˚C for 4-6 hrs with end-over-end mixing.  Beads were washed 4X with 
ice cold M-PER.  Immune complexes were eluted in 1X SDS sample buffer and analyzed 
by SDS-PAGE and Coomassie staining or Western blotting. 
 
SDS-PAGE, Western blotting, and Densitometric analyses 
SDS-PAGE and Western blotting was performed as described in the previous 
Chapter.  Densitometry of the immunoreactive bands was performed using the 
ImageQuant software version 5.2 (Molecular Dynamics, Sunnyvale, CA). 
 
Recombinant fusion protein production  
cDNA fragments encoding various AHNAK1 domains were a kind gift from Dr. 
Takashi Hashimoto (Keio University School of Medicine, Tokyo, Japan).  Domains were 
AHNAK N (residues 2-252), AHNAK M (residues 821-1330), AHNAK C1 (residues 
4646-5145), and AHNAK C2 (residues 5146-5643).  GST-AHNAK N, GST-AHNAK M, 
GST-AHNAK C1, and GST-AHNAK C2 were kindly provided by Dr. Silvère M. van der 
Maarel (Leiden University Medical Center, Leiden, Netherlands) [231].  All constructs 
were confirmed by DNA sequencing.  Plasmids were transformed into competent E. coli 
BL21 (DE3) (Amersham Biosciences) for expression.  Positive clones were grown in 
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2XYT kanamycin medium (16g/L tryptone, 10 g/L yeast extract, 5g/L NaCl, pH 7.0) at 
37 ˚C.  Isopropyl-d-thiogalactoside (IPTG) induction was performed at an optical density 
(OD600) of 0.4 by adding IPTG to a final concentration of 0.01 M.  GST-AHNAK N was 
obtained by traditional methods and GST-AHNAK M, C1, C2 were solubilized from 
inclusion bodies, as described in Chapter 4.  Bacterial cells were lysed by sonication, and 
the fusion protein was batch purified using Glutathione Sepharose 4B.  Purity of the 
fusion protein was analyzed by SDS-PAGE and Coomassie blue staining.  Identity of the 
fusion protein was confirmed by Western blotting and by mass spectrometry (MS) 
analysis (Proteomics Dept. at the Moffitt Cancer Center, Tampa FL). 
 
GST pull-down assay 
  Two hundred μg of total protein cell lysate was incubated together with 25 
μg of purified GST-β-arrestin 1, GST-β-arrestin 2, GST-AHNAK1 N, GST-AHNAK1 M, 
GST-AHNAK1 C1, or GST-AHNAK1 C2 (as described above) or 25 μg of purified GST 
protein at 4 ˚C for 2 hrs with end-over-end mixing.  The resulting complexes were 
incubated with 40 μl of prewashed 75% glutathione Sepharose slurry at 4 ˚C for 4 hrs 
with end-over-end mixing.  Beads were washed 4X with 1 mL of ice cold GST lysis 
buffer (200 mM NaCl, 20 mM Tris-Cl (pH 8.0), 1 mM ethylenediaminetetraacetic acid 
(EDTA) (pH 8.0), 0.5% Igepal CA-630, 25 μg/mL phenylethylsulfonyl fluoride (PMSF), 
2 μg/μl aprotinin, 1 μg/μl leupeptin, 0.7 μg/mL pepstatin).  Bound proteins were eluted 
with 50 μl of 20 mM reduced glutathione in 50 mM Tris-Cl (pH 8.0) and then analyzed 
by SDS-PAGE and Western blotting. 
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Overlay binding assay (far-Western) 
25 μg of cell lysate was separated by SDS-PAGE and blotted onto nitrocellulose 
membranes.  The blots were blocked in 5% BSA 1X PBS for 1 hr at RT.  The membranes 
were overlaid with purified GST or GST-NPRC (see Chapter 4) in blocking solution for 2 
hours at RT, washed with 1X PBS, and probed for GST.  A schematic of the overlay 
binding assay, or far-Western blot is illustrated in Figure 14.         
 
Mammalian two hybrid and dual-luciferase assay 
          The mammalian two-hybrid and the dual-luciferase reporter assay system 
(CheckMate; Promega, Madison, Wis) was optimized for investigating the assocaiton 
between NPRC and β-arrestins or NPRC and AHNAK1 in situ.  A schematic of the 
mammalian two hybrid assay is illustrated in Figure 15. For the mammalian two-hybrid 
assay, two positive control vectors that encode and express two proteins known to 
interact in vivo, Id and MyoD, were included in the assay kit for use as pBIND-Id 
(GAL4-Id) and pACT-MyoD (VP16-MyoD) fusion constructs.  In order to confirm the 
association between NPRC and β-arrestins or AHNAK1 in situ, pACT NPRC and pBIND 
NPRC, pACT β-arrestin1 and pBIND β-arrestin1, pACT AHNAK1 and pBIND 
AHNAK1 constructs were created as shown in Appendix B-F.  Between 48 to 72 hrs 
after transfection, the cells were lysed with 1X passive lysis buffer (Promega) and the 
activities of firefly (Photinus pyralis) and Renilla (Renilla reniformis) Luciferases were 
measured sequentially.  The activity of the firefly luciferase reporter was measured first 
by adding Luciferase assay reagent II (LAR II) to generate a luminescent signal.  After 
quantifying the firefly luminescence, the reaction was quenched, and the Renilla 
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luciferase reaction was initiated simultaneously by adding Stop & Glo® reagent to the 
same sample.  
 
Statistics 
Results are expressed as the mean ± SE of three independent experiments, as 
indicted.  Repeated measures ANOVA was conducted and statistical significance was set 
at p<0.05.  Here, by convention, *p<0.05, **p<0.005, ***p<0.0005.  Student’s t-test was 
used to compare two groups and one-way ANOVA was used to compare multiple groups. 
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Results 
The cytoplamic domain of NPRC contains consensus sequence binding motifs for β-
arrestin  
The 37 amino acid cytoplamic domain of both rat and human NPRC contains at 
least a single consensus sequence binding motif for β-arrestin, as shown in Figure 16.  
The binding motif consists of a serine or threonine residue followed by any four to five 
amino acids followed by a serine or threonine residue, (-S/TX4-5S/T) [372].  Although 
no GRK phosphorylation motifs were identified within the cytoplasmic domain of NPRC, 
several putative PKA, PKB, and PKC phosphorylation sites were identified using motif 
scanner (http://scansite.mit.edu/motifscan_seq.phtml) and NetPhos 2.0 
(www.cbs.dtu.dk/services/NetPhos) (Figure 16). 
 
NPRC associates with β-arrestin in vitro 
          Preliminary immunoprecipitation studies were performed using β-arrestin specific 
antibody to pull-down β-arrestin and its protein bind partners in A-10 VSMCs.  
Subsequent SDS-PAGE analysis of the elutants from the β-arrestin immunoprecipitation 
studies, revealed several putative protein binding partners for β-arrestin as indicated by 
Ponceau staining.  Probing the membranes with an antibody against NPRC revealed an 
immunoreactive band at 66 kDa, corresponding to NPRC (Figure 17A).  Similary, β-
arrestins were also shown to associate with NPRC in vitro in HeLa cells as indicated by 
immunoprecipitation studies (Figure 17B).  Mouse embryonic fibroblasts (MEF) lacking 
β-arrestin 1, β-arrestin 2, or both β-arrestin 1 and β-arrestin 2 were evaluated for NPRC 
expression as they could serve as a nonspecific control while performing 
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immunoprecipitation studies.  Interestingly, Western blot analysis revealed NPRC is 
expressed in each of the MEF cell lines, with the exception for MEF β-arrestin knockout 
1 (Figure 17C).     
 
The in vitro association between NPRC and β-arrestins is dependent on NPRC 
occupancy 
 Next, additional immunoprecipitation studies were performed to determine if 
NPRC associates with β-arrestin in NIH 3T3 cells and if the association was dependent 
on receptor occupancy.  NIH-3T3 cells were treated with 1 µM cANF for 0, 2, 5, and 20 
minutes before harvesting the cells for protein, in the presence of phosphatase inhibitiors 
in order to perform IP-Western blot analysis.  The association between NPRC and β-
arrestins was significantly augmented with the treatment of cANF over time, as indicated 
by increasing intensity of the immuoreactive band at 66 kDa corresponding to NPRC 
shown in Figure 18.            
 
NPRC predominantly associates with β-arrestin 1 in vitro 
 Afterwards, the ability of NPRC to associate with β-arrestins in RGM1 cells and 
specificity of the β-arrestin isoform involved in the association was investigated.  GST-β-
arrestin 1 and 2 were expressed and purified, and then used as bait proteins in GST pull-
down assays.  GST-β-arrestin 1 was found to be the predominant isoform to be associated 
with NPRC in vitro, although β-arrestin 2 was also able to pull-down NPRC in RGM1 
cells, but to a lesser extent (Figure 19).      
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NPRC associates with AHNAK1 isoform 1 
         In order to identiy other putative NPRC binding partners and to confirm the 
association between NPRC and β-arrestins, NPRC was immunoprecipitated from 
AoSMC or RGM1 cell lysates.  The elutants were electrically separated by SDS-PAGE, 
and the resulting bands from Coomassie blue stained gels were excised and subjected to 
MS analysis for protein identification.  While using either AoSMC or RGM1 cell lysates 
as a source of the prey protein, Coomassie stained gels revealed several bands 
representing putative NPRC associating proteins, including a high molecular weight 
double band above 250 kDa.  For experiments utilizing AoSMC lysate, Mascot results of 
the excised double band revealed multiple signature peptides corresponding to human 
AHNAK1 isoform 1 (Figure 21). Similarly, for experiments utilizing RGM1 lysate, 
Mascot results of the excised double band revealed multiple signature peptides 
corresponding to rat AHNAK1 isoform 1 (Figure 22).  Also, NPRC was found to 
associate with AHANK in 3T3-L1 preadipocytes (Figure 23).  The ability of at least 
AHNAK1 isoform 1 to associate with NPRC was corroborated by IP Western blot 
analysis, while utilizing a polyclonal antibody against the carboxy terminal domain of 
AHNAK1, which is known to differ between the two AHNAK1 isoforms.  A band 
corresponding to NPRC was observed after immunoprecipitating AHNAK1 with this 
antibody from AoSMC, RGM1, or 3T3-L1 lysates and probing for NPRC with a 
polyclonal antibody against the cytoplasmic domain of NPRC, as demonstrated in Figure 
21C, 22C, and 23C respectively.  
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The C1 Domain of AHNAK1 1 associates with NPRC 
      The association between NPRC and AHANK1 was corroborated in AoSMCs by 
expression and purifying GST fusion proteins specific to each of the distinct functional 
domains of AHNAK1, (i.e. AHNAK1 N (amino terminal residues 2-252), AHNAK1 M 
(central repeat unit residues 821-1330), and two carboxy terminal domains (AHNAK1 
C1, residues 4646-5145 and AHNAK1 C2, residues 5146-5643), as shown in Figure 24) 
and then performing GST pull-down assays.  Verification of molecular weight and purity 
of GST-AHNAK1N, GST-AHNAK1M, GST-AHNAK1C1, and GST-AHNAK1C2 was 
determined by SDS-PAGE followed by Coomassie blue staining and direct Western blot 
analysis for GST (Fig 24B, C).  Thereafter, in vitro GST pull-down assays were 
performed using cell lysate from AoSMCs and the purified GST-AHNAK1 fusion 
proteins.  Only GST-AHNAK1C1 was able to pull-down NPRC (Figure 24D).  In similar 
experiments, GST-AHNAK1C1 was not able to pull-down NPRA or NPRB, and in other 
experiments, NPRA and NPRB specific antibodies also failed to pull-down AHNAK1 
(Figure 25).   
 
Phosphorylation and occupancy of NPRC is not required for it to associate with 
AHNAK1           
          Unphosphorylated GST-NPRC was overlaid on nitrocellulose membranes 
containing endogenous AHNAK1 from phosphatase treated or untreated RGM1 lysate.  
In the presence or absence of phosphatase inhibitors, GST-NPRC was able to bind to 
AHNAK1 (Figure 26).  GST pull-down assays demonstrated NPRC occupancy by ligand 
was not necessary for it to associate with AHNAK1.  RGM1 cells pretreated with the 
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NPRC agonist cANF for increasing periods of time did not augment the association 
between NPRC and AHNAK1 (Figure 27).       
 
Experssion of AHNAK1, NPRs, Gαi and PLC isoforms in 3T3-L1, AoSMCs, and RGM1 
cells 
          Endogenous protein expression levels of AHNAK1 and NPRC were assessed in the 
cell lines intended for use in the investigation of the role of the association between 
NPRC and AHNAK1.  Both AHNAK1 and NPRC are coexpressed in 3T3-L1 
preadipocytes, RGM1 cells, and AoSMCs (Figure 28).  NPRA and NPRB proteins are 
expressed in 3T3-L1 preadipocytes and AoSMCs, but are not expressed in RGM1 cells 
(Figure 28).  Because AHNAK1 and NPRC are known to activate different isoforms of 
PLC, these cell lines were screened for expression of various PLC isoforms.  
Interestingly, 3T3-L1 preadipocytes, RGM1 cells, and AoSMCs do express various levels 
of endogenous PLCγ1, but do not express any appreciable levels of PLCγ2, and do 
express various levels of endogenous PLCβ3 (Figure 29).  Also, the expression of Gαi 
was investigated in these cell lines, since NPRC is known to couple to Gαi, which could 
potentially be involved in the function role between NPRC and AHNAK1.  Gαi was 
found to be expressed in HeLa cells, AoSMCs, RGM1 cells, and 3T3-L1 preadipocytes 
(Figure 29D).      
 
NPRC and AHNAK1 are differentially expressed during mouse adipogenesis 
The progression of the differentiation of 3T3-L1 cells into mature adipocytes was 
monitored every other day by phase-contrast microscopy and Oil Red O staining for the 
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accumulation of lipid droplets (Figure 30A, B).  At each corresponding day, protein 
expression of the NPRs, AHNAK1, and PPARγ were assessed by Western blot analyses.   
There were no significant changes in NPRA or NPRB protein expression during the 
course of differentiation for days 0-6 (Figure 31B, C).  However, AHNAK1 protein 
expression significantly decreased (Figure 31A, E) and NPRC protein expression 
significantly increased from days 0-6 (Figure 31D, F).  The differential regulation of 
AHNAK1 and NPRs proteins during the course of 3T3-L1 differentiation was confirmed 
in later stages of differentiation of 3T3-L1 preadipocytes and also in mouse adipose 
tissues.  NPRA and NPRB protein expression was low and constant in days 8-12, while 
NPRC protein expression was high and constant for days 8-12 of 3T3-L1 differentiation 
(Figure 32), and in adipose tissues from three different mouse donors for AHNAK1 and 
NPRs (Figure 33).   
 
Translocation of AHNAK1 from the nucleus to the plasma membrane  
     Various determinants were investigated for the translocation of AHNAK1 
from the nucleus to the plasma membrane.  The addition of PMA resulted in a subtle 
increase in AHNAK1 translocation from the nucleus to the cytoplasm (Figure 34).  A 
switch in medium containing low calcium to medium containing high calcium resulted in 
AHNAK1 translocation from the nucleus to the plasma membrane of 3T3-L1 
preadipocytes (Figure 35).  siRNA mediated knockdown of NPRC resulted in AHNAK1 
accumulation in the nucleus and less AHNAK1 associated with the plasma membrane 
(Figure 36, 37).   
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Discussion 
 Two different types of scaffolding/adaptor proteins were identified as novel 
binding partners of NPRC.  The β-arrestins, which are known to associate with the 
intracellular domains of various cell surface receptors [372] were found to associate with 
NPRC in vitro.  AHNAK1, a large and versatile protein implicated in a wide range of 
functions was also found to associate NPRC in vitro and in situ.     
 Many biological processes are governed or dependent on protein-protein 
interactions.  The interaction of two or more proteins may directly or indirectly affect 
various cellular functions by different means including altering the specificity of a protein 
for its substrate, altering the kinetic properties of an enzyme, targeting the protein for 
degradation, and coupling the protein to downstream signaling pathways.    The 
interactions between proteins arise from the physical interactions between specific 
regions on the surface of the proteins.  The association or dissociation between proteins 
may be dependent on various physiological conditions.  Protein-protein interactions may 
be stable or transient in nature and either type of interaction may be strong or weak and 
fast or slow.  Transient protein-protein interactions, which are temporary, are more 
prevalent in nature and are also more difficult to study than stable protein-protein 
interactions because the interacting proteins may dissociate during the study.  Both the 
association between NPRC and β-arrestins and the association between NPRC and 
AHNAK1 may be considered to be weak and transient.             
    The bait-prey system is commonly used to investigate protein-protein 
interactions.  By convention, the bait protein is the known protein or protein of interest 
that is used to capture the prey protein or unknown protein binding partner.  The two 
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phases of protein-protein investigations are the discovery and the confirmation phases.   It 
may be useful to use an endogenous source for the bait and/or prey proteins, in which 
both native proteins are functional to allow for physiological relevant findings.  
Conversely, it may be beneficial to use an artificial source for the bait and/or prey 
proteins to confirm a previously identified protein-protein association because it allows 
for the ability to work with a larger quantity of the protein than would normally be 
expressed in the endogenous environment, and it reduces complexities that would arise 
from additional interacting protein binding partners present in the endogenous 
environment.       
NPRC is known to couple to Gαi and participate in the activation of the PLC 
cascade and inhibition of the adenyyl cyclase cascade, but the direct association between 
NPRC and putative protein binding partners that would mediate its role in signal 
transduction cascades has not been identified.  Therefore, a proteomic approach to 
identify putative protein binding partners of NPRC was carried out in various cell lines, 
in which NPRC was shown to be expressed.  The cell lines were used as model systems 
to subsequently decipher the physiological role of NPRC and its protein binding partners.  
Initial co-IP studies identified the β-arrestins as being putative binding partners for NPRC 
in vitro.  The association between GPCRs and β-arrestins has significant implications 
because the 7TMRs represent the largest and most versatile family of membrane 
receptors.  Consequently, 7TMRs regulate metabolism, secretion, cell shape, motility 
electrical activity in response to wide range of hormones and stimuli and are therefore the 
most common target of therapeutic drugs [373]. 
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     The ability of NPRC to associate with β-arrestins could contribute to the 
regulation of NPRC protein and the regulation of NPRC signaling.  Phosphorylation and 
activation of NPRC by ligand binding may result in the recruitment and interaction of 
cytosolic β-arrestins.  The association between NPRC and β-arrestins may result in the 
complex binding to components of the clathrin endocytic machinery, leading to 
downregulation, or a decrease in the number of NPRC molecules at the cell surface.  
Alternatively, the association between NPRC and β-arrestins may result in homologous 
desensitization, as the association precludes the coupling between NPRC and Gi, leading 
to termination of signaling by G protein effectors.  Moreover, the ability of NPRC to 
associate with β-arrestins may implicate NP mediated activation of NPRC in in other 
signaling cascades in addition to AC and PLC, since β-arrestins are known to function as 
adaptor proteins.     
Since the AHNAKs, AHNAK1 and AHNAK2, are known to possess differences 
between the amino and carboxy terminal domains, the utilization of a polyclonal antibody 
against the carboxy terminal domain of AHNAK1 was expected to pull-down AHNAK1 
and not cross-react with AHANK 2 in immunoprecipitation experiments.  Although 
immunoprecipitating AHNAK1 with this antibody and probing for NPRC cannot be used 
to definitively determine the specific interacting AHNAK1 isoform, it was used to 
demonstrate the ability of at least AHNAK1 to associate with NPRC in vitro.  In order to 
identify the specific AHNAK1 isoform that associates with NPRC, NPRC was 
immunoprecipitated from AoSMC or RGM1 cell lysates and the bands on Coomassie 
blue stained gels representing putative NPRC associated proteins were excised and 
subject to MS analysis for protein identification.  The elutants from the NPRC 
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immunoprecipitation experiments may have contained AHNAK1, AHNAK2, or 
AHNAK-like proteins.  However, Mascots results revealed multiple signature peptides 
corresponding only to AHANK1, thus confirming AHNAK1 and not AHNAK 2 
associates with NPRC.   
After determining AHNAK1 associates with NPRC in vitro, GST pull-down 
assays utilizing distinct functional domains of AHANK1 as GST fusion proteins were 
performed in order to identify the specific AHNAK1 domain that associates with NPRC 
in vitro.  Although it was theoretically possible for any of the four distinct and functional 
domains of AHNAK1 to interact with NPRC, GST pull-down assays only revealed 
AHANK1 C1 as being able to pull-down NPRC from an AoSMC lysate.  Identification 
of the AHNAK1 domain that interacts with NPRC was necessary for the design and 
construction of AHNAK1 fusion proteins for investigating the role of molecular 
association in mediating calcium signaling in situ, as AHNAK1 is an extraordinary large 
protein and if used in its entirety, would most likely pose major difficulties in 
experiments involving transfection.  Therefore, only a portion of AHNAK1 containing 
several repeating units and the carboxy terminal domain of AHNAK1 were used to create 
a pBIND-AHNAK1 fusion protein.  Several repeating units of AHNAK1 were included 
because these segments are necessary for the binding and activation of PLCγ and the 
carboxy terminal domain of NPRC were included because this domain was shown to 
interact with NPRC.   
Several attributes were considered for the selection of a suitable cell line for the 
functional interrogation of the association between NPRC and AHNAK1 in situ.  In 
addition to expressing endogenous NPRC, AHNAK1, and PLCγ1 proteins, the cell line 
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needed to tolerate transfection of siRNAs for knockdown of NPRC and AHNAK1 or 
plasmid DNA for overexpression of an AHNAK1 fusion protein.  Preliminary studies for 
the optimization of transient transfection of the AHNAK1 fusion protein presented 
difficulties in RGM1 cells and in AoSMCs, while desirable transfection efficiencies were 
achieved in 3T3-L1 preadipocytes using the Fugene method.  The cell line also needed to 
tolerate loading with the calcium indicator dye Fluo-3, respond to various exogenous 
agents in the micro molar range, and be suitable for real time live cell confocal 
microscopy imaging studies for motoring changes in intracellular calcium mobilization.  
AoSMCs and 3T3-L1 cells met these requirements and responded to various exogenous 
agents used as positive controls (e.g. ET-1) or used as a loading control (e.g. ionomycin).  
However, RGM1 cells did not tolerate Fluo-3 loading nor did it respond to any of the 
positive controls or loading control. As shown in Figure 31, NPRC and AHNAK1 protein 
expression is inversely proportional over the course of differention of 3T3-L1 
preadipocytes into mature adipocytes after insulin, dexamethasone, and IBMX treatment. 
While both NPRC and AHNAK1 proteins are expressed in 3T3-L1 preadipocytes and in 
the early stages of differentiation, NPRC protein is overexpressed and AHNAK1 protein 
is attenuated in mature adipocytes.  Future studies may be performed to determine if 
NPRC and AHNAK1 proteins are directly affected by insulin, dexamethasone, and 
IBMX treatment.  Since 3T3-L1 preadipocytes express both NPRC and AHNAK1 
proteins, tolerate transient transaction of siRNAs and plasmid DNA, and tolerate loading 
with Fluo-3 AM these cells were used for all in situ studies involving transient 
transfection of either siRNAs or plasmid DNA.   
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Haase et al. investigated the role of the C1 domain of AHNAK1 in the signal 
transduction pathway between the beta-adrenergic receptor and the L-type Ca2+ channel 
[374].  The association between the C1 domain of AHNAK1 and the β2 subunit was 
shown to be dependnet on PKA phosphorylation of both proteins, as the binding affinity 
decreased approximately 50% upon PKA phosphorylation of both protein partners [374].  
Haase et al. suggested that the C1 domain of AHNAK1 operates as a phosphorylation-
dependent suppressor of the L-type Ca2+ channel, and liberation of this suppression results 
in more available β2 subunit to associate with the L-type Ca2+ channel, resulting in 
enhanced current density [374].  Furthermore, in another report Haase et al. reported the 
carboxy terminal domain of AHNAK1 as the interacting domain for the regulatory β 
subunit of L-type Ca2+ channels and for F-actin and suggested that this domain links the 
Ca2+ channels to the actin-based cytoskeleton.  Lee et al. showed the M domain of 
AHNAK1, consisting of the repeating units of AHNAK1 function as a scaffolding motif 
networking PLC-gamma and PKC-alpha [239].  While considering the distinct structural 
domains of AHNAK1 and the reports of specific AHANK1 domains to interact with 
other proteins, the ability of the C1 domain of AHANK1 to associate with NPR-C is 
structurally and functionally revelvant.  It is plausible that the extraordinary size and 
conformation of AHNAK1 contributes to its distinct structural domains to be positioned 
or accessible for the direct interaction with its various protein binding partners.  For 
example, the C1 domain of AHNAK1 was found to associate presumably, with the 
intracellular domain of NPRC.  It may be expected and conceivalble for either the amino 
terminal domain or the carboxy terminal domain of AHANK1 to associate with NPRC 
and not the middle reigon of AHNAK1, since it is likely to be occupied after forming a 
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complex with PLC and PKC.  Furthermore, due to the carboxy terminal domain of 
AHNAK1 being considerably larger and containing more putative binding regions than 
the amino terminal domain of AHNAK1, it would seem more likely for the carboxy 
terminal domain of AHNAK1 to associate with NPRC than it would for the amino 
terminal domain of AHANK1 to associate with NPRC. 
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Figure 14. Schematic of the far-Western (protein overlay assay) technique.
Proteins from various cell lines/tissues, the Recombinant Fusion Protein
(RFP) that will be used to probe for putative protein-protein interactions,
and the unfused Glutathione S Transferase (GST) protein are loaded onto
separate lanes of a polyacrylamide gel so that lanes 1-6, lanes 7-12, and
lanes 13-18 are analogous. Proteins are separated by SDS PAGE and then
electrically transferred onto a Nitrocellulose Membrane (NCM). The
NCM is cut in three identical strips to allow for two far Westerns and one-
Western to be run in parallel. Two of the NCM strips are overlaid with
either RFP or GST (for far-Westerns) and the third NCM strip is incubated
with a specific antibody for the prey protein. For far-Westerns a
peroxidase conjugated anti GST antibody is used to detect an interaction
between the RFP and the prey protein. The protein interaction is
confirmed by the absence of a signal in the far-Western blot using GST as
the probe and by the presence of a signal for the prey protein in the
Western blot using a specific antibody. In this figure the 100 kDa RFP
bound to a 55 kDa prey protein present in heart, stomach, and kidney, but
not lung. As controls, the peroxidase conjugated anti-GST antibody bound
to the RFP in lane 1 and to GST at 26 kDa in lane 6.
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Figure 15. Representation of constructs used in the mammalian two
hybrid dual luciferase assay. The reporter construct is designated pG5
Luc, positive controls know to interact are designated pACT-MyoD and
pBIND-ID, negative empty vectors are designated pACT and pBIND, and
expression constructs include pACT-AHNAK1C2, pBIND-AHNAK1C2,
pACT-NPRC, and pBIND-NPRC. B. Experiments demonstrating
functionality of the assay based on the fold induction of the interaction
between pBIND-ID with pACT-MyoD compared to the controls.
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Human NPR-C
R K K Y R I T I E R R T Q Q E E S N L G K H R E L R E D S I R S H F S V A                                 
Rat NPR-C
R K K Y R I T I E R R N H Q E E S N I G K H R E L R E D S I R S H F S V A
(-S/TX4-5S/T-)(-S/TX4-5S/T-)
                              
(-S/TX4-5S/T-)
Thr 507: Ser 529: Ser 532: Ser 535:
PKC: (RXTXXR) (RXXS) (RS)                  
PKA: (RXT) (RXXS)
PKG: (RXT) (RXXS) (RXXXS)
Figure 16. Sequence alignment of the 37 amino acid
cytoplasmic domain of human and rat NPRC. Two independent
consensus sequence binding motifs for β arrestin ( S/TX4 5S/T)- - -
are shown for human NPRC and one such motif is shown for rat
NPRC. Several consensus sequences for protein kinase C, A,
and G are shown for both human and rat NPRC.
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Figure 17. In vitro IP-Western demonstrating the association
between NPRC and β-arrestins. A: A-10 VSMC; B: HeLa
cells; C: Western blot showing NPRC expression in different β-
arrestin mouse embryonic fibroblast knockouts. IgG HC refers
to the heavy chain (50 kDa) of reduced and SDS-denatured
rabbit IgG. POSITIVE refers to positive control consisting of
whole cell lysate from NIH 3T3 cells.
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Figure 18. Effect of NPRC occupancy on its association with
β-arrestins . NIH3T3 cells were treated with 1 µM cANF for
the indicated times, β-arrestin was immunoprecipitated from
the lysate, and Omori anti-NPRC antibody was used to probe
for NPRC protein. POSITIVE refers to positive control
consisting of whole cell lysate from NIH 3T3 cells.
NEGATIVE refers to negative control in which β-arrestin
specific antibody was omitted and the nonspecific binding of
the protein G agarose beads was assessed. IgG HC refers to
heavy chain of immunoglobulin G.
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Figure 19. In vitro GST pulldown assay showing specificity of β
arrestin isoforms for NPRC. GST-βArrestin1, GST-βArrestin2,
GST, or beads alone were used to pulldown NPRC from RGM1
cell lysate. The blots were probed for NPRC. POSITIVE refers
to positive control of whole cell lysate from RGM1 cells.
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Figure 20. Model illustrating the hypothesized role of β-arrestin
1/2 in mediating NPRC signaling. Natriuretic peptides bind and
activate the membrane bound phosphorylated NPRC homodimer.
Thereafter, cytosolic β-arrestin is recruited and binds to specific
consequence sequences within the C-terminal domain of
NPRC. β-arrestin is shown (blue dotted lines) to desensitize
NPRC signaling by uncoupling the receptor from Gi and further
G protein dependent signaling. The association of NPRC with β-
arrestin is shown to internalize and downregulate NPRC (orange
dotted line). The association of NPRC with β-arrestin is shown
(green lines) to activate other signaling cascades including that of
MAPK and ERK. Inhibitory guanine nucleotide-regulatory
protein (Gi) 3'-5' cyclic adenosine monophosphate (cAMP). ,
inositol triphosphate (IP3), diacylglycerol (DAG), calcium ions
(Ca2+), phospholipase C (PLC), mitogen activated protein
kinase (MAPK) and extracellular signal-regulated kinase (ERK).
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Figure 21. Molecular association of NPRC and AHNAK1 in
AoSMC. (A) Coomassie blue staining of immunoprecipitates
from AoSMC lysate using anti-NPRC antibody (JAH84)
revealed a high molecular weight double band with a
molecular weight above 250 kDa. (B) MASCOT results of the
excised double band indicated in (A) revealed multiple
signature peptides corresponding to human AHNAK1 isoform
1 (C) f i i f A S C l. IP Western o mmunoprec pates rom o M ysate
using anti-NPRC antibody probing for AHNAK1 protein (top)
or NPRC protein (bottom). In panels A and C POSITIVE
refers to positive control consisting of whole cell lysate and
NEGATIVE refers to negative control in which NPRC specific
antibody was omitted and the nonspecific binding of the
protein G agarose beads was assessed The labeled bands are.
AHNAK1 (1), NPRC (2), and IgG (3). Data are representative
of at least three independent experiments.
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Figure 22. Molecular association of NPRC and AHNAK1 in
RGM1 cells. (A) Coomassie blue staining of
imm noprecipitates from RGM1 l sate sing anti NPRCu y u -
antibody revealed a high molecular weight double band with a
molecular weight above 250 kDa. (B) MASCOT results of the
excised double band indicated in (A) revealed multiple
signature peptides corresponding to rat AHNAK1 isoform 1.
(C) IP Western of immunoprecipates from RGM1 lysate using
anti-NPRC antibody probing for AHNAK1 protein (top) or
NPRC protein (bottom). In panels A and C POSITIVE refers to
positive control consisting of whole cell lysate and NEGATIVE
refers to negative control in which NPRC specific antibody was
omitted and the nonspecific binding of the protein G agarose
beads was assessed. The labeled bands are AHNAK1 (1),
NPRC (2), and IgG (3). Data are representative of at least three
independent experiments.
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IP:  anti-NPRC
IP:  anti-NPRC
WB:  anti-AHNAK1
IP: anti-NPRC
Figure 23. Molecular association of NPRC and AHNAK1 in
3T3-L1 cells. (A) Coomassie blue stained gel and IP Western
confirming the association between NPRC and AHNAK1 in
  
WB:  anti-NPRC
3T3-L1 cells. (B) IP Western confirming the association
between NPRC and AHNAK1 in 3T3-L1 preadipocytes. In
panels A and B POSITIVE refers to positive control consisting
of whole cell lysate and NEGATIVE refers to negative control
in which NPRC specific antibody was omitted and the
nonspecific binding of the protein G agarose beads was
assessed. The labeled bands are AHNAK1 (1). Data are
representative of at least three independent experiments.
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Figure 24. Identification of AHNAK1 domains that associate
with NPRC in AoSMC cells. (A) A scheme of the molecular
structure of human AHNAK1 and the location of GST fusion
protein fragments AHNAK1 N (aa 2-252), AHNAK1 M (aa 821-
1330), and AHNAK1 C (aa 4642-5643). The C-terminal domain
was divided into two separate fragments C1 (aa 4646-5145) and
C2 (aa 5146-5643). (B) Coomassie blue staining of purified
GST-AHNAK1 domains. (C) Direct Western blot of purified
GST-AHNAK1 domains revealed the presence of a single band
for each of the purified AHNAK1 fusion proteins. (D) In vitro
GST pull-down assay using AoSMC lysate and purified GST
fusion proteins corresponding to each of the AHNAK1 domains
or GST alone showed direct interaction between GST-
AHNAK1C1 and NPRC.
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WB: AHNAK1
Figure 25. Specificity of the association
between NPRC and AHNAK1. IP-
Westerns showing NPRC and not NPRA
or NPRB specific antibodies are able to
lld AHNAK1
  
pu own
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FAHNAK1
in vitro overlay binding assay
WB:  anti-NPRC
Figure 26. The role of phosphorylation in the association between
NPRC and AHNAK1. (A) Coomassie blue staining of purified
GST-NPRC revealed the presence of a single band. (B) In vitro
overlay binding assay of rat gastric mucosa cell lysate treated with
or without phosphatase inhibitors (PI) and overlaid with GST-
NPRC d b d f GST fi d bi di f NPRCan pro e or con rme n ng o to
AHNAK1 (arrow).
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in vitro GST pull-down assay
GST-AHNAK1C1
WB: anti-NPRC
Figure 27. Effect of NPRC occupancy on the association
between NPRC and AHNAK1. In vitro GST pull-down assay
after preincubation of RGM1 cells with 1 µM cANF for the
  
indicated time intervals.
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Figure 28. Expression of endogenous AHNAK1
and NPRs proteins. HeLa, AoSMC, RGM1, and
3T3-L1 cells express endogenous AHNAK1
protein (A) and NPRC protein (D). HeLa,
AoSMC, and 3T3-L1 cells express NPRA protein
(B) and NPRB protein (C). Blots are
representative of at least three independent
experiments. POSITIVE refers to positive control
consisting of whole cell lysate from A-10 cells
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Figure 29. Expression of endogenous PLC and Gαi
proteins in various cell lines. HeLa, AoSMC, RGM1, and
3T3-L1 cells express varying level of endogenous PLCγ1
(A), no PLCγ2 (B), varying levels of PLCβ3 (C), and
i l l f G i (D) Bl t t ti f tvary ng eve s o α . o s are represen a ve o a
least three independent experiments. POSITIVE refers to
positive control consisting of whole cell lysate from NIH
3T3 cells for panels A, C, and D or whole cell lysate from
Ramos cells for panel B.
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Figure 30. Assessment of the differentiation of 3T3-L1 cells. A:
Phase-contrast microscopy. B: Oil Red O Staining at the
indicated days. C: Western blot of peroxisome proliferator-
activated receptor γ (PPARγ) protein expression as a marker of
differentition
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Figure 31. Regulation of AHNAK1 and NPR protein
expression from day 0 to 6 of 3T3-L1 cell differentiation.
AHNAK1 (A) protein expression decreases, NPRA (B) and
NPRB (C) protein expression remain constant and NPRC (D),
protein expression increases with differentiation of 3T3-L1
preadipocytes. The densitometric analysis for the decrease in
AHNAK1 protein expression is shown in panel E. The
densitometric analysis for the increase in NPRC protein
expression is shown in panel F. POSITIVE refers to positive
control consisting of 3T3-L1 whole cell lysate from day 2 of
3T3-L1 preadipocyte differentiation. Student’s t-test was used
to compare two groups. Here, by convention *P<0.05,
**P<0.005, ***P<0.0005
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Figure 32. Regulation of AHNAK1 and NPR protein
expression from day 0 to 12 of 3T3-L1 cell differentiation.
AHNAK1 (A), NPRA (B), NPRB (C), and NPRC (D)
t i i d t f th d ipro e n express on oes no ur er ecrease or ncrease
beyond day 8 of differentiation of 3T3-L1 preadipocytes.
Panel E shows PPARγ protein expression as a positive
control for differentiation of 3T3-L1 preadipocytes into
mature adipocytes.
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WB:  anti-AHNAK1
WB:  anti-NPRC
WB:  anti-PPARγ
WB:  anti-actin
Figure 33. Endogenous expression of AHNAK1 and NPRC
proteins in mouse adipose tissue. Low or no appreciable levels
of AHNAK1 protein and high levels of NPRC protein were
detected in adipose tissue from three different mouse donors.
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Figure 34. The effect of AHNAK1 translocation in response to PMA
treatment in RGM1 cells. (A) Sucrose gradient centrifugation
analysis of the translocation of AHNAK1 protein in response to PMA
treatment. (B) AHNAK1 protein demonstrates more of a
cytoplasmic distribution and less of a nuclear distribution with PMA
treatment . NPRC was probed for as a membrane marker, Lamin A/C
was probed for as a nuclear marker, and GAPDH was probed for as a
cytoplasmic marker. Blots are representative of at least three
independent experiments.
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Figure 35. Immunofluorescence showing the effect of
increased [Ca2+]e on AHNAK1 translocation in 3T3 L1-
preadipocytes. 3T3-L1 preadipocytes were initially cultured in
medium containing normal Ca2+ (1.8 mM) and were then
switched to medium containing high Ca2+ (7.2 mM) and
cultured for an additional 6 hours before fixing the cells and
staining for AHNAK1. The left column shows the merged
image the middle column shows Texas red staining for,
AHNAK1, and the right column shows nuclear counterstaining
with DAPI
108
Figure 36. Knockdown of NPRC protein in 3T3-L1
preadipocytes. A: Western blot analysis in which the arrow
indicates a marketed reduction in NPRC protein; B:
densitometric analysis of (A). MOCK refers to the use of
nontargeting siRNA instead of NPRC SMARTpool siRNA. The
top band in panel A is nonspecific and the bottom band at 66
kD d t NPRC H b ti *P<0 05a correspon s o . ere, y conven on . ,
**P<0.005, ***P<0.0005
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Figure 37. Role of NPRC knockdown on AHNAK1 subcellular
localization in 3T3-L1 preadipocytes. A: Sucrose gradient
if i l i f h l i f A A 1 icentr ugat on ana ys s o t e trans ocat on o HN K prote n
in response to NPRC knockdown. B: Densitometric analysis of
(A). NPRA was probed for as a membrane marker, lamin A/C
was probed for as a nuclear marker, and GAPDH was probed for
as a cytoplasmic marker. Blots are representative of at least
three similar independent experiments. In panel A, mock refers
to the use of nontargeting siRNAs instead of NPRC SMART
pool siRNAs. POSITIVE refers to positive control consisting of
whole cell lysate before subcellular fractionation of the lysate.
Student’s t-test was used to compare two groups. Here, by
convention *P<0.05, **P<0.005, ***P<0.0005
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Chapter 3: Role of NPRC in Signal Transduction 
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Background 
 As demonstrated in the previous chapter, NPRC associates with AHNAK1 in 
various cell types.  Both proteins are known to activate specific isoforms of PLC, as 
described earlier.  Although AHNAK1 has been implicated in calcium signaling, its 
ability to associate with and modulate various proteins directly involved in maintaining 
calcium homeostasis is dependent on AHNAK1s recruitment/translocation to the plasma 
membrane.  Therefore, the hypothesis is NPRC recruits and anchors AHNAK1 to the 
plasma membrane, where AHNAK1 serves as a receptor for AA and binds to and 
activates PLCγ1.    
Accordingly, a system to monitor transient changes in the second messenger 
downstream of the PLC signaling cascade, intracellular Ca2+, was employed to test this 
hypothesis.  After demonstrating a functional system to measure small real time changes 
in intracellular Ca2+ mobilization in live cells, the physiological role and significance of 
the association between NPRC and AHNAK1 was investigated in situ.  Furthermore, 
functional implications from the intracellular Ca2+ mobilization mediated by the 
association between NPRC and AHNAK1 were proposed for each cell type investigated.         
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Materials and Methods 
Reagents and antibodies 
In addition to the reagents and antibodies mentioned in the previous chapters, the 
following reagents and antibodies were purchased or acqueired as described.  Glass 
bottom culture dishes were purchased from MatTek (Ashland, MA).  All other cell 
culture plasticware was purchased from Nalge Nunc (Rochester, NY).  Fluo-3 AM dye 
was purchased from Molecular Probes (Eugene, OR)  All other chemicals were 
purchased from Sigma (St. Louis, MO) unless otherwise noted.  Gαi antibody was kindly 
provided by Dr. Dave Manning  (University of Pennsylvania, Philadelphia, PA), NPRA 
and NPRB polyclonal antibodies were kindly provided by Dr. David L Garbers, 
University of Texas Southwestern, Dallas, TX), PLCβ3, PLCγ1, PLCγ2, GAPDH, Lamin 
A/C, and PPARγ antibodies were purchased from Cell Signaling Technology (Danvers, 
MA).     
 
Cell lines and cell culture 
  In addition to the cell lines mentioned in the previous chapters, the 3T3-L1 cell 
line was purchased from the American Type Culture Collection (Manassas, VA).  All 
other cell culture media, antibiotic/antimycotic, and calcium-free Hank's balanced salt 
solution (HBSS) were purchased from GIBCO Invitrogen (Grand Island, NY).  Only low 
passage cells were used for experiments.   
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3T3-L1 preadipocyte differentiation 
3T3-L1 preadipocytes were cultured in high glucose DMEM Medium 
supplemented with 10% Newborn Calf Serum (NCS) (Sigma) and maintained at 37 °C in 
a 10% CO2 humidified atmosphere.  At confluency, 3T3-L1 preadipocytes were treated 
with 10 μg/mL insulin, 0.25 μM dexamethasone, and 0.5 mM 3-isobutyl-1-
methylxanthine (IBMX), cultured in high glucose DMEM Medium supplemented with 
10% FBS and maintained at 37 °C in a 10% CO2 humidified atmosphere.  Culture 
medium was replaced 48 hrs after differentiation with fresh culture medium containing 
insulin and supplemented with 10% FBS.  Culture medium was replaced every 48 hrs 
thereafter with fresh culture medium supplemented with 10% FBS 
 
Oil Red O Staining 
 3T3-L1 cells cultured to 70% confluency on chamber slides were fixed with 10% 
formalin in PBS, washed with 1X PBS, and stained for 1 hr at room temperature (RT) 
with 0.15% Oil Red O (60:40 mix of isopropanol and water).  Slides were evaluated 
microscopically for the accumulation of lipid droplets.  
 
SDS-PAGE, Western blotting, and Densitometric analyses 
SDS-PAGE and Western blotting was performed as described in Chapter 1, but 
with the following modifications.  Briefly, twenty five μg of protein was separated by 
electrophoresis for 8 hours at 25 V on 7.5% gradient polyacrylamide gels.  Separated 
proteins were electrically transferred onto Hybond-C extra nitrocellulose membranes for 
75 minutes at 100 V in Towbin buffer.  Transferred proteins were stained with Ponceau 
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solution to confirm the transfer of the bands, destained with 1X TBS, and then blocked in 
5% (w/v) nonfat powdered milk in 1X TBS at RT for 1 hour.  Membranes were washed 
with 1X TBS and then incubated with anti-AHNAK1 or anti-NPRB antibody at a dilution 
of 1:500, or anti-NPRA antibody at a dilution of 1:4000, or anti NPRC, Gαi, PLCβ3, 
PLCγ1, PLCγ2, GAPDH, Lamin A/C at a dilution of 1:1000 in 5% BSA in TBS at 4°C 
overnight.  Membranes were washed with 1X TBS and incubated with horseradish 
peroxidase (HRP)-conjugated goat anti-rabbit secondary antibody (BioRad) at a dilution 
of 1:3000 in blocking solution at RT for 60 minutes.  Immunoreactive bands were 
detected by SuperSignal West Pico chemiluminescent substrate according to the 
manufactures instructions and developed using Hyperfilm-ECL.  As a loading control, 
membranes were probed for β-actin at a dilution of 1:10000.  Densitometric analysis was 
performed as described in the previous chapter.     
 
Confocal fluorescence imaging and measurement of Intracellular Calcium 
Cells were cultured in complete growth media (containing calcium and FBS or 
NCS) in 35mm glass bottom culture dishes.  At 70% confluency, cells were made 
quiescent by serum deprivation for 6 hrs.  Cells were washed with calcium-free HBSS, 
loaded with the calcium-sensitive Fluo-3 AM dye at a final concentration of 10 μM in 
extracellular solution (complete growth media) and incubated at 37 °C for 20 minutes.  
Cells were washed with calcium-free HBSS and returned to extracellular solution 
(complete growth media unless otherwise noted) for 10 minutes to allow for de-
esterification of the dye.  A confocal imaging system (Leica) equipped with an inverted 
microscope, an Argon 488 laser, and a 63 X 1.4NA objective lens was used to record 
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calcium fluorescence at RT.  The excitation wavelength of the laser was set at 488 nm 
and the emission wavelength for monitoring fluorescence was set at 520-580nm.  Images 
were acquired at a rate of 1 frame every 2.5 seconds and recorded with LASAF software.  
A field of at least 12 cells was chosen and focused in differential interference contrast 
(DIC) mode.  After measuring baseline fluorescence for 2 minutes, 100 μl of vehicle was 
added directly to the extracellular solution and fluorescence intensity was measured for 
an additional 2 minutes.  Thereafter, 100 μl of the test agent was added and fluorescence 
intensity was measured for 2 minutes.  Cells were then stimulated with 10 μM ionomycin 
 to confirm equivalent loading. 
 
Sucrose density gradient centrifugation 
Confluent 3T3-L1 cells were harvested from 100 mm tissue culture dishes for 
protein in TES buffer (20 mM Tris HCl pH 7.4, 1 mM EDTA, 255 mM sucrose) 
supplemented with protease inhibitors.  The protein lysate was subjected to moderate 
sonication and then centrifuged at 17 000 X g for 45 min at 4 °C.  The supernatant was 
collected and contained the cytosolic fraction.  The pellet was resuspended in 0.5 mL 
TES buffer and layered on 0.3 mL of a 1.12 M sucrose cushion and then centrifuged at 
250 000 X g for 30 min at 4 °C in a TL 55 swinging bucket rotor.  The resulting 
supernatant layer was carefully removed and discarded.  The intermediate layer was 
carefully collected and contained the membrane fraction.  The bottom layer was then 
carefully removed and discarded.  The pellet was resuspended in 100 μl of TES buffer 
and contained the nuclear fraction.  Each fraction was quantified by the BCA assay and 
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subjected to SDS-PAGE and Western blot analysis using specific subcellular marker 
antibodies.  
 
Transfection of siRNA and constructs 
 3T3-L1 cells were transfected with siGenome SMARTpool reagents (Dharmacon; 
Lafayette, CO) specific for mouse NPRC, AHNAK1, or nontargeting siRNA using 
DharmaFECT3 transfection reagent (Dharmacon; Lafayette, CO) according to the 
manufacturer’s instructions.  The different siRNA used in various experiments are listed 
in Table 10.  Cells were harvested 72 hrs after transfection and protein knockdown was 
determined by Western blot and densitometric analysis.  3T3-L1 cells were transfected 
with pBINDAHNAK1 using FuGENE 6 according to the manufactures instructions.  
Cells were harvested 72 hours after transfection.  Transfection efficiency was assessed by 
performing luciferase assays according to the manufactures instructions.    
 
Statistics 
Results are expressed as the mean ± SD.  Repeated measures ANOVA was 
conducted for confocal microscopy experiments.  Statistical significance was set at 
p <0.05 
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Results 
Optimization of a system to measure intracellular Ca2+ mobilization in situ 
Endothelin-1 (ET-1) is one of the most potent endogenous vasoconstricting agents 
known [375] and is also known to bind to its receptors on vascular smooth muscle cells 
(VSMCs) and subsequently raise the intracellular free Ca2+ concentration ([Ca2+]i) [376].  
Since A-10 VSMCs have been reported to respond to ET-1 treatment with a rapid and 
transient increase in intracellular Ca2+ [377], this system was used in parallel to optimize 
a system to monitor realtime changes in intracellular Ca2+ mobilization of Fluo-3 loaded 
cells by confocal microscopy.  The addition of 1 µM of ET-1 to quiescent A-10 VSMCs 
stimulated a rapid and transient increase in intracellular Ca2+ compared to background 
fluorescence, as shown in Figure 38.  There was between a two-fold to three-fold increase 
in intracellular Ca2+ of the eight randomly selected cells, when compared to baseline 
fluorescence and after normalizing to background fluorescence.             
  
An increase in intracellular Ca2+ is observed in AoSMCs in response to exogenous AA  
Next, the human equivalent to the rat A-10 VSMC line, the AoSMC line, was 
used to investigate the effect of exogenous AA on intracellular Ca2+ mobilization.  
Quiescent AoSMCs failed to respond to 1 µM exogenous AA (Figure 39), but did 
respond with a four to ten-fold increase in intracellular Ca2+ in response to 10 µM 
ionomycin in the presence of extracellular Ca2+ (Figure 40).  Quiescent AoSMCs also 
responded with approximately a three-fold increase in intracellular Ca2+ in response to 25 
µM AA, and subsequently responded to ionomycin treatment in the presence of 
extracellular Ca2+ (Figure 40A,B).   
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Calcium is released from intracellular Ca2+ stores in response to AA in AoSMCs or 3T3-
L1 cells 
 In order to determine if the source of increase of intracellular Ca2+ in AoSMCs 
was from the release of Ca2+ from intracellular Ca2+ stores or an influx of extracellular 
Ca2+, AoSMCs were stimulated with 25 µM AA in the absence of extracellular Ca2+ and 
changes in intracellular Ca2+ were monitored over time.  The exclusion of Ca2+ from the 
extracellular medium did not affect the increase in intracellular Ca2+ in response 25 µM 
AA, as shown in Figure 41.  In order to confirm the souce of increase in intracellular Ca2+ 
was from intracellular Ca2+ stores, AoSMCs were stimulated with 1 µM of Thapsigargin 
(TG), then ionomycin (Figure 42), and followed by AA and PMA (data not recorded).  
TG stimulation inhibited the AA or PMA induced release of intracellular Ca2+ increase.   
 
Effect on intracellular Ca2+ in AoSMCs in response to increasing concentration of 
exogenous AA 
The fold increase in intracellular Ca2+ in quiescent AoSMCs did not quadruple 
after quadrupling the concentration of exogenous AA.  Only a moderate increase in 
intracellular Ca2+ in AoSMCs was observed after increasing the concentration of 
exogenous AA from 25 µM to 100 µM (Figures 40 and 43).  Interestingly, the response 
to the same concentration of ionomycin was significantly decreased after increasing the 
concentration of exogenous AA from 25 µM to 100 µM (Figures 40 and 43).       
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Effect on intracellular Ca2+ in AoSMCs in response to PMA 
 Since PMA has previously been shown to increase intracellular Ca2+ in NIH 3T3 
cells, the abilty of PMA to induce an increase in intracellular Ca2+ was evaluated in 
AoSMCs.  As shown in Figure 44, PMA was able to stimulate an increase in intracellular 
Ca2+ in AoSMCs.    
 
 Addition of cANF fails to induce an increase in intracellular Ca2+ in AoSMCs  
Since NPRC activation is known to activate PLCβ3, the ability of NPRC 
activation by ligand binding to elicit an increase in intracellular Ca2+ in AoSMCs was 
investigated.  The addition of 1 µM of the specific NPRC agonist cANF to quiescent 
AoSMCS did not result in any appreciable increase in intracellular Ca2+, but the same 
cells later responded to 10 µM ionomycin (Figure 45).       
 
Effect on intracellular Ca2+ in 3T3-L1 preadipocytes in response to AA or PMA 
 Because AoSMCs could not easily be transfected with various expression 
constructs or siRNAs, the 3T3-L1 cell line was used to assess the physiological 
significance and role of the association between NPRC and AHNAK1 in mediating the 
increases in intracellular Ca2+ in response to AA or PMA.  3T3-L1 preadipocytes 
responded with an increase in intracellular Ca2+ in response to exogenous AA (Figure 46 
and 47).   
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Calcium is released from intracellular Ca2+ stores in response to AA in  3T3-L1 cells 
 In order to determine if the source of increase of intracellular Ca2+ in 3T3-L1 
preadipocytes was from the release of Ca2+ from intracellular Ca2+ stores or an influx of 
extracellular Ca2+, 3T3-L1 preadipocytes were stimulated with 25 µM AA in the absence 
of extracellular Ca2+ and changes in intracellular Ca2+ were monitored over time.  The 
exclusion of Ca2+ from the extracellular medium did not affect the increase in 
intracellular Ca2+ in response 25 µM AA, as shown in Figure 48.  In order to confirm the 
souce of increase in intracellular Ca2+ was from intracellular Ca2+ stores, 3T3-L1 
preadipocytes were stimulated with 1 µM of TG, then ionomycin (Figure 49), and 
followed by AA and PMA (data not recorded).  TG stimulation inhibited the AA or PMA 
induced release of intracellular Ca2+ increase.   
 
 Effect on intracellular Ca2+ in 3T3-L1 preadipocytes in response to PMA 
 3T3-L1 preadipocytes were used for assessing the physiological significance 
between NPRC and AHNAK1 because they are more similar to NIH 3T3 cells and can be 
transfected with better efficiency than differentiated 3T-L1 adipocytes.  Accordingly, an 
increase in intracellular Ca2+ was observed in 3T3-L1 preadipocytes in response to PMA 
in a dose dependent manner (Figures 50, 51).     
 
siRNA mediated knockdown of NPRC results in attenuation of the observed increase in 
intracellular Ca2+ in response to PMA 
 The role of NPRC in potentiating the AHNAK1 mediated AA-dependent 
intracellular Ca2+ mobilization was demonstrated by siRNA mediated knockdown of 
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NPRC in 3T3-L1 preadipocytes.  A statistically significant decrease in intracellular Ca2+ 
in response to 25 µM PMA was observed for cells transfected with siRNA targeting 
NPRC compared to untreated cells (Figures 52 and 59).      
 
Overexpression of an AHNAK1 construct results in augmentation of the observed 
increase in intracellular Ca2+ in response to PMA 
 In order to demonstrate a role for AHNAK1 for the increase in intracellular Ca2+ 
observed in 3T3-L1 preadipocytes and to show the response was not exclusively from 
PMA or AA, an AHNAK1 construct was created and transfected into 3T3-L1 
preadipocytes (Appendix D-F, I-M).  The AHNAK1 construct, pBIND-AHNAK1, 
consisted of the carboxy terminal domain of AHNAK1 and several repeating segments of 
AHANK, and the vector itself coded for luciferse, which was used to monitor 
transfection effeciency.  A statistically significant augmentation of the increase in 
intracellular Ca2+ in response to PMA was observed in 3T3-L1 preadipocytes transfected 
with the pBIND-AHNAK1 construct compared to untreated preadipocytes (Figures 53 
and 54).    
 
siRNA mediated knockdown of AHNAK1 results in attenuation of the observed increase 
in intracellular Ca2+in response to PMA 
 The role of AHNAK1 in mediating the AA-dependent intracellular Ca2+ 
mobilization was further corroborated by siRNA mediated knockdown of AHNAK1 in 
3T3-L1 preadipocytes.  A statistically significant decreases in intracellular Ca2+ in 
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response to 25 µM PMA was observed for cells transfected with siRNA targeting 
AHNAK1 compared to untreated cells (Figures 55, 56, and 59). 
 
cPLA2 is required for the AHNAK1 mediated intracellular Ca2+ mobilization in 3T3-L1 
cells 
In order to show the increases in intracellular Ca2+ were a result of endogenous 
AA released in response to PMA, 3T3-L1 preadipocytes were pretreated with the specific 
cPLA2 inhibitor AACOCF3 for 5 minutes.  Afterwards, the cells were stimulated with 25 
µM PMA.  A significant attenuation in the response to PMA was observed when cells 
pretreated with AACOCF3 (Figures 57, 59) were compared to untreated cells (Figures 
50, 59).   
 
Addition of cANF fails to induce an increase in intracellular Ca2+ in 3T3-L1 
preadipocytes  
Since NPRC activation is known to activate PLCβ3, the ability of NPRC 
activation by ligand binding to elicit an increase in intracellular Ca2+ in 3T3-L1 
preadipocytes was investigated.  The addition of 1 µM of the specific NPRC agonist 
cANF to quiescent 3T3-L1 preadipocytes did not result in any appreciable increase in 
intracellular Ca2+, but the same cells later responded to 10 µM ionomycin (Figure 58).       
 
 
 
123
AHNAK1 translocates to the plasma membrane in response to an increase in 
extracellular Ca2+ 
 Since AHNAK1s ability to execute Ca2+ signaling is determined by its presence at 
the plasma membrane, the translocation of AHNAK1 from the nucleus to the plasma 
membrane was investigated in 3T3-L1 preadipocytes.  The switching of 3T3-L1 
preadipocytes from medium containing normal Ca2+ to high Ca2+ resulted in AHNAK1 in 
less AHNAK1 present in the nucleus, as shown by subcellular fraction studies, and 
subsequent Western blot and densitometric analysis (Figure 61A,B).  Accordingly, the 
translocation of AHNAK1 to the cytoplasm and plasma membrane resulted in abrogation 
of the increase in intracellular Ca2+ in response to PMA stimulation (Figure 62).     
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Discussion 
The role of NPRC in mediating AHNAK1 calcium signaling in the presence of 
AA was investigated in AoSMCs and in 3T3-L1 preadipocytes.  The roles of NPRC and 
AHNAK1 in the presence of exogenous AA or through PMA induced release of 
endogenous AA from lipid bilayers was investigated by monitoring real time changes in 
intracellular Ca2+ mobilization in live fluo-3 loaded quiescent cells.  The roles of NPRC 
and AHNAK1 in intracellular Ca2+ mobilization were corroborated by siRNA mediated 
knockdown of each protein or by overexpression of an AHNAK1 construct.  Moreover, 
subcellular fraction studies demonstrated NPRC plays a role in determining the 
subcellular localization of AHNAK1 protein.       
The 3T3-L1 cell line is an excellent model for the study of adipogenesis at the 
cellular level [343-345].  The results presented here suggest a functional role for NPRC 
and AHNAK1 in the regulation of mouse adipogenesis.  Interstingly, NPRC and 
AHNAK1 protein expression was shown to be inversely proportional during 
differentiation of 3T3-L1 preadipocytes into mature adipocytes.  However, the 
coexpression of NPRC and AHNAK1 proteins in the early stages of differentitaon may 
suggest a role for the association between NPRC and AHNAK1 in promoting 
adipogenesis.  Interestingly, the role of intracellular Ca2+ in 3T3-L1 preadipocytes has 
been investigated by other groups.  For example, increasing levels of intracellular Ca2+ 
were reported to have an inhibitory effect in the early stages of differentiation of 3T3-L1 
preadipocytes into adipocytes [378].  Ntambi and Takova demonstrated that Ca2+ 
mobilization repressed the synthesis of an intermediate involved in DNA replication to 
prevent the expression of transcription factors required for differentiation [378].  A report 
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by Jensen et al. provided evidence for high [Ca2+]e attenuating adipogeneis in 3T3-L1 
preadipocytes [379].  Jensen et al. reported the direct role of [Ca2+]e in attenuating 
adipogenesis in 3T3-L1 preadipocytes was in part the result of inhibition of the C/EBPα 
and PPARγ2 transcription factors [379].  Both transcription factors have been shown in 
other reports to positively modulate adipogenic gene transcription [380, 381].  This group 
also observed that increases in [Ca2+]e also interfered with the normal down-regulation of 
the transcription factor Pref-1, which is downregulated in differentiated 3T3-L1 
preadipocytes and overexpressed in undifferentiated 3T3-L1 preadipocytes [381].  Jensen 
et al. provided compelling evidence that demonstrated calcium specifically inhibited 
differentiation by showing in parallel experiments that the divalent cation MgCl2 used to 
offset the changes in osmolarity associated with the use of CaCl2 did not inhibit 3T3-L1 
differentiation [379].  Consistent with the findings of both Ntambi and Takova [378] and 
Jensen et al.[379], AHNAK1 translocation to the plasma membrane in response to 
elevated levels of extracellular calcium resulted in augmentation of intracellular calicum 
mobilization with the addition of PMA in 3T3-L1 preadipocytes (Figure 62).  Taken 
together, the results presented here may suggest the association between NPRC and 
AHNAK1 could have an inhibitory effect in the early stages of differentiation of mouse 
preadipocytes into mature adipocytes.  However, additional studies that actually monitor 
markers of differentiation, such as PPARγ expression or the accumulation of lipid 
droplets would be necessary to ascertain this theory.       
Several groups have reported increases in [Ca2+]e modulate cell proliferation of 
various cell types [382-385].  As previously mentioned, calcium plays an important role 
in cell survival and death.  Chronic elevated levels of intracellular calicum are toxic to 
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various cell types.  In accordance with findings from Jensen et al., increasing [Ca2+]e by 
itself did not chronically elevate [Ca2+]i as there was no significant change in Ca2+ 
released from intracellular stores after TG treatment [379].  Also, similar to findings from 
Jensen et al.., increasing the levels of extracellular calcium did not affect cell number or 
viability according to trypan blue staining.  Interestingly, Jensen et al. presented data that 
showed elevated levels of [Ca2+]e did not acutely or chronically impact [Ca2+]i in 3T3-L1 
preadipocytes [379].  This finding is in contrast to the finding presented here for the 
translocation of AHNAK1 to the plasma membrane upon increases in [Ca2+]e.  However, 
the AHNAK1 induced mobilization of [Ca2+]i is dependent on AA or PMA mediated 
release of AA, which was not tested in the study by Jensen et al. [379].     
Intracellular Ca2+ was reported to exert a biphasic regulatory role in human 
adipocyte differentiation and lipid filling, as increasing levels of intracellular Ca2+ were 
found to inhibit differentiation and lipid filling in the early stages and promotion of 
differentiation and lipid filling in the late stages of human adipocyte differentiation [386].  
Up to 48 hours of differentiation of human adipocyte differentiation, Shi et al. showed 
increasing Ca2+ causes a significant inhibition in PPARγ expression, but during 48 to 72 
hours of human adipocyte differentiation increasing Ca2+ causes a significant increase in 
PPARγ expression [386].  PPARγ expression was proposed to directly induce late 
differentiation gene expression, including that of fatty acid synthase (FAS), steroyl-CoA 
desaturase (SCD-1), and phosphoenol-pyruvate carboxykinase (PEPCK) [386].  
Moreover, Shi et al. proposed intracellular Ca2+ may work synergistically with various 
differentiation transcriptional factors to stimulate late differentiation gene expression 
[386].  In other reports, increases in intracellular Ca2+ from the stimulation of voltage-
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mediated calcium channels were found to promote triglyceride accumulation in mouse 
and human adipocytes by stimulating lipogenesis and suppressing lipolysis [304, 387].  
The increases in intracellular Ca2+ were found to induce the expression and activity of 
FAS and inhibit both basal and agonist-stimulated lipolysis in mouse and human 
adipocytes [387]. 
Taken together, the numerous reports in the literature describing the role for 
[Ca2+]i or [Ca2+]e in modulating rodent or human adipocyte differentiation are largely 
limited to the in vitro state.  Additional in vivo studies should be performed to 
demonstrate the role of [Ca2+]i or [Ca2+]e levels in body fat accumulation and its link to 
associated diseases.   
TG (Tg), an endoplasmic reticulum Ca2+ ATPase inhibitor is a useful means to 
test various Ca2+ dependent intracellular functions since it rapidly elevates [Ca2+]I.  Tg 
was used to test the source of increase in [Ca2+]I in response to AA or PMA in 3T3-L1 
preadipocytes transfected with NPRC or AHNAK1 specific siRNA.  After depleting 
intracellular calcium stores with Tg, the addition of exogenous AA to 3T3-L1 
preadipocytes or AoSMC failed to elicit an increase in [Ca2+]I, suggesting the source of 
increase in [Ca2+]I was from release of Ca2+ from intracellular stores and not an influx of 
Ca2+ from the extracellular solution.  Similarly, the addition of exogenous AA to either 
3T3-L1 preadipocytes or AoSMC resulted in a rapid and transient increase in intracellular 
calcium in cells cultured in the presence or absence of calcium in the extracellular 
medium, further suggesting the source of increase was from the release of Ca2+ from 
 intracellular stores.   
    The association between NPRC and AHNAK1 in human AoSMCs and the 
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observed increase in intracellular Ca2+ in response to AA or PMA seen in human 
AoSMCs may also have implications for vascular diseases attributed to vascular smooth 
muscle cell proliferation, migration, and apoptosis.  Also, it is well established that 
intracellular calcium mobilization is crucial for VSMC contractility. Vascular smooth 
muscle contraction is triggered by an increase in intracellular Ca2+ concentration [388].   
The accepted mechanism for VSMC contractility includes a series of steps, which begins 
with Ca2+ binding to calmodulin (CaM) to form the Ca2+-CaM complex.  The Ca2+-CaM 
complex binds to and activates myosin light chain kinase (MLCK).  The activated MLCK 
then catalyzes the phosphorylation of the regulatory myosin light chain (MLC), which 
triggers myosin-actin interaction, leading to the shortening of muscle and generation of 
force.  The decrease in intracellular Ca2+ results in the dephosphorylation of myosin by 
myosin phosphatase, resulting in muscle relaxation [389].  Furthermore, it was reported 
that smooth muscle contraction is regulated by Ca2+ sensitization, suggesting Ca2+ 
dependent contractions may occur at lower Ca2+ concentration than expected [390].  Ca2+ 
sensitization may result in an increase in MLC phosphorylation due to reduced activity of 
myosin phosphatase.  A major pathway for smooth muscle contraction involves an 
increase in intracellular Ca2+ from the opening of voltage-dependent L-type Ca2+ 
channels in response to membrane depolarization through high concentrations of 
extracellular K+  [391].  Another major pathway for smooth muscle contraction involves 
an increase in intracellular Ca2+ from release of Ca2+ from intracellular calcium stores 
after G-protein coupled activation of PLC in response to various agonist [391].  
Accordingly, hypercontraction is known to cause vascular diseases including increased 
systemic blood pressure, acute vasospasm, and microcirculatory ischemia [392-394].  
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Therefore, abnormal VSMC contractility may contribute to abnormal vascular tone and 
disorders of blood pressure regulation, including hypertension [395].   
The ratiometric indicators, low-affinity indicators, long-wavelength indicators, 
and indicator-dextran conjugates are among the various different types of fluorescent 
Ca2+ indicators currently available.  Fura-2 and indo-1 are the most widely used 
ratiometric indicators and both require ultraviolet excitation.  Ratiometric indicators 
produce an excitation or emission spectral shift upon ion binding and allows for 
calibration of the ratio of fluorescence intensities measured at two different wavelengths.  
The excitation of these probes only by UV light results in significantly less interference 
than fluorescent compounds excited by visible wavelength. Ratiometric indicators 
prevent variations from artifacts including photobleaching, non-uniform loading of the 
indicator, and variable cell thickness, which would contribute to misinterpretation in 
changes of Ca2+ concentrations.  Low-affinity indicators are useful for detecting 
intracellular Ca2+ levels in the micromolar range.  Low-affinity indicators have faster ion 
dissociation rates to allow for the ability to better track rapid Ca2+ flux kinetics.    Long-
wavelength indicators are useful for photoactivateable “caged” probes, and argon-ion 
laser-based confocal microscopes and flow cytometers.  Examples of long-wavelength 
indicators include fluo-3, fluo-4, rhod-2, and x-rhod-1, and the fura-2 analog fura-red   
Dextran-linked indicators are conjugated to water-soluble dextrans and exhibit long-term 
intracellular retention and little vacuolar sequestration.  Dextran-linked indicators are 
particularly useful for measuring Ca2+ concentrations in plant and fungal cells.  There are 
several selection criteria for calcium indicators including the mode of measurement, 
dissociation constant (Kd), and the form of the indicator.  The mode of measurement is 
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determined by whether qualitative or quantitative ion concentration data is desired.  The 
Kd is determined by the Ca2+ concentration range of interest.  The form of the indicator is 
determined by the method of cell loading and the requirements for intracellular 
distribution and retention of the indicator. Indicators are available in salt, acetoxymethyl 
(AM) ester or dextran form.  Some fluorescent indicators are cell impermeant, while 
others are derivatized with an AM that is cell permeable.  The AM form of the 
fluorescent indicator is designed to passively diffuse across cell membranes to inside the 
cell, where esterases cleave off the AM group leading to a cell-impermeant indicator 
[396].  Furthermore, the final intracellular concentration of the hydrolyzed Ca2+ indicator 
is dependent on factors including the concentration and type of indicator, number and 
type of cells loaded, and loading time and temperature [396].    
The Ca2+-sensitive fluorescent indicator fluo-3 was chosen to measure 
intracellular Ca2+ in situ. Fluo-3 is a newer generation of fluorescent Ca2+ indicator dyes 
that offers several advantages.  Potential problems with fluorescent indicators include 
compartmentalization, intracellular buffering, autofluorescence, autofluorescence, and 
cytotoxicity.   Fluo-3 has a higher Kd to allow for more sensitive measurements at higher 
[Ca2+]i in stimulated cells, and has a higher quantum yield to allow for  measurement of 
[Ca2+]i at lower cytosolic concentrations of the dye.  Ca2+ indicators such as fluo-3 have 
been widely used to monitor transient increases in intracellular Ca2+ due to Ca2+ release 
from intracellular stores through IP3 receptors [397-400].  Fluo 3 is especially useful for 
monitoring small changes in Ca2+ inside the cell and results in a fluorescence intensity 
increase of approximately 200 times when bound to calcium compared to unbound dye 
[401].  Confocal microscopy is often utilized to investigate localized Ca2+ fluorescence 
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events due to its small depth of field, which minimizes the accumulation of out-of-focus 
light [402].  The ability to monitor changes in intracellular Ca2+ in real-time in live fluo-3 
labeled cells by confocal microscopy allows for collection and interpretation of 
physiologically relevant data.  Although millions of cells were cultured in glass bottom 
tissue culture dishes for these experiments, under 63X magnification, a typical field 
consist of between 8-12 3T3-L1 preadipocyte cells and between 6-10 human AoSMCs 
under subconfluent conditions.  Cells were synchronized, or made quiescent prior to 
imaging or the addition of any test agent by serum deprivation for 6 hours.  Thereafter, 
the cells were loaded with the calcium indicator fluo-3 at 37 °C, washed, and then 
returned to completed growth medium and incubated at 37 °C to allow for 
deesterification of the dye.  The cells were then allowed to equilibrate at room 
temperature prior to real time confocal imaging performed at room temperature.  Cells 
were observed and focused in differential interference contrast mode, while changes in 
fluorescent intensities were measured in response to various agents.        
In order to eliminate the possibility of the vehicle eliciting the observed effect, a 
short baseline was established, the vehicle itself was added directly to the cells, and the 
cells were monitored for 2 minutes.  In each case, the vehicle, either DMSO diluted in 
HBSS without calcium or oxygen depleted water failed to elicit a response.  Thereafter, 
the test agent was added directly to the cells and another short baseline was established 
before the addition of ionomycin, which served as a loading control.  Changes in 
intracellular Ca2+ were monitored in real time and images were collected at a rate of no 
faster than 1 frame/second to prevent photobleaching.  The fluorescence intensity, 
measured in arbitrary units, in response to the test agent was normalized to the 
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background fluorescence.  In order to compensate for fluctuations due to focusing, data 
from every 25 time points were analyzed and the mean fluorescence of at least 8 
independent cells were plotted as a function of time.            
 Several factors were taken into consideration prior to the transfection of plasmid 
DNA into eukaryotic cells, in order to minimize the possibility of disrupting cellular 
mechanisms and increase the ability to generate physiologically relevant data and achieve 
high transfection efficiency.   Endotoxins are known to reduce transfection efficiency and 
subsequent protein expression levels.  The levels of endotoxins that are released during 
the cell lysis step of plasmid preparation may vary in bacterial lysates.  Endotoxin-free 
plasmid preparation kits were utlilzed to minimize the presence of endotoxins when 
transfecting plasmid DNA into mammalian cells.  Cytotoxicity, a measurement of cell 
death was monitored during the transfection of mammalian cells.  In addition to carefully 
selecting a transfection reagent characteristic of possessing low cytoxicity, the quantity of 
transfection reagent used was kept to a minimum.  Off-target effects may include 
unintended up-regulation or down-regulation of genes within transfected cells.  Of the 
various transfection reagents used (Appendix O), the nonliposomal transfection reagent 
FuGENE6® provided the highest transfection efficiency of pBINDAHNAK1 into 3T3-
L1 cells.  The use of FuGENE6® also allowed for convenient delivery of the plasmid 
DNA, as it is highly efficient both in the presence and absence of serum and reduced the 
amount of time and effort by eliminating many handling steps.  Because most DNA 
transfection reagents are incompatible with siRNA, DharmaFECT transfection reagent 
was used to transfect a pool of siRNAs into 3T3-L1 and RGM1 cells.     
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 For either transient transfection of plasmid DNA or siRNA, transfection 
efficiency was determined by fluorescent microscopy and Western blot and densitometric 
analysis.  To allow the cells to incorporate and process the plasmid DNA or siRNA, 
transfection efficiency was assessed between 48 and 72 hours after transfection.  Since 
the pBINDAHNAK1 construct codes for a luciferase gene, transfection efficiency of 
pBINDAHANK was also assessed by performing luciferase assays.  Transfection 
reactions of plasmid DNA or siRNA were performed in the absence of antibiotic and 
antimycotic, as preliminary optimization experiments demonstrated the presence of either 
antibiotic or antimycotic significant reduced transfection efficiency.  
 Due to AHNAK1’s extraordinary large size, a portion containing the carboxy 
terminal domain and several repeating units were used to create a fusion protein for 
transient transfection into mammalian cells.  The truncated AHNAK1 protein was 
subcloned into a pACT and pBIND vector to generate a VP16AHNAK1 or 
pACTAHNAK1 and GAL4AHNAK1 or pBINDAHNAK1.   The desired AHNAK1 
portion was subcloned into both the empty pACT and pBIND vectors because some 
constructs may demonstrate directionality depending on the insert.        
 Although mice completely lacking AHNAK1 do not appear to show a change in 
cardiac function, it is possible AHNAK2 may compensate for the deficiency in AHNAK1 
production.  Future studies using mouse embryonic fibroblasts deficient in AHNAK1, 
AHNAK2, and both AHNAKs will be necessary to determine the functional role and 
phenotype of AHNAK1 disregulation. Furthermore, there are no alternative spliced 
variants of AHNAK1, since AHNAK1 is encoded by an intronless gene.  The AHNAKs 
contain distinct features that allow them to function as multipurpose scaffolding proteins.  
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AHNAK1 contains a PI3 kinase-related regulatory site, while AHNAK2 contains a PDZ 
domain, and both AHNAKs contain multiple highly conserved repeating units [217].  
Another attribute of the AHNAKs that may allow them to function as scaffolding 
proteins is their ability to translocate from the nucleus to the plasma membrane of the cell 
upon various stimuli and posttranslation modification (e.g. phosphorylation).           
 
 
 
 
Table 4.  Sequences for siRNAs used in various experiments 
 
Target Sequence 
Mouse NPR3  UGGACGACAUAGUGCGCUA 
Mouse NPR3  AGCACAAGGACACGGAAUA 
Mouse NPR3 CAAGCUAAACUAAGCGUAU 
Mouse NPR3 GGUCUACAGCGACGACAAA 
Mouse AHNAK1 GUGCCACCAUCUACUUUGA 
Mouse AHNAK1 CCGUAGCUCUGAAGUGGUU 
Mouse AHNAK1 GAAGUUGCACCGUAAAGGG 
Mouse AHNAK1 UGACCCAGUUGCUGAAUAC 
Individually listed ON-TARGETplus set of siRNA reagents.  NPR3 represents NPRC.  
DharmaFECT 1 or DharmaFECT 3 transfection regents were used to deliver siRNA into 
cells.   
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ET-1
Figure 38. Response to ET-1 in A-10 VSMCs . A: Traces from
eight randomly selected cells respond to 1 µM ET-1 with a
id d i i i i ll l C 2+ h irap an trans ent ncrease n ntrace u ar a . T e trans ent
increase in intracellular Ca2+ was measured by plotting the
mean fluorescence intensity as a function of time (sec) and was
compared to background fluorescence (green trace). B: The
actual cells shown in the traces in panel A are outlined in panel
B, with the green square representing background fluorescence.
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Figure 39. Intracellular Ca2+ mobilization in quiescent AoSMC
in response to 1 µM AA. Superimposed traces showing fluo-
3 fluorescence plotted as a function of time, in which each
color trace represents an individual cell. AoSMC pre-loaded
with Fluo-3 AM were stimulated with vehicle (Veh) and then
arachidonic acid (AA) in the presence of extracellular Ca2+.
Fluorescent intensity was compared to background
fluorescence.
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Figure 40. Intracellular Ca2+ mobilization in quiescent AoSMC in response to
25 µM AA. A: Superimposed traces showing fluo-3 fluorescence plotted as a
function of time, in which each color trace represents an individual cell. B:
Line graph showing fluo-3 fluorescence intensity plotted as a function of time
f i ht ll i hi h 25 ti i t f i t d t 1or e g ce s, n w c every me po n s rom mages cap ure a
frame/second were plotted as mean+/-SE as a function of time. AoSMC pre-
loaded with Fluo-3 AM were stimulated with Veh, AA, and then ionomycin
(Ion) in the presence of extracellular Ca2+. Fluorescent intensity was
compared to background fluorescence.
138
Figure 41. Intracellular Ca2+ mobilization in quiescent AoSMC in response
to 25 µM AA in calcium free medium. A: Superimposed traces showing
fluo-3 fluorescence plotted as a function of time, in which each color trace
represents an individual cell B: Line graph showing fluo-3 fluorescence.
intensity plotted as a function of time for eight cells, in which every 25
time points from images captured at 1 frame/second were plotted as
mean+/-SE as a function of time. AoSMC pre-loaded with Fluo-3 AM
were stimulated with Veh, AA, and then Ion in the absence of extracellular
Ca2+. Fluorescent intensity was compared to background fluorescence.
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Figure 42. Intracellular Ca2+ mobilization in quiescent Aosmc in
response to 1 µM TG. A: Superimposed traces showing fluo-3
fluorescence plotted as a function of time, in which each color trace
represents an individual cell. B: Line graph showing fluo-3
fluorescence intensity plotted as a function of time for eight cells, in
which every 25 time points from images captured at 1 frame/second
were plotted as mean+/-SE as a function of time. AoSMC pre-loaded
with Fluo-3 AM were stimulated with Veh, thapsigargin (TG) and then
Ion in the absence of extracellular Ca2+. Fluorescent intensity was
compared to background fluorescence.
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Figure 43. Intracellular Ca2+ mobilization in quiescent AoSMC in response
to 100 µM AA A: Superimposed traces showing fluo-3 fluorescence.
plotted as a function of time, in which each color trace represents an
individual cell. B: Line graph showing fluo-3 fluorescence intensity
plotted as a function of time for eight cells, in which every 25 time points
from images captured at 1 frame/second were plotted as mean+/-SE as a
function of time. AoSMC pre-loaded with Fluo-3 AM were stimulated
with Veh, AA, and then Ion in the presence of extracellular Ca2+.
Fluorescent intensity was compared to background fluorescence.
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Figure 44. Intracellular Ca2+ mobilization in quiescent AoSMC in
response to 25 µM PMA. A: Superimposed traces showing fluo-3
fluorescence plotted as a function of time in which each color trace,
represents an individual cell. B: Line graph showing fluo-3 fluorescence
intensity plotted as a function of time for eight cells, in which every 25
time points from images captured at 1 frame/second were plotted as
mean+/-SE as a function of time. AoSMC pre-loaded with Fluo-3 AM
were stimulated with Veh, Phorbol 12-myristate-13-acetate (PMA), and
then Ion in the presence of extracellular Ca2+. Fluorescent intensity was
compared to background fluorescence.
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Figure 45. Intracellular Ca2+ mobilization in quiescent AoSMC in
response to 1 µM cANF. A: Superimposed traces showing fluo-3
fluorescence plotted as a function of time in which each color trace,
represents an individual cell. B: Line graph showing fluo-3 fluorescence
intensity plotted as a function of time for eight cells, in which every 25
time points from images captured at 1 frame/second were plotted as
mean+/-SE as a function of time. 3T3-L1 preadipocytes pre-loaded with
Fluo-3 AM were stimulated with Veh, des[Gln18, Ser19, Gly20, Leu21,
Gly22]-ANP(4-23)-NH2 (cANF), and then Ion in the presence of
extracellular Ca2+. Fluorescent intensity was compared to background
fluorescence.
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AA
Figure 46. Intracellular Ca2+ mobilization in quiescent 3T3-L1
preadiocytes in response to 100 µM AA. A: Superimposed
traces showing fluo-3 fluorescence plotted as a function of time,
in which each color trace represents an individual cell. B: Line
graph showing fluo-3 fluorescence intensity plotted as a
function of time for eight cells, in which every 25 time points
from images captured at 1 frame/second were plotted as
mean+/-SE as a function of time. 3T3-L1 preadipocytes pre-
loaded with Fluo-3 AM were stimulated with Veh, AA, and then
Ion in the presence of extracellular Ca2+. Fluorescent intensity
was compared to background fluorescence.
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Figure 47. Intracellular Ca2+ mobilization in quiescent 3T3-L1
preadiocytes in response to 25 µM AA. A: Superimposed traces
showing fluo-3 fluorescence plotted as a function of time, in which
each color trace represents an individual cell. B: Line graph showing
fluo-3 fluorescence intensity plotted as a function of time for eight
cells, in which every 25 time points from images captured at 1
frame/second were plotted as mean+/-SE as a function of time. 3T3-
L1 preadipocytes pre-loaded with Fluo-3 AM were stimulated with
Veh, AA, and then Ion in the presence of extracellular Ca2+.
Fluorescent intensity was compared to background fluorescence.
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Figure 48. Intracellular Ca2+ mobilization in quiescent 3T3-L1
preadiocytes in response to 25 µM AA in the absence of extracellular Ca2+.
A: Superimposed traces showing fluo-3 fluorescence plotted as a function
of time, in which each color trace represents an individual cell. B: Line
graph showing fluo-3 fluorescence intensity plotted as a function of time
for eight cells, in which every 25 time points from images captured at 1
f / d l tt d +/ SE f ti f ti 3T3 L1rame secon were p o e as mean - as a unc on o me. -
preadipocytes pre-loaded with Fluo-3 AM were stimulated with Veh, AA,
and then Ion n the abssence of extracellular Ca2+. Fluorescent intensity
was compared to background fluorescence.
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Figure 49. Intracellular Ca2+ mobilization in quiescent 3T3-L1 preadiocytes
in response to 1 µM TG. A: Superimposed traces showing fluo-3
fluorescence plotted as a function of time, in which each color trace
represents an individual cell. B: Line graph showing fluo-3 fluorescence
intensity plotted as a function of time for eight cells, in which every 25 time
points from images captured at 1 frame/second were plotted as mean+/-SE
as a function of time. 3T3-L1 preadipocytes pre-loaded with Fluo-3 AM
were stimulated with Veh, TG and then Ion in the abssence of extracellular
Ca2+. Fluorescent intensity was compared to background fluorescence.
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Figure 50. Intracellular Ca2+ mobilization in quiescent 3T3-L1
preadiocytes in response to 1 µM PMA. A: Superimposed
traces showing fluo-3 fluorescence plotted as a function of time,
in which each color trace represents an individual cell. B: Line
graph showing fluo-3 fluorescence intensity plotted as a
function of time for eight cells in which every 25 time points,
from images captured at 1 frame/second were plotted as
mean+/-SE as a function of time. 3T3-L1 preadipocytes pre-
loaded with Fluo-3 AM were stimulated with Veh, PMA, and
then Ion in the presence of extracellular Ca2+. Fluorescent
intensity was compared to background fluorescence.
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Figure 51. Intracellular Ca2+ mobilization in quiescent 3T3-L1 preadiocytes
in response to 25 µM PMA. A: Superimposed traces showing fluo-3
fluorescence plotted as a function of time, in which each color trace
represents an individual cell. B: Line graph showing fluo-3 fluorescence
intensity plotted as a function of time for eight cells in which every 25 time,
points from images captured at 1 frame/second were plotted as mean+/-SE
as a function of time. 3T3-L1 preadipocytes pre-loaded with Fluo-3 AM
were stimulated with Veh, PMA, and then Ion in the presence of
extracellular Ca2+. Fluorescent intensity was compared to background
fluorescence.
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Figure 52. Effect of NPRC knockdown on intracellular Ca2+ mobilization in
quiescent 3T3-L1 preadiocytes in response to 25 µM PMA. A:
Superimposed traces showing fluo-3 fluorescence plotted as a function of
time, in which each color trace represents an individual cell. B: Line graph
showing fluo-3 fluorescence intensity plotted as a function of time for eight
cells, in which every 25 time points from images captured at 1 frame/second
were plotted as mean+/-SE as a function of time. 3T3-L1 preadipocytes
pre-loaded with Fluo-3 AM were stimulated with Veh, PMA, and then Ion in
the presence of extracellular Ca2+. Fluorescent intensity was compared to
background fluorescence.
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Figure 53. Effect of overexpression of an pBINDAHNAK1 construct on
intracellular Ca2+ mobilization in quiescent 3T3-L1 preadiocytes in response
t 1 M PMA A S i d t h i fl 3 fl l tt do µ . : uper mpose races s ow ng uo- uorescence p o e
as a function of time, in which each color trace represents an individual cell.
B: Line graph showing fluo-3 fluorescence intensity plotted as a function of
time for eight cells, in which every 25 time points from images captured at 1
frame/second were plotted as mean+/-SE as a function of time. 3T3-L1
preadipocytes pre-loaded with Fluo-3 AM were stimulated with Veh, PMA,
and then Ion in the presence of extracellular Ca2+. Fluorescent intensity was
compared to background fluorescence.
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Figure 54. Effect of overexpression of an pBINDAHNAK1 construct on
intracellular Ca2+ mobilization in quiescent 3T3-L1 preadiocytes in response
to 25 µM PMA. A: Superimposed traces showing fluo-3 fluorescence
plotted as a function of time, in which each color trace represents an
individual cell. B: Line graph showing fluo-3 fluorescence intensity plotted
as a function of time for eight cells, in which every 25 time points from
images captured at 1 frame/second were plotted as mean+/-SE as a function
of time. 3T3-L1 preadipocytes pre-loaded with Fluo-3 AM were stimulated
with Veh PMA and then Ion in the presence of extracellular Ca2+, , .
Fluorescent intensity was compared to background fluorescence.
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Figure 55. Effect of AHNAK1 knockdown on intracellular Ca2+
mobilization in quiescent 3T3-L1 preadiocytes in response to 25 µM PMA.
A: Superimposed traces showing fluo-3 fluorescence plotted as a function
of time, in which each color trace represents an individual cell. B: Line
graph showing fluo-3 fluorescence intensity plotted as a function of time for
eight cells, in which every 25 time points from images captured at 1
frame/second were plotted as mean+/-SE as a function of time. 3T3-L1
preadipocytes pre-loaded with Fluo-3 AM were stimulated with Veh, PMA,
and then Ion in the presence of extracellular Ca2+. Fluorescent intensity was
compared to background fluorescence.
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Figure 56. Effect of AHNAK1 knockdown on intracellular Ca2+
mobilization in quiescent day 2 differentiated 3T3-L1 preadipocytes in
response to 25 µM PMA. A: Superimposed traces showing fluo-3
fluorescence plotted as a function of time, in which each color trace
represents an individual cell. B: Line graph showing fluo-3 fluorescence
intensity plotted as a function of time for eight cells, in which every 25 time
points from images captured at 1 frame/second were plotted as mean+/-SE
as a function of time. 3T3-L1 preadipocytes pre-loaded with Fluo-3 AM
were stimulated with Veh, PMA, and then Ion in the presence of
extracellular Ca2+. Fluorescent intensity was compared to background
fluorescence.
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Figure 57. Intracellular Ca2+ mobilization in quiescent 3T3-L1 preadiocytes
pretreated with AACOCF3 in response to 25 µM PMA. A: Superimposed
traces showing fluo-3 fluorescence plotted as a function of time, in which
each color trace represents an individual cell. B: Line graph showing fluo-3
fluorescence intensity plotted as a function of time for eight cells, in which
every 25 time points from images captured at 1 frame/second were plotted as
mean+/-SE as a function of time. 3T3-L1 preadipocytes pre-loaded with
Fluo-3 AM were stimulated with Veh, PMA, and then Ion in the presence of
extracellular Ca2+. Fluorescent intensity was compared to background
fluorescence.
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Figure 58. Intracellular Ca2+ mobilization in quiescent 3T3-L1 preadiocytes
in response to 1 µM cANF. A: Superimposed traces showing fluo-3
fluorescence plotted as a function of time, in which each color trace
represents an individual cell. B: Line graph showing fluo-3 fluorescence
intensity plotted as a function of time for eight cells, in which every 25 time
points from images captured at 1 frame/second were plotted as mean+/-SE
as a function of time. 3T3-L1 preadipocytes pre-loaded with Fluo-3 AM
were stimulated with Veh, cANF, and then Ion in the presence of
extracellular Ca2+. Fluorescent intensity was compared to background
fluorescence.
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Figure 59.  Comparisons of various intracellular 
Ca2+ experiments 
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Figure 60. Proposed role of NPRC in intracellular Ca2+
mobilization through AHNAK1 and AA. AHNAK1
translocates from the nucleus to the plasma membrane upon
various stimuli The C1 domain of AHNAK1 associates with.
the cytoplasmic tail of NPRC. AHNAK1 is tethered by NPRC
to the plasma membrane, where it functions as a receptor for
AA liberated from membrane phospholipid bilayers by cPLA2.
Together, AHNAK1 and AA, potentiate the release of
intracellular Ca2+ from ER stores. The highly conserved central
repeating units of AHNAK1 have been reported to bind to PKC.
PKC is known to activate cPLA2. The central repeating units of
AHNAK1 have also been reported to directly bind to and
activate PLCγ1 in the presence of AA. The activation of cPLA2
by PKC results in the release of AA, while the activation of
PLCγ1 by AHNAK1 and free AA results in the production of
IP3. IP3 triggers Ca2+ release from intracellular Ca2+ stores
through binding to IP3 receptors
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Figure 61. Western blot and densitometric analysis showing the effect of
increasing [Ca2+]e on AHNAK1 translocation in 3T3-L1 preadipocytes. A:
Western blot analysis after subcellular fraction of 3T3-L1 preadipocytes
showing less AHANK1 in the nuclear fraction and more AHNAK1 in the
membrane fraction after switching 3T3-L1 preadipocytrs from normal to
high Ca2+. B: Densitometric analysis of (A). 3T3-L1 preadipocytes were
initially cultured in medium containing normal Ca2+ (1 8 mM) and were.
then switched to medium containing high Ca2+ (7.2 mM) and cultured for
an additional 6 hours before fixing the cells and performing subcellular
fraction experiments . CTRL refers to whole cell lysate control, CYT
refers to cytosolic fraction, MEM refers to membrane fraction, and NUC
refers to nuclear fraction.
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Figure 62. Effect of increased [Ca2+]e on [Ca2+]i
bili ti i 3T3 L1 di t 3T3 L1mo za on n - prea pocy es. -
preadipocytes were initially cultured in medium
containing normal Ca2+ (1.8 mM) and were then
switched to medium containing high Ca2+ (7.2 mM) and
cultured for an additional 6 hours before loading the
cells with Fluo-3 AM and monitoring changes in [Ca2+]I.
3T3-L1 preadipocytes pre-loaded with Fluo-3 AM were
stimulated with vehicle (Veh), Phorbol 12-myristate-13-
acetate (PMA), and then ionomycin (Ion) in the
presence of extracellular Ca2+. Fluorescent intensity
was compared to background fluorescence.
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Chapter 4: Post-Translational Modifications of NPRC 
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Background  
 As mentioned earlier, NPRC undergoes various posttranslational modifications.  
However, the role of these postranslational modifications in mediating the structure 
and/or function of NPRC are either controversial or have not been thoroughly 
investigated.  Therefore, in addition to the creating and characterizing a polyclonal 
antibody against NPRC (please refer to Chapter 1), a recombinant GST-NPRC fusion 
protein was created to investigate the requirement of glycosylation for NPRC 
dimerization, identify putative phosphorylation sites of NPRC, and ascertain the kinases 
responsible for the phosphorylation.  The identification of phospho-acceptor residues and 
kinases responsible for the phosphorylation is a prerequisite for determining the 
significance of phosphorylation in context to a specific cellular process, such as NPRC 
mediated clearance of NPs from circulation, turnover of NPRC protein, and NPRC 
mediated signal transduction.  In addition, the sequence and kinetics of phosphorylation 
and dephosphorylation events can be investigated using a combination of phospho-
specific antibodies and various established methodologies.      
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Materials and Methods 
Reagents and antibodies 
 In addition to the reagents and antibodies mentioned in the previous chapters, the 
following reagents and antibodies were purchased or acquired as described.  Precast gels 
(5%, 7.5%, and 10% resolving with 4% stacking) were purchased from Bio-Rad 
(Hercules, CA).  Plasmid pGEX-4T3, E. coli strain BL21, Glutathione-Sepharose 4B 
medium, and Hyperfilm-ECL were purchased from Amersham Pharmacia Biotech 
(Piscataway , NJ). GelCode Phosphoprotein Stain Reagent Set was purchased from 
Pierce (Rockford, IL).  All other chemicals were purchased from Sigma (St. Louis, MO) 
unless otherwise noted.   
 
Cell Culture and cell lysate preparation 
Rat gastric mucosal (RGM1) epithelial cells were cultured and harvested for 
protein as previously described in Chapter 2. 
 
Plasmid construction of GST-NPRC 
GST-NPRC was prepared as previously described for GST-β-arrestins and the 
various GST-AHNAK1 domains, but with the following modifications.  The cDNA 
fragment (NM 012868) encoding rat C type natriuretic peptide receptor (rNPRC) (kindly 
provided by Dr. David Lowe, Genentech, San Francisco, CA) was subcloned into a 
pGEX4T3 expression vector between EcoR1 sites and confirmed by restriction analysis 
and DNA sequencing (Molecular Biology Core facility at the H Lee Moffitt Cancer 
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Center and Research Institute; Tampa, FL).  The reactions and parameters for subcloning 
rat NPRC into pGEX4T3 are shown in Appendix N. 
 
Preparation of competent E.coli cells 
 Competent BL21 cells were prepared using the DMSO method according to 
Chung et al. [403], with modifications.  Briefly, single colonies were used to inoculate 50 
mL LB in a 250 mL erlenmeyer flask and then grown at 37 ˚C with shaking at 225 rpm.  
Cells were grown to an OD600 of 0.4, harvested by centrifugation at 2500 g for 15 
minutes at 4 ˚C, and resuspended in 5 mL of ice cold TSS buffer (Luria–Bertani (LB) 
broth with 10% (w/v) polyethylene glycol (PEG), 5% (v/v) dimethyl sulfoxide (DMSO), 
50 mM MgCl2, pH 6.5).  Single use aliquots of the competent cells were frozen at -80 ˚C 
for use within 3 months.   
 
Expression of GST-NPRC 
The constructed expression vector was transformed into the host cell E. coli BL21 
(DE3) strain for expression.  Transformants were selected by growth on LB agar plates 
containing 100 μg/mL ampicillin.  Single isolated colonies were used to inoculate 5 mL 
of 2XYTA medium (16g/L tryptone, 10 g/L yeast extract, 5g/L NaCl, pH 7.0, containing 
100μg/mL ampicillin) and grown at 37 ˚C with shaking at 225 rpm for 12 hours.  The 
starter culture was diluted 1:100 into fresh prewarmed 2XYTA.  At an OD600 of 0.3 to 
0.6, isopropyl-d-thiogalactoside (IPTG) was added to a final concentration of 0.1 mM to 
1 mM for induction of the lac promoter.   
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Solubilization of GST-NPRC from inclusion bodies 
 Recombinant fusion protein was solubilized from inclusion bodies according to 
Frangioni and Neel (17), with modifications.  Briefly, bacterial cells were harvested at 
5000 g for 10 minutes at 4 ˚C.  The supernatant was removed and the pellet was washed 
once with a volume of ice cold 1X PBS (1/15 the original culture volume) (Table 5).  The 
pellet was resuspended in a volume of ice cold STE buffer (10 mM Tris HCl, pH 8.0, 1 
mM EDTA, 150 mM NaCl) (1/50th the original culture volume) (Table 5).  A volume of 
lysozyme from chicken egg white was added (1/5000th the original culture volume) 
(Table 5) followed by a 15 minute incubation on ice.  A volume of freshly prepared 
dithiothreitol (DTT) (1M) and Sarkosyl (10% w/v) was added (1/5000th and 1/350th the 
original culture volume, respectively) (Table 5) and then mixed by inversion three times.  
The lysate was sonicated twice for 5 second intervals and then centrifuged at 13000 rpm 
for 15 minutes to pellet cellular debris.  The supernatant was transferred to a new tube 
and a volume of 10% Triton X-100 and STE was added (1/125th and 1/25th the original 
culture volume, respectively) (Table 5) and allowed to incubate at room temperature for 
30 minutes.     
 
Batch purification of GST-NPRC 
 A volume of prewashed 50% glutathione Sepharose 4B slurry (1/100 the lysate 
volume) (Table 5) was added to the lysate and incubated at 4 ˚C for 45 minutes with end-
over-end rocking.  Bound proteins were collected by centrifugation at 500 g for 2 
minutes.  The complex was washed twice with a volume of ice cold 1X PBS (10X the 
initial slurry volume) (Table 5).  Protein was eluted by resuspending the complex in a 
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volume of elution buffer (1/1000 the culture volume) (50 mM Tris-HCl, 10 mM reduced 
glutathione, pH 8.0) (Table 5), incubating for 30 minutes at 4 ˚C with end-over-end 
rocking, and collecting the supernatant after centrifugation for 2 minutes at 500 g.  The 
elution step was repeated twice and the resulting fractions were pooled.             
 
Identification of GST-NPRC 
 Purity of the fusion protein was analyzed by SDS-PAGE and Coomassie blue 
staining using Colloidal Coomassie blue stain according to manufactures instructions 
(Genomic Solutions; Ann Arbor, MI).  The NPRC portion of the fusion protein was 
identified by indirect Western blot analysis for NPRC using a polyclonal antibody 
(JAH84) directed against the carboxy terminal tail of NPRC.  The GST portion of the 
fusion protein was identified by direct Western blot analysis for GST using peroxidase 
conjugated anti-GST polyclonal antibody (Sigma; St. Louis, MO) 
 
Estimation of MW of GST-NPRC using a molecular weight marker kit and Ferguson 
plots 
The electrophoretic mobilities of GST-NPRC and the different molecular weight 
markers were determined after subjecting them to electrophoresis on a set of gels of 
increasing polyacrylamide concentrations.  Thereafter, the retardation coefficients of each 
protein were determined from the slope of the plot of the log of the electrophoretic 
mobilities against the percent gel concentrations.  Next, the logarithm of the negative 
slope was plotted against the logarithm of the molecular weight of the fusion protein and 
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the molecular weight markers, and the resulting linear plot was used to estimate the 
molecular weight of GST-NPRC. 
 
MS of GST-NPRC 
     MS was performed to confirm the identity of the recombinant fusion protein 
(Proteomics Department at the Moffitt Cancer Center, Tampa Fl).  Briefly, the gel band 
was subjected to in-gel tryptic digestion followed by liquid extraction of the gel 
fragments.  LC-MS/MS was used to analyze collected peptides and was performed on an 
LTQ mass spectrometer (Thermo Electron Corporation, Waltham, MA) with an LC 
packings ultimate dual gradient nano-LC system (Dionex, Sunnyvale, CA).  The Mascot 
algorithm (Matrix Science, London UK) was used to search the collected data against the 
nonredundant rodentia database at the National Center for Biotechnology Information 
(NCBInr) with the following parameters:  peptide mass tolerance, 2.5 DA; MS/MS ion 
mass tolerance, 0.8 DA; allowing up to 2 missed cleavages.  Significant hits, defined by 
Mascot probability analysis and hits that exceeded the arbitrarily set acceptance threshold 
were regarded as positive identifications. 
 
Circular dichroism of GST-NPRC 
     CD spectra were obtained using a JASCO (Easton, MD) J710 spectropolarimeter 
calibrated for signal intensity and wavelength maxima using an aqueous solution of d-10-
camphosulfonic acid.  UV CD spectra were obtained in 10 mM phosphate buffer, 
containing 0.1 mM EDTA, pH 7.0, using a cylindrical quartz cell of 0.1 cm path length 
(300 µL total volume), while visible CD spectra were obtained in 10 mM MOPS buffer, 
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containing 0.1 mM EDTA, pH 7.0, using a cell of 1 cm path length (90 µL total volume). 
All spectra were corrected for the appropriate buffer contributions and expressed in terms 
of molar ellipticities (M-1 cm-1). 
 
In vitro phosphorylation of GST-NPRC 
GST-NPRC immobilized on glutathione Sepharose 4B beads was incubated with 
200 µg of RGM1 cell lysate in kinase buffer (50 mM Tris [pH 7.4], 10 mM MgCl2, 5 mM 
DTT, 2 mM ATP) for a total volume of 300 µl, and incubated at 30°C for 1 hr.  The 
beads were rinsed three times with 1X PBS before the addition of 150 µl of elution buffer 
(50 mM Tris-HCl, 10 mM reduced glutathione, pH 8.0). 
 
Detection of phosphorylated proteins 
Recombinant GST-NPRC fusion protein or RGM1 protein lysate was subjected to 
SDS-PAGE, then gels were stained using the GelCode Phosphoprotein Stain reagent set 
according to the manufactures instructions.  Alternatively, proteins were transferred to 
nitrocellulose membranes and then membranes were probed with phosphospecific and 
substrate motif antibodies to identify phosphorylation of proteins. 
 
Overlay binding assay 
Overlay binding assays were performed as described in Chapter 2, but instead the 
membranes were overlaid with purified GST or GST-NPRC in blocking solution for 2 
hours at RT, washed with 1X PBS, and probed for GST.      
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Results 
Construction, expression, and purification of GST-NPRC 
 In order to create a fusion protein that would maintain the signaling function 
mediated by the carboxy terminal domain of NPRC, the GST tag was strategically placed 
on the amino terminal end of the full length sequence of rat NPRC (Figure 63).  Several 
expression conditions of GST-NPRC, including temperature of bacterial cultivation, 
optical density of bacteria upon IPTG induction, IPTG concentration, and duration of 
IPTG induction were considered.  Expression of GST-NPRC was favored at a higher 
temperature with IPTG induction at a lower optical density (Figure 64).  Attempts to 
prevent misfolding of GST-NPRC by reducing the rate of expression of GST-NPRC by 
culturing the bacteria harboring the fusion protein at 30 °C instead of 37 °C resulted in 
less product, as indicated by the bands at 75 kDa in Coomassie stained gels. The 
expression of GST-NPRC appeared to be 5-fold less at 30 ˚C than at 37 °C, as indicated 
by densitometric analysis. 
  Despite the inclusion of the GST tag to facilitate solubilization of GST-NPRC, a 
desirable yield of purified fusion protein could not be achieved by traditional methods.  
Overexpression of the foreign protein in the bacteria resulted in aggregation and 
formation of insoluble inclusion bodies.  The fusion protein was found exclusively within 
intracellular inclusion bodies and represented approximately 10% of total bacterial 
proteins as indicated by densitometric analysis. Therefore, a similar approach as 
originally described by Frangioni and Neel [366] to recover our fusion protein from 
bacterial inclusion bodies was taken.  GST-NPRC was able to be purified to 
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homogeneity, as indicated by a single band of an apparent molecular weight of 75 kDa 
(Figure 65).   
 Next, the purity of GST-NPRC was confirmed and the NPRC portion 
demonstrated to be intact by MS analysis.  MASCOT results only revealed several 
signature peptides corresponding to rat NPRC and full sequence coverage from the amino 
terminal domain to the carboxy terminal domain of NPRC observed (Figure 66A).  
However, MASCOT results did not reveal sequence coverage for the GST moiety.  The 
expected size of GST-NPRC was between 86 and 92 kDa, since NPRC is known to have 
a molecular mass of between 60 and 66 kDa and GST is known to have a molecular mass 
of 26 kDa.   
 
Predicted and Observed MW of GST-NPRC 
A GST-NPRC fusion protein was constructed using the entire sequence of rat 
NPRC.  The molecular weight of GST is 26 kDa and the molecular of rat NPRC is 
between 60 and 66 kDa.  Therefore, the predicted MW of GST-NPRC is between 86 and 
92 kDa.  SDS-PAGE analysis of purified GST-NPRC and subsequent indirect Western 
blot analysis probing for NPRC resulted in an immunoreactive band at 75 kDa (Figure 
66B).  Similarly, direct Western blot analysis probing for GST also resulted in an 
immunoreactive band at 75 kDa (Figure 66C).   
Native PAGE analysis of purified GST-NPRC resulted in a high molecular weight 
Coomassie blue stained band above 120 kDa, as indicated by a Native PAGE molecular 
weight marker kit.  The molecular weight of the band corresponding to GST-NPRC 
observed in the Native PAGE studies was then estimated by using a protein molecular 
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weight marker kit and Ferguson plots.  The estimated molecular weight of GST-NPRC’s 
approximately 150 kDa (Figure 67).        
 
Dimerization of GST-NPRC does not require receptor occupancy 
 The GST tag of GST-NPRC was removed by thrombin cleavage prior to 
investigating the dimerization of NPRC in vitro.  An immunoreactive band at 66 kDa 
band corresponding to NPRC was detected after 18 hours of thrombin cleavage (Figure 
66D).  The ability of the NPRC agonist, cANF to induce dimerization of NPRC resulting 
from thrombin cleavage of GST-NPRC was evaluated.  The addition of cANF in 
increasing concentrations did not augment the observed dimerization of NPRC and the 
primary sequence of NPRC was sufficient for its spontaneous dimerization in vitro 
(Figure 68).      
 
The observed and theoretical secondary structures of GST-NPRC are in agreement 
 The GST moiety of GST-NPRC has the potential to dimerize by itself, although it 
is unlikely since a large portion of the tag of GST-NPRC is prematurely cleaved during 
the purification process.  In order to determine if thrombin cleavage of GST-NPRC was 
necessary, the ability of the GST moiety to effect the secondary and tertiary structure of 
GST-NPRC was investigated.  The amino acid sequences of GST and of rat NPRC were 
used to perform secondary structure predictions analysis.  Circular Dichroism (CD) 
revealed a minima negative peak at 215 followed by an immediate positive peak, as 
indicated by the far UV CD spectra in Figure 69A.  The peak profile within the region of 
260 of the spectra demonstrated the fusion protein was not globular and maintained a 
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defined tertiary structure.  The results from the CD analysis were in agreement with the 
proportions of  and structures from the PSIPRED protein structure prediction server 
shown in Figure 69B.       
           
The intracellular domain of NPRC contains putative phosphorylation consensus 
sequences 
The intracellular domain of rat NPRC contains several putative phosphorylation 
consensus sequences, as shown in Figure 70.  Two PKA, two PKB, and one PKC 
phosphorylation sites were identified within the 37 amino acid intracellular domain of rat 
NPRC.  
 
Immobilized GST-NPRC can be phosphorylated in vitro using a crude RGM1 cellular 
lysate 
  The ability to phosphorylate GST-NPRC in vitro using a crude lysate from 
RGM1 cells was investigated.  While immobilized to glutathione Sepharose 4B beads, 
GST-NPRC was subject to RGM1 lysate at increasing concentrations and increasing 
periods of time.  Compared to untreated GST-NPRC, the addition of increasing 
concentrations of RGM1 lysate for increasing periods of time did not affect the ability to 
purify the fusion protein to homogeneity (Figure 71A).  However, compared to untreated 
GST-NPRC, incubation of GST-NPRC with 600 µg of phosphatase inhibitor treated 
RGM1 lysate in the presence of ATP for 1 hr resulted in a phosphostained band 
corresponding to 75 kDa (Fig. 71B).    
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Rat NPRC does not exist as a constitutively phosphorylated protein in RGM1 cells 
 The various different antibodies used to investigate the phosphorylation state of 
NPRC are listed in Table 6.  A polyclonal phospho-Thr antibody, which recognizes 
phosphorylated Thr residues, but also phospho Ser residues was in initial experiments to 
determine if NPRC exist as a constitutively phosphorylated protein in vivo.  A polyclonal 
NPRC specific antibody was used to immunoprecipitate NPRC from an RGM1 cell lysate 
treated with or without phosphatase inhibitors and was then probed for phosphorylated 
Thr and Ser residues using the polyclonal phospho-Thr antibody.  In parallel experiments, 
the polyclonal phospho Thr antibody was used to immunoprecipitate total phosphorylated 
proteins from the RGM1 cell lysate treated with or without phosphatase inhibitors and 
specific NPRC antibody was used to probe for NPRC.  Immunoreactive bands 
corresponding to phosphorylated NPRC were markedly reduced in the absence of 
phosphatase inhibitors, as shown in Figure 72.  In other experiments a monoclonal 
phospho Thr specific antibody, which only detects phosphorylated Thr residues was also 
used to probe for phosphorylated Thr residues after immunoprecipitation NPRC with 
NPRC specific antibody.  Accordingly, the monoclonal phospho Thr specific antibody 
was used to immunoprecipitate total phosphorylated proteins from the RGM1 cell lysate 
treated with or without phosphatase inhibitors and NPRC specific antibody was used to 
probe for NPRC.  In each case, NPRC phosphorylation at threonine residues was 
essentially nondetectable in the absence of phosphatase inhibitors after probing with a 
phosphospecific antibody that recognizes only phosphorylated threonine residues (Figure 
72A).   
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Rat NPRC is a substrate for PKA  
 In order to determine if NPRC was a substrate for a specific kinase, NPRC was 
immunoprecipitated from the RGM1 cell lysate and probed for phosphorylation using 
PKA, PKB, and PKC substrate motif antibodies (Table 6).  Probing for phosphorylation 
with PKB and PKC substrate motif antibodies did not reveal any immunoreactive bands 
corresponding to NPRC.  However, probing for phosphorylation with a PKA substrate 
motif antibody did reveal an immunoreactive band at 66 kDa corresponding to NPRC 
that was markedly reduced in the absence of phosphate inhibitors (Figure 72C).  
However, immunoreactive NPRC bands of equal intensity were detected after probing 
NPRC with specific NPRC antibody from both phosphatase treated and untreated RGM1 
cell lysates (Figure 72D).        
 
Rat NPRC is phosphorylated on Thr 505  
 Global phosphorylation of NPRC by PKA was investigated using a PKA 
consensus sequence prediction algorithm, pkaPS [404].  Six distinct phosphorylation sites 
were identified over the entire sequence of rat NPRC (Table 7).   However, only one of 
these sites included a threonine residue, Thr 505 (Table 7).  
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Discussion 
A recombinant GST-NPRC fusion protein was created and used to investigate 
posttranslational modifications of NPRC.  The expected molecular mass of GST-NPRC 
was predicted to be between 86 and 92 kDa, since NPRC is known to have a molecular 
mass of between 60 and 66 kDa and GST is known to have a molecular mass of 26 kDa.  
However, Western blot analysis consistently revealed an immunoreactive band at 75 kDa, 
using a polyclonal antibody against the cytoplasmic domain of NPRC (Figure 66B).  
Accordingly, a GST peroxidase antibody also revealed an immunoreactive band at 75 
kDa (Figure 66C).  Although it was apparent the GST-NPRC fusion protein was 
truncated, it was immediately apparent that the GST fusion tag and not the NPRC parent 
protein was most likely truncated, since each of the polyclonal antibody against NPRC 
used in the Western blot analysis is against the a region within the last 37 amino acids of 
the carboxy terminal domain of NPRC.  Thrombin cleavage of GST-NPRC revealed an 
immunoreactive band at approximately 66 kDa (Figure 66D), which was also observed in 
Western blots of uncleaved GST-NPRC, suggesting the fusion protein may be cleaved as 
a result of proteolysis.  Since the entire sequence of GST was used to create the 
peroxidase conjugated GST antibody it was expected the antibody would recognize 
multiple epitopes of GST.  It was also expected that the presence of only a few amino 
acids of GST would be necessary for recognition of this antibody.  MS sequence analysis 
revealed multiple signature peptides corresponding to rat NPRC spanning from the first 
amino acid at the amino terminal domain to the last amino acid of the carboxy terminal 
domain of NPRC.   
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Since proteins are neither uniform in charge/mass ratio nor in shape, the 
molecular weight of GST-NPRC was assessed in parallel with molecular weight 
standards while performing non-denaturing native polyacrylamide gel electrophoresis 
(PAGE), as described by others [405, 406].  The estimation of the molecular weight of 
GST-NPRC by this method minimized the influence of charge/mass ratio, but 
conformational differences between GST-NPRC and the molecular weight standards 
could influence an accurate estimation.  Ferguson plots and a protein molecular weight 
marker kit were also used to further confirm NPRC was intact by indirectly estimating 
the molecular weight of GST-NPRC (Figure 67).  Because all proteins have the same 
backbone, the nature of the side chains comprising the backbone determines the overall 
three-dimensional structure of the protein. In some cases, the primary structure of a 
protein alone may be sufficient to dictate the three-dimensional shape or tertiary structure 
of the protein.  In other cases, protein chaperonins may induce protein folding.  It was 
expected that in the absence of β-mercaptoethanol, S-S bridges will remain intact and a 
mixture of GST-NPRC monomer and GST-NPRC homodimers, formed from 
spontaneous dimerization would be present after performing native PAGE.  Although the 
exact site of cleavage of GST could not be determined by these methods, the truncation 
of the GST moiety was not a concern since it was removed by thrombin cleavage in some 
experiments.      
The molecular design of GST-NPRC involved using the entire coding sequence of 
rat NPRC instead of a partial sequence, because the original intent was to be able to study 
global posttranslational modifications of NPRC.  Endogenous NPRC exists as a monomer 
and a disulfide-linked homodimer [82, 83], but the dimeric structure of NPRC is not 
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necessary for ligand binding activity [83].  It is generally thought that the cytoplasmic 
domain of NPRC is phosphorylated upon ligand binding [370].  Under non-denaturing 
native-PAGE conditions dimerization of GST-NPRC (Figure 68) or NPRC alone in both 
the absence and presence of increasing amounts of the NPRC ligand, cANF was 
observed.   In addition to using the GST-NPRC fusion protein as a tool to study the 
phosphorylation state of NPRC, it could also be used to study the importance of 
glycosylation of NPRC for its ability to dimerize, bind ligand, and mediate signal 
transduction.  NPRC undergoes N terminal glycosylation as its extracellular (ECD) 
contains multiple N-linked glycosylation sites, but the role of NPRC glycosylation 
remains controversial.  Glycosylation and ligand binding are thought to contribute to the 
homodimerization and subsequent activation of NPRC.  Furthermore, ligand induced 
dimerization of single transmembrane spanning receptors, such as cytokine receptors and 
growth factor receptors appear to be a general mechanism for receptor activation and 
downstream signaling [407, 408].  Multiple groups have shown glycosylation of NPRA 
and NPRB is important for ligand binding [409, 410].  Heim et al. demonstrated that 
inhibition of N-glycosylation of NPRA by tunicamycin did not alter the ability of ANP, 
but did affect ANP analogs to bind to rat glioma cells stably transfected with NPRA and 
activate guanylyl cyclase [411].  Fenrick et al. showed lower guanylyl cyclase activity 
after deglycosylation of NPRB compared to fully glycosylated receptor [409].  
Independent from its role in modulating ligand binding, glycosylation does not appear to 
be required for distribution of NPRs to the cell surface [409, 410].  Glycosylation of 
NPRC has not been shown to be a prerequisite for its ligand binding.  Preliminary results 
suggest N terminal glycosylation of NPRC is not required for NPRC homodimerization, 
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since GST-NPRC spontaneously dimerized in vitro and the addition of ligand, in 
increasing amounts did not further enhance the dimerization (Figure 68).  This finding 
suggests the primary sequence of NPRC alone is sufficient for its dimerization in vitro.  
Furthermore, because GST-NPRC completely lacks glycosylation, as this 
posttranslational modification is absent in E. coli, GST-NPRC could provides a 
simplified means to investigate the requirement of glycosylation for the NPRC activation 
and function.  
 Several methods exist for prediction of the secondary structure of various 
proteins. The de novo PSIPRED [412, 413], JNET [414] and PHD [415] secondary 
structure prediction programs are among the best secondary structure prediction methods 
available and can achieve a performance or Q3 score of between 75-77% [416].  These 
methods utilize BLAST searches of the non-redundant protein sequence database to 
obtain evolutionary information which is then fed into a multi-layered feed-forward 
neural network to acquire sequence/structure patterns, which are subsequently used to 
predict the secondary structure of the query protein [417].    
Since mammalian posttranslational modifications including phosphorylation are 
absent in bacteria, the GST-NPRC fusion protein may be useful for the investigation of 
phosphorylation events of NPRC.  MS and site-directed mutagenesis are commonly used 
to investigate the phosphorylation state of a protein.  Alternatively, the availability of 
phosphospecific antibodies can be used to probe for protein phosphorylation.  
Phosphorylation motif antibodies are useful resources for the identification and 
characterization of the phosphorylation state of a protein.  Consensus sequences are 
commonly used as substrate specificity determinants for protein kinases [418].  The 
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carboxy terminal domain of NPRC is rich in serine and threonine residues and consensus 
sequence motifs for PKA, PKB, and PKC.  In one report, NPRC was shown to be 
phosphorylated exclusively on serine residues in rat aortic smooth muscle cells.  It is 
possible multiple serine residues of NPRC are phosphorylated simultaneously or 
sequentially by one or more kinases.  In agreement with a recent report, evidence is 
provided here for the phosphorylation of Thr 505 of NPRC in RGM1 cells.  The 
discrepancy between the phoshorylated residues of NPRC may be attributed to the 
phosphorylation state of NPRC being species and cell type dependent.  A future study 
that may be performed to confirm the phosphorylation of NPRC at Thr 505 include 
mutating Thr 505 to an Ala and then performing in vitro phosphorylation assays, while 
comparing the mutant construct to wildtype NPRC.  The functional significance of the 
phosphorylation of NPRC at Thr-505 in RGM1 cells may be evaluated by utilizing the 
mutant construct and wildtype NPRC, while performing I125 ligand binding experiments 
after transiently transfecting and radiolabeling RGM1 cells to assess the clearance 
function of NPRC.  Similarly, other cell lines, capable of being transiently transfected can 
be used to determine the role of phosphorylation of NPRC at Thr-505.  Phosphorylation 
of Thr-505 of NPRC may have significant implications because it is within the 
intracellular domain of NPRC.  The intracellular domain of NPRC has been reported to 
contain G protein activator sequences and participate in signal transduction.  Therefore, 
the functional significance of the phosphorylation of NPRC at Thr-505 on NPRC 
signaling mediated by Gi or independent of G-proteins (i.e. via AHNAK1) can be studied 
while utilizing the mutant construct and wildtype NPRC.  Although this is the first report 
of phosphorylation of NPRC at Thr-505 by PKA, NPRC has been reported to be 
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phosphorylated on Thr-505 by PKG [419].  The Thr-505 residue of NPRC was reported 
to be part of a consensus sequence for phosphorylation by cGMP-dependent protein 
kinase (PKG) [419].  After expression of various NPRC mutants into COS-1 cells, 
desensitization by PKG was found to be mediated by phosphorylation of Thr-505 of 
NPRC [419].            
In order to identify the kinase responsible for phosphorylation of Thr-505 
substrate motif antibodies for various kinases were utilized.  Only a PKA substrate motif 
antibody and not PKB or PKC substrate motif antibodies resulted in immunoreactive 
bands after immunoprecipatating NPRC from RGM1 lysate with NPRC specific 
antibody.  PKA phosphorylates proteins on Serine (Ser) and Threonine (Thr) residues 
within the motif Arg-X-X-Ser/Thr, where X may represent any amino acid residue.  The 
motif is not absolute and some variations in basic residues and spacing are allowed.  It 
has been reported that the 2nd or 3rd position prior to the phosphorylated serine or 
threonine should be occupied by an arginine.  Several algorithms exist for predicting 
putative PKA phosphorylation sites.  The pkaPS algorithm was used because it offers 
both high sensitivity and specificity for predicting PKA phosphorylation sites of a given 
protein sequence based on various parameters.  PkaPS was used to identify all putative 
PKA phosphorylation sites within the entire sequence of rat NPRC.  Of the six predicted 
phosphorylation sites (Table 7), only amino acid 505 contained a Thr residue.  Since the 
phospho-Thr specific antibody used in IP-Western blot analyses only recognizes 
phosphorylated Thr residues and does not cross-react with phosphorylated Ser residues, 
Thr-505 of rat NPRC is most likely phosphorylated by PKA.  NPRC may be 
phosphorylated on multiple residues, but does not exist as a constitutively phosphorylated 
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protein in RGM1 cells, since treatment of RGM1 lysate with phosphatase inhibitors was 
necessary to achieve phosphorylation. 
MS is routinely used to identify phosphorylation sites of a protein of interest.  
However, the ability to accurately detect phosphorylated residues is dependent on the 
abundance of the phosphorylation.  Therefore, it was not suprising that the MS approach 
to detect phosphorylation of NPRC failed, since there is no evidence of NPRC being 
abundantly phosphorylated.  The ability to detect NPRC phosphorylation by MS in future 
experiments can be improved by incorporating a separation technique, such as 
immobilized metal affinity chromatography (IMAC).  The IMAC method may be used to 
enrich for phosphopeptides that are present at low amounts and is therefore useful for a 
more accurate identification of phosphorylation sites by LC-MS/MS.  Furthermore, 
protein phosphorylation is dynamic and constantly changes over time.  As shown in 
Figure 72, NPRC does not exist as a constitutively phosphorylated protein and most 
likely undergoes a series of phosphorylation and dephosphorylation events.   This finding 
may be used to troubleshoot future experiments, in which a specific kinase may be 
overexpressed in the cell line of interest by transient transfection, or the cells may be 
treated with an activator of a specific kinase in order to enhance the phosphorylation.      
 Future studies will be necessary to determine if this phosphorylation is conserved 
in other species and to determine sequential phosphoryaltion and dephosphorylation 
events.  Additional studies will also be necessary to determine if PKA phosphorylation of 
NPRC is necessary for receptor homodimerization, activation, desensitization, and/or 
internalization. 
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Table 5.  Solubilization and purification scheme for GST-NPRC 
Culture volume 60 mL culture 500 mL culture 
Centrifugation (5000 g for 10 min. at 4 °C)   
   1X PBS wash buffer 4 mL 33 mL 
   Resuspension buffer (STE)           1.2 mL 10 mL 
   Lysozyme 12 μl 100 μl 
   1M DTT  12 μl 100 μl 
   10% Sarkosyl 170 μl 1.43 mL 
Sonication (2X for 5 sec. intervals)   
Centrifugation (3000 rpm for 15 min. at room temp.)   
   10% Triton X-100 480 μl 4 mL 
   STE 2.4 mL 20 mL 
Incubation (30 min. at room temp.)   
Elution    
   Glutathione Sepharose Bed Volume 30 μl 240 μl 
   Glutathione elution buffer 60 μl 500 μl 
   1X PBS wash buffer (2X) 300 μl 2.4 mL 
   Approx. GST-NPRC yield 30 μg 200 μg 
Approximate volumes for a 60 mL culture and 500 mL culture are provided 
 
 
 
Table 6.  Various antibodies used to characterize the phosphorylational state of NPRC    
Antibody Specificity/Sensitivity Motif Source 
JAH84  Total NPRC None  Our laboratory 
Phospho-Thr-
polyclonal 
Phospho-Try, Ser, Thr None Cell Signaling 
Phospho-Thr-
monoclonal 
Phospho-Thr None  Cell Signaling 
Phospho-PKA 
Substrate  
Phospho-Ser, Thr (RRXS/T) Cell Signaling 
Phospho-PKB 
(Akt) Substrate 
Phospho-Ser, Thr (R/K)X(R/K)XX(T/S) Cell Signaling 
Phospho-PKC 
Substrate 
Phospho-Ser (R/K)X(S)(Hyd)(R/K) Cell Signaling 
 
 
 
Table 7.  Prediction of NPRC phosphorylation by PKA using the pkaPS algorithm 
Position Residue Score Profile 
193 S 0.04    0.82 
337 S 0.31  1.08 
441 S 0.65 1.09 
505 T 0.41  0.74 
527 S 0.14 0.81 
533 S 0.18 0.40 
    
 
182
rat NPRC
pGEX-4T3-NPRC
GST LBD TMD ICD COOH
rat NPRC
Figure 63. Construction of recombinant GST-NPRC.
Schematic of the pGEX4T3-NPRC construct and
d i f GS C h li d bi di d ioma ns o T-NPR . T e gan n ng oma n
(LBD), transmembrane domain (TMD), and
intracellular domain (ICD) of NPRC are depicted
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SDS-PAGE
Figure 64. Optimization of the expression conditions of GST-
NPRC. Coomassie blue stained gel illustrating the effects of
temperature, cell density, and IPTG concentration on the
expression of GST-NPRC. The arrow indicates expression of
th GST NPRC f i t i L t bt i d f Ee - us on pro e n. ysa es were o a ne rom .
coli BL21 cells transformed with the pGEX4T3-NPRC
construct. Lane 1, unstained molecular weight markers
(MWM). CTRL in lane 2 refers to control, in which lysate
from pGEX4T3 empty vector was compared to lysate from
pGEX4T3-NPRC (GST-NPRC) as shown in each of the other
indicated lanes.
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SDS-PAGE
Figure 65. Coomassie blue stained gel showing the purification
of GST-NPRC. Lane 1, unstained molecular weight markers
(MWM). Lane 2, purified fraction (PRFD) of GST-NPRC.
Lane 3, control (CTRL) in which lysate from empty vector was
purified in parallel with lysate from bacteria harboring the GST-
NPRC construct.
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Figure 66. Confirmation of the sequence of GST-NPRC. (A) Sequence
alignment/Mascot results from LC-MS/MS. Matched peptides are italicized
in red. (B) Indirect Western blot showing an immunoreactive band of an
apparent molecular mass of 75 kDa using anti-NPRC antibody. The band at
66 kDa from RGM1 lysate and purified GST-NPRC corresponds to the GST-
NPRC fusion protein in which GST is truncated and NPRC is intact. (C)
Di t W t bl t h i i ti b d f trec es ern o s ow ng an mmunoreac ve an o an apparen
molecular mass of 75 kDa using a peroxidase conjugated anti GST antibody.
(D) Indirect Western blot showing an immunoreactive band of an apparent
molecular mass of approximately 60 kDa after thrombin cleavage of GST-
NPRC.
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Figure 67. Grayscale of Coomassie blue stained gels used to
determine the molecular weight of GST-NPRC under native
PAGE conditions. Rf= distance of protein migration/distance of
tracking die migration. A: 5% gel; B: 7.5% gel; C: 10% gel
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Figure 68. Spontaneous versus ligand induced dimerization of
of GST-NPRC . Native PAGE (nonreducing and nondenaturing
conditions) analysis of GST-NPRC using a 10% Tris HCl gel
and after Coomassie blue staining. Lane 1, albumin dimer at
132 kDa and monomer at 66 kDa . Lane 2, control (CTRL) of
untreated GST NPRC Lanes 3 5 incubation of GST NPRC- . - , -
with increasing amounts of cANF. GST-NPRC was able to
dimerize spontaneously independent of ligand.
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Figure 69. Predicted secondary structure for GST-NPRC. (A)
Far UV CD spectra; the region around 260 indicates the protein
has a defined tertiary structure and is not globular. The minima
at 215 followed by an immediate positive peak indicates the
protein is mainly helical. (B) PSIPRED protein structure
prediction server results for rat GST-NPRC.
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Figure 70. Phosphorylation consensus sequences within the
intracellular domain of rat NPRC. Two phosphorylation
consensus sequences are shown for PKA, two phosphorylation
consensus sequences are shown for PKB, and one
phosphorylation consensus sequence is shown for PKC
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Figure 71. In vitro phosphorylation of GST-NPRC (A) Lane 1,
molecular weight marker (MWM). Lane 2, untreated control
(CTRL). Lanes 3-5, purification of GST-NPR fusion protein
after incubating the fusion protein, immobilized on glutathione
Sepharose 4B beads with increasing amounts of RGM1 cell
lysate (200, 400, or 600 µg, respectively) for 30 min in the
presence of ATP. Lanes 6-8, purification of GST-NPRC fusion
protein after incubating the fusion protein, immobilized on
glutathione Sepharose 4B beads for increasing time intervals (15
min, 30 min, 1 hour, respectively) with 400 µg of RGM1 lysate
in the presence of ATP. (B) Phosphostained gel after SDS-
PAGE, in which GST-NPRC was treated with or without 400 µg
RGM1 lysate and ATP for 1 hour.
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Figure 72. Identification of putative residues and kinases involved in NPRC
phosphorylation. (A) IP Western blot analysis after immunoprecipatating
NPRC from RGM1 whole cell lysate (WCL) treated with phosphatase
inhibitors (+ PI) and probing with phospho-Thr specific antibody revealed an
immunoreactive band at 66 kDa The immunoreactive band at 66 kDa was.
absent after immunoprecipatating NPRC from untreated (- PI) RGM1 lysate
and probing with phospho-Thr specific antibody (B) Similarly, IP Western
blot analysis after immunoprecipatating with NPRC specific antibody and
probing with NPRC specific antibody revealed an immunoreactive band at
66 kDa. (C) IP Western blot analysis after immunoprecipatating NPRC
from RGM1 lysate treated with phosphatase inhibitors and probing with a
PKA substrate motif antibody revealed an immunoreactive band at 66 kDa.
The immunoreactive band at 66 kDa was attenuated after
immunoprecipatating NPRC from untreated RGM1 lysate and probing with
PKA substrate motif antibody. (D) Similarly, IP Western blot analysis after
immunoprecipatating with NPRC specific antibody and probing with NPRC
specific antibody revealed an immunoreactive band at 66 kDa.
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Chapter 5:  Potential Functions of AHNAK1 
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Background 
 As mentioned earlier, the AHNAK family of proteins has been implicated in 
several different cell-type dependent functions, and there may be other possible functions 
that are still unknown.  While considering the versatity of AHNAK1 to serve as an 
adaptor/scaffolding protein and its abilty to associate with a wide range of proteins, the 
identification of AHNAK1 protein expression in different cell types is a preliminary step 
for discovering novel functions of this protein.  As demonstrated earlier, AHNAK1 
associates with NPRC in RGM1 cells.   Since AHNAK1 is a barrier protein and the 
RGM1 cell line demonstrates barrier type properties, the role of AHNAK1 in modulating 
the paracellular permeability of normal rat gastric epithelial cells was investigated.  Also, 
the expression profile of AHNAK1 in normal human stomach organ donors was 
investigated to correlate the findings from studies in which the RGM1 cell line was used 
as a model system and to further elucidate the functional significance of AHNAK1.        
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Materials and Methods 
Reagents and antibodies 
 In addition to the reagents and antibodies mentioned in the previous chapters, the 
following reagents and antibodies were purchased or acqueired as described.  ZO-2 
antibody was purchased from Cell Signaling Technologies.  
 
Cell culture 
RGM1 cells were cultured as described in Chapter 2.   
 
SDS-PAGE, Western blotting, and densitometric analysis   
SDS-PAGE, Western blotting, and densitometric analyses were performed as 
described in the previous chapters.   
 
Immunohistochemistry and immunofluorescence 
 Immunohistochemistry and immunofluorescence was performed as described in 
Chapter 1, but with the following modifications.  ZO-2 antibody was used at a dilution of 
1:250.    
  
Sucrose density-gradient centrifugation 
 Sucrose density-gradient centrifugation studies were performed exactly as 
described in Chapter 3. 
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siRNA Transfection   
AHNAK1 specific SMARTpool siRNAs (Table 4)  or  negative control 
nontargeting siRNA were purchased from Dharmacon (Lafayette, CO).  siRNAs were 
transfected into RGM1 cells using DharmaFECT Transfection Reagent (Dharmacon)  
according to the manufactures instructions. 
 
In vitro Cell Permeability Assay 
Permeation of fluorescein isothiocyanate (FITC)-dextran (MW: 2000 kD) across 
RGM1 monolayers was assessed by in vitro Permeability Assay kit (Millipore, Billerica, 
MA) according to the manufactures instructions, but with the modifications.  Briefly, 
RGM1 cells were transfected with non-targeting siRNA or AHNAK1 specific 
SMARTpool siRNA and allowed to reach confluency.  As controls, permeation of FITC-
dextran was also assessed across collagen coated inserts without an RGM1 monolayer, 
and across RGM1 monolayers treated with 50 µM EDTA for 20 minutes. 
 
Statistical analysis 
Results are presented as mean ± SEM.  Statistical analyses were performed using 
Student's t test or one-way ANOVA.  All data are representative of at least two 
independent experiments. 
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Results 
AHNAK1 colocalizes with ZO-2 in confluent RGM1 cells 
 In order to determine if AHNAK1 could affect the integrity of the junctional 
complex of epithelial cells (Figure 73), colocalization of AHNAK1 and ZO-2 was 
initially investigated.  Both AHNAK1 and ZO-2 were found to colocalize along the cell 
boundary of confluent RGM1 cells, as shown in Figure 74A.  Strong AHNAK1 
immunoreactivity, using polyclonal AHNAKC2 antibody (Figure 74B) and strong ZO-2 
immunoreactivity, using monoclonal ZO-2 antibody (Figure 74C) was observed after 
staining RGM1 cells cultured on type 1 collagen chamber slides.       
 
AHNAK1 is predominantly plasma membrane bound in confluent RGM1 cells 
 Subcellular fraction studies and Western blot analysis revealed AHNAK1 protein 
expression in the cytoplasmic, membrane, and nuclear fraction (Figure 75A).  Pan-
Cadherin was probed for as a membrane marker, Lamin A/C was probed for as a nuclear 
marker, and GAPDH was probed for as a cytoplasmic marker (Figure 75A).  The highest 
level of AHNAK1 protein expression was found in the cytoplasmic fraction (Figure 
75A).  Immunofluorescence staining revealed strong cytoplasmic and membrane staining 
for AHNAK1, but very weak nuclear staining for AHANK1 (Figure 75B).      
 
AHNAK1 is expressed in various regions of healthy human stomach organ donors  
 As shown in the schematic shown in Figure 76, the stomach is composed of 
various types of cells that perform specialized functions.  Haematoxylin and eosin (H&E) 
staining and PAS/alcian blue staining demonstrated tissue samples taken from three 
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different human organ stomach donors were normal and were from healthy individuals 
(Figure 77).  Western blot analysis demonstrated AHNAK1 expression in the antrum and 
body of three different human organ stomach donors (Figure 78A).  Actin was probed for 
as a loading control (Figure 78A).  Immunohistochemical analysis revealed AHNAK1 is 
expressed at the basolateral plasma membrane in surface epithelial cells (Figure 79).  
Also, immunohistochemical analysis showed AHNAK1 is expressed in the capillaries 
and muscle of the stomach (Figure 79).     
 
AHNAK1 protein knockdown results in increased paracellular permeability    
 As demonstrated by Western blot (Figure 80A) and densitometric analysis (Figure 
80B), transfection of siRNAs targeting AHNAK1 into RGM1 cells resulted in 
approximately a 50% knockdown in AHNAK1 protein.  The knockdown in AHNAK1 
protein resulted in increased permeability to FITC-Dextran in confluent RGM1 cells 
(Figure 81).  The increased permeability to FITC-Dextran seen after siRNA mediated 
knockdown of AHNAK1 protein was greater than the increased permeability to FITC-
Dextran observed after EDTA treatment of RGM1 cells in adjacent wells (Figure 81).         
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Discussion 
AHNAK1 is a versatile protein that has been implicated in several cell-type 
dependent functions.  Novel findings presented here for AHNAK1 include AHNAK1 
protein expression in normal rat gastric mucosal cells and in surface epithelial cells of the 
antrum and body of healthy human stomach organ donors, AHNAK1 co-expression with 
ZO-2 in confluent RGM1 cells, and increased paracellular permeability with siRNA 
mediated knockdown of AHNAK1 protein in RGM1 cells.       
Gentil et al. demonstrated the co-localization of AHNAK1 with ZO-1 in the brain 
[232].  The co-localization of AHNAK1 with ZO-1 or other ZOs in other tissues has not 
been reported.  This may in part be due to AHNAK1 and the different ZOs being highly 
tissue specific and serving nonredundant functions.  The evidence provided here for the 
expression of AHNAK1 in RGM1 cells and its association with ZO-2 may have 
significant implications.  An important function of gastric epithelial cells is to provide a 
protective barrier and selective permeability of various substances between the external 
and internal compartments of the stomach.  Paracellular permeability and intramembrane 
diffusion of various components between the apical and basolateral membranes of 
epithelial cells is attributed to TGs.  TJs are a major component of the junctional complex 
of epithelial cells (Figure 73) and are composed of different types of transmembrane 
proteins, which connect to the cytoskeleton via adaptor/scaffold proteins including the 
ZOs.  Therefore, the association with AHNAK1 with ZO-2 may affect the integrity of 
TGs of normal gastric epithelial cells.  AHNAK1 does not possess any transmembrane 
domains, and therefore its expression and function is not at the site of the TGs located 
between epithelial cells, but instead is mostly likely nuclear and/or cytoplamic.  Although 
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AHNAK1 was found to co-localize with ZO-2 at the cell boundary in confluent RGM1 
cells, additional experiments will be necessary to determine if AHNAK1 associates with 
ZO-2 in the nucleus, which could prevent its translocation to the plasma membrane, 
where it binds to the cytoplasmic C termini of junctional transmembrane proteins and 
link them to the actin cytoskeleton.  The existance of ZO-2 in the nucleus has been 
reported, as Traweger et al. identified the localization of ZO-2 to the nucleus of 
migratory EC and subconfluent epithelial cells in response to environmental stress [420].  
The function of AHNAK1 protien may be dependent on its ability to translocate 
from the nucleus to the plasma membrane.  The cell type-dependent subcellular 
distribution of AHNAK1 is likely attributed to AHNAK1s ability to translocate from the 
nucleus to the plasma membrane.  For example, in epithelial cells AHNAK1 has been 
shown to translocate from the nucleus to the plasma membrane in response to an increase 
in extracellular Ca2+ or stimulation of PKC [224].  Furthermore, AHNAK1s ability to 
associate with the plasma membrane may be due to N-myristoylation, as AHNAK1 
contains nine potential in vitro N-myristolyation sites, in which N-myristoylation 
promotes membrane association [234].  In addition to being cell type-dependent, it is also 
plausible that AHNAK1’s recruitment to the plasma membrane is cell cycle-dependent, 
as the phosphorylation state of AHNAK1 is substantially repressed in quiescent cells and 
its expression increases in the Go stage of the cell cycle [421].   
The organization and integrity of epithelial cells is crucial for its function.  
Benaud et al. showed down-regulation of AHNAK1 affects the cell membrane 
cytoarchitecture of epithelial cells [226].  A report by Hieda et al. provided evidence of 
desmoyokin/AHNAK1 being restricted to the desmosome of bovine snout epidermis and 
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was suggested to play an role in plaque assembly [228].  Salim et al. reported a role for 
AHNAK1 in the establishment of cell-matrix contacts of Schwann cells [221].   Taken 
together, these findings may suggest a role for AHNAK1 in the regulation of epithelial 
cell adhesion and permeability.   
Although this is the first report of AHNAK1 expression in surface epithelial cells 
of the stomach, Gentil et al. reported AHNAK1 positive staining in the muscularis 
mucosae and smooth muscle layers in the stomach of adult mice [219].  Similar to Gentil 
et al,. AHNAK1 expression in the muscularis mucosae and smooth muscle in the 
stomach of healthy human organ donors was observed (Figure 79).  There are several 
explanations for AHNAK1 not previously being observed in the different secretory 
epithelial cells of the stomach.  A difference in species, the use of different antibodies, 
and epitope accessibility are some explanations for the discrepancies in AHNAK1 
immunoreactivity in the stomach. 
In addition to providing a selective barrier, the epithelium signals to innate 
immune cells in the mucosa to combat infection and repair wounds [422].  The gastric 
mucosal barrier is routinely exposed to trauma, and since gastric mucosal restoration 
involves cell migration and proliferation (23), AHNAK1 may also serve a role in 
mediating each of these processes.  The non-transformed RGM1 cell line was found to be 
an excellent model to investigate gastric epithelial restoration in vitro [342], as it displays 
a tight phenotype in vitro.  Therefore, the RGM1 cell line is suitable for the determination 
of epithelial-regeneration and permeability changes in future studies.   
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Figure 73. Schematic of the junctional complex of epithelial
cells. The tight junctions (TJs) constitute the most apical
component of the junctional complex. The adherens junctions
(Ajs) anchors the cells together through Ca2+-dependent cell
adhesion molecules. The desmosomes junctions hold cells
together and provide anchoring sites for intermediate
filaments. Gap junctions allow small molecules to pass from
the cytoplasms of neighboring cells.
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MERGE AHNAK1C2        
(FITC)
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gure .  o oca za on o   an  -  pro e ns n 
confluent RGM1 cells. DAPI was used to counterstain nuclei. 
Negative control (omission of AHNAK1 specific antibody)
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Figure 75. Subcellular localization of AHNAK1 in RGM1
cells. B: Immunofluorescent staining of RGM1 cells using
antibody specific for AHNAK1 C2 illustrates the presence of
AHNAK1 (FITC green) predominanlty localized in the
cytoplasm and at the plasma membrane. DAPI was used
to counterstain the nucleus. Negative control (omission of
AHNAK1 specific antibody)
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Figure 76. Schematic illustrating the various sections of the
stomach. Each section is composed of different cells with
i li d f ispec a ze unct ons.
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Figure 77. Histochemical analysis of representative tissue
sections from healthy human organ stomach donors. Human
stomach antrum (A) and body (B); Haematoxylin and Eosin (H
and E) (left) PAS/Alcian Blue staining (right)
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Figure 78. Western blot analysis of endogenous AHNAK1,
NPRA d NPRC t i i i h lth h, an pro e n express on n ea y uman
stomach.. (A) Immunoblot analysis showing (A) AHNAK1;
(B) NPRA; (C) NPRC protein expression in different regions
from three healthy human organ stomach donors
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Figure 79. Immunohistochemistry analysis of endogenous
AHNAK1 in healthy human stomach. A: Negative control
(staining in the absence of AHNAK1 specific antibody); B:
AHNAK1 protein immunoreactivity in surface epithelial cells
(SEC) and at the basolateral plasma membrane (BPM); C:
AHNAK1 protein immunoreacivity in capillaries (C); D:
AHNAK1 protein immunoreactivity in muscle fibers (MF) from
the muscularis mucosae; E: AHNAK1 protein immunoreactivity
in the lamina propria but not in the cells of the gastric gland
(GG)
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Figure 80 Knockdown of AHNAK1 protein in RGM1 cells. .
A: Western blot analysis of AHNAK1 after siRNA
knockdown. B: Densitometric analysis of (A). MOCK refers
to the use of nontargeting siRNA instead of AHNAK1
SMARTpool siRNA.
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Figure 81. In vitro permeability assay demonstrating the role of
AHNAK1 in maintaining paracellular cellular permeability and
the barrier properties of RGM1 cells. Each group was performed
in triplicates and the results shown are representative of two
independent experiments. Controls shown include the absence
of a cell monolayer, EDTA treatment for 20 minutes, and the use
of nontargeting (NT) siRNA instead of AHNAK1 SMARTpool
siRNA.
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Appendix A:  EMBOSS alignment needle program results of AHANK1 and AHNAK2 
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EMBOSS alignment needle program results of 
AHANK1 (top) and AHNAK2 (bottom).  The % 
identity, which represents the percentage of identical 
matches between the two sequences over the reported 
aligned region was 1908/6955 (27.4%); the 
%similarity, which  represents the percentage of 
matches between the two sequences over the reported 
aligned region where the scoring matrix value is 
greater or equal to 0.0 was 2916/6955 (41.9%)  
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Appendix B:  reverse and forward sequence for pACT-NPRC and pBIND-NPRC 
 
 
 
LNPRCPACT+T3 
  
AGGCCTTAGTTATTCAGGTACCTGCGGCCGCTCTAGAGTCGACCGTTTCATTGATGTCTTTCAACCCGTCTATCTCCT
TAAAGAATCTCAGGCAGAAAAAAAAAAGTGGGGGGCTTCCTTTAAGCTACTGAAAAATGGGATCTGATGGAATCTTCC
CGTAATTCCCGATGTTTTCCAAGGTTACTTTCTTCTTGCTGGGTTCGCCTCTCAATGGTTATTCTGTATTTCTTCCTGAA
AAAGTAGAAGGCCATTAGCAAGCCAGCTCCTAGTAAAGCCCCCACGACAATTCCTGTCACTGCCGATTCTTCTAGGC
CACATGATTTGCAGGGAGAGCTGTTTGTATGCTCTACAATTCGGTTTTCATCTATTCTCAGTTTTAAAGGGCCCCAAG
GATATTTGACATTCGGCCGCATTTCAAAACGACCTTCTTTTCCAAAATAATCACCAATAACCTCCTGGGTGCCCGCCT
CCACATCAGTCATGGCAATCACAGAGAAATCCCCATATCGGTCTCCGTTGGCATCTATGGACACCTGCCCGGCGATA
CCTTCAAATGTTCTGTTCCAAGTCTGCTGTATAATTTTCCCTCCATCCTTTTTGCTGTAACCAGCTCTGAGTACTTCATG
TAGAGCCAAGACGTAGAGGAGGATGGCATCGTGGAATCCTTCAACAAACATGTTAACGTAATCCTCCATATTGAGCC
CTTGTTTCTCAACTGAACTTTTCACCTCCATGGAAAACTTCTCAAACTCAGGTTTCACTGTCCTCAGTAGAGTGACTGT
CTGGAGGGACGAGTATGCTTGCTTAGCTTCAAAGTCGTGTTTGTCTCCTCTCTTCCATGAGCCATCTCCATAGGAAGA
GCTGTTGAAGAGCTCAATGTTGAAGAAGCGTAGTCTCCACTGGTCATGCCATGCCTGTGCGCCACCAGCATGATGCT
CCGGATGGTGTCACTGCTCGCACACATGATCACCACTCTCTCACT 
  
LNPRCPACT+T7 
  
AGCTGAGCAGCCTCCTGAAGATGAAGCTACTGTCTTCTATCGAACAAGCATGCCCAAAAAAGAAGAGAAAGGTAGAT
GAATTCCCGGGGATCTCGACGGCCCCCCCGACCGATGTCAGCCTGGGGGACGAGCTCCACTTAGACGGCGAGGAC
GTGGCGATGGCGCATGCCGACGCGCTAGACGATTTCGATCTGGACATGTTGGGGGACGGGGATTCCCCGGGTCCG
GGATCGCCAGGGATCCGTCGACTTGACGCGTTGATATCGAATTCCTGCAGGTCGACCGGGGGCAGAAGGGCGAGT
CGGCGGCGGCGAGGGCAAGCTCTTTCTTGCGGCACGATGCCGTCTCTGCTGGTGCTCACTTTCTCCCCGTGCGTAC
TACTCGGCTGGGCGTTGCTGGCCGGCGGCACCGGTGGCGGTGGCGTTGGCGGCGGCGGCGGTGGCGCGGGCATA
GGCGGCGGACGCCAGGAGAGAGAGGCGCTGCCGCCACAGAAGATCGAGGTGCTGGTGTTACTGCCCCAGGATGAC
TCGTACTTGTTTTCACTCACCCGGGTGCGGCCGGCCATCGAGTATGCTCTGCGCAGCGTGGAGGGCAACGGGACTG
GGAGGCGGCTTCTGCCGCCGGGCACTCGCTTCCAGGTGGCTTACGAGGATTCAGACTGTGGGAACCGTGCGCTCTT
CAGCTTGGTGGACCGCGTGGCGGCGGCGCGGGGCGCCAAGCCAGACCTTATCCTGGGGCCAGTGTGCGAGTATG
CAGCAGCGCCAGTGGCCCGGCTTGCATCGCACTGGGACCTGCCCATGCTGTCGGCTGGGGCGCTGGCCGCTGGCT
TCCAGCACAAGGACTCTGAGTACTCGCACCTCACGCGCGTGGCGCCCGCCTACGCCAAGATGGGCGAGATGATGCT
CGCCCTGTTCCGCCACCACCACTGGAGCCGCGCTGCACTGGTCTACAGCGACGACAGCTGAC 
  
LNPRCPPBIND+T3 
  
AGGCCTTAGTTATTCAGGTACCTGCGGCCGCTCTAGAGTCGACCGTTTCATTGATGTCTTTCAACCCGTCTATCTCCT
TAAAGAATCTCAGGCAGAAAAAAAAAAGTGGGGGGCTTCCTTTAAGCTACTGAAAAATGGGATCTGATGGAATCTTCC
CGTAATTCCCGATGTTTTCCAAGGTTACTTTCTTCTTGCTGGGTTCGCCTCTCAATGGTTATTCTGTATTTCTTCCTGAA
AAAGTAGAAGGCCATTAGCAAGCCAGCTCCTAGTAAAGCCCCCACGACAATTCCTGTCACTGCCGATTCTTCTAGGC
CACATGATTTGCAGGGAGAGCTGTTTGTATGCTCTACAATTCGGTTTTCATCTATTCTCAGTTTTAAAGGGCCCCAAG
GATATTTGACATTCGGCCGCATTTCAAAACGACCTTCTTTTCCAAAATAATCACCAATAACCTCCTGGGTGCCCGCCT
CCACATCAGTCATGGCAATCACAGAGAAATCCCCATATCGGTCTCCGTTGGCATCTATGGACACCTGCCCGGCGATA
CCTTCAAATGTTCTGTTCCAAGTCTGCTGTATAATTTTCCCTCCATCCTTTTTGCTGTAACCAGCTCTGAGTACTTCATG
TAGAGCCAAGACGTAGAGGAGGATGGCATCGTGGAATCCTTCAACAAACATGTTAACGTAATCCTCCATATTGAGCC
CTTGTTTCTCAACTGAACTTTTCACCTCCATGGAAAACTTCTCAAACTCAGGTTTCACTGTCCTCAGTAGAGTGACTGT
CTGGAGGGACGAGTATGCTTGCTTAGCTTCAAAGTCGTGTTTGTCTCCTCTCTTCCATGAGCCATCTCCATAGGAAGA
GCTGTTGAAGAGCTCAATGTTGAAGAAGCGTAGTCTCCACTGGTCATGCCATGCCTGTGCGCCACCAGCATGATGCT
CCGGATGGTGTCACTGCTCGCACACATGATCACCACTCTCTCACTGGCCTGGATATTGCGCACGAT 
 
LNPRCPPBIND+T7 
  
GCTGAGCAGCCTCCTGAAAGATGAAGCTACTGTCTTCTATCGAACAAGCATGCGATATTTGCCGACTTAAAAAGCTCA
AGTGCTCCAAAGAAAAACCGAAGTGCGCCAAGTGTCTGAAGAACAACTGGGAGTGTCGCTACTCTCCCAAAACCAAA
AGGTCTCCGCTGACTAGGGCACATCTGACAGAAGTGGAATCAAGGCTAGAAAGACTGGAACAGCTATTTCTACTGAT
TTTTCCTCGAGAAGACCTTGACATGATTTTGAAAATGGATTCTTTACAGGATATAAAAGCATTGTTAACAGGATTATTTG
TACAAGATAATGTGAATAAAGATGCCGTCACAGATAGATTGGCTTCAGTGGAGACTGATATGCCTCTAACATTGAGAC
AGCATAGAATAAGTGCGACATCATCATCGGAAGAGAGTAGTAACAAAGGTCAAAGACAGTTGACTGTATCGCCGGAA
TTCCCGGGGATCCGTCGACTTGACGCGTTGATATCGAATTCCTGCAGGTCGACCGGGGGCAGAAGGGCGAGTCGG
CGGCGGCGAGGGCAAGCTCTTTCTTGCGGCACGATGCCGTCTCTGCTGGTGCTCACTTTCTCCCCGTGCGTACTAC
TCGGCTGGGCGTTGCTGGCCGGCGGCACCGGTGGCGGTGGCGTTGGCGGCGGCGGCGGTGGCGCGGGCATAGG
CGGCGGACGCCAGGAGAGAGAGGCGCTGCCGCCACAGAAGATCGAGGTGCTGGTGTTACTGCCCCAGGATGACTC
GTACTTGTTTTCACTCACCCGGGTGCGGCCGGCCATCGAGTATGCTCTGCGCAGCGTGGAGGGCAACGGGACTGG
GAGGCGGCTTCTGCCGCCGGGCACTCGCTTCCAGGTGGCTTACGAGGATTCAGACTGTGGGAACCGTGCGCTCTTC
AGCTTGGTGGACCGCGTGGCGGCGGCGCGGGGCGCCAAGCCAGACCTTATCCTGGGGCCAGTGTGCGAGT 
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Appendix C:  sequence for pACT-β-arrestin and pBIND-β-arrestin 
 
BAR-PACT+VP16 
ACGCGTTGATATCATCTAGAATGGGCGACAAAGGGACACGAGTGTTCAAGAAGGCAAGCCCCAATGGAAAGCTCAC
CGTCTACCTGGGAAAGCGGGACTTTGTGGACCACATTGACCTGGTGGACCCCGTGGATGGCGTGGTCCTGGTGGAT
CCTGAGTATCTCAAAGAAAGGCGAGTCTACGTGACACTGACCTGCGCCTTCCGGTATGGCCGGGAAGACCTGGATG
TCTTGGGTCTGACTTTTCGCAAAGACCTGTTTGTGGCTAACGTGCAGTCCTTCCCACCGGCCCCTGAGGACAAGAAG
CCACTGACTCGGCTACAAGAGCGACTCATCAAGAAGCTGGGCGAGCATGCCTACCCCTTCACCTTTGAGATCCCGC
CAAACCTTCCGTGCTCAGTCACATTGCAACCTGGGCCTGAGGAC 
BAR-PBIND+GAL4 
TGACGCGTTGATATCATCTAGAATGGGCGACAAAGGGACACGAGTGTTCAAGAAGGCAAGCCCCAATGGAAAGCTCA
CCGTCTACCTGGGAAAGCGGGACTTTGTGGACCACATTGACCTGGTGGACCCCGTGGATGGCGTGGTCCTGGTGGA
TCCTGAGTATCTCAAAGAAAGGCGAGTCTACGTGACACTGACCTGCGCCTTCCGGTATGGCCGGGAAGACCTGGAT
GTCTTGGGTCTGACTTTTCGCAAAGACCTGTTTGTGGCTAACGTGCAGTCCTTCCCACCGGCCCCTGAGGACAAGAA
GCCACTGACTCGGCTACAAGAGCGACTCATCAAGAAGCTGGGCGAGCATGCCTACCCCTTCACCTTTGAGATCCCG
CCAAACCTTCCGTGCTCAGTCACATTGCAACCTGGGCCTG 
 
 
 
Appendix D:  reverse and forward sequence for pBIND-AHNAK1 
 
 
 
 
PZF187PBIND+T3 
  
GGCTTAGTTATTCAGGTACCTGCGGCCGCCCACTCTTTCTTTGTGGAAACTGACAGCTCCACCTCGGGAAGCTGGAT
GCCAACCTTATTCCCACTGTCATTGCTAGAAGAGGAGGACAGTCGGGACTTCTTAGAGGCCAGGGACACCCCACTCC
CCTGTAACTTGCCTGTCTCATCATCGCTCCCAGTCACCTCATAATGACCTTTGCTCTTTGACCCCAATCCACCAAAGG
TACCGAATTTCAGCTTCCCGTGTTTCCCTTTAACTTTCCCACCTTCCAGAGACACTTCCCCACCTTCAAACTCCAGCGT
CCCCGTCGGGGTGGAAGGTCCAGAGAACTCTCTTTCATCACTGAATGAATTTGAGCGGTGCCGTGGCTTCTTACTTT
TAAATAAGGAGAATTTGCCTTTCGGTGAAGAGGCTTCGGCCTCTGCCTCTCCTTCCAGAGAGCCCAGGCTGGCCTTT
GAACTTTTCAGGTCACCTTTGGACCCAGAAATTGATGCTTCTGGTGAGCCAGTGACACCACCTTTCCCTTTAGGTTTG
GAAAAATTAAACTTGGGCATTTTGATCTTGGACTTTTTCAGTTTGACTTCAGACTCTTCCCACTCGCCGTCTCCAGCAC
CAGCTTGGATGCTGGCCTCTGCTTTAGGGAAGTGAACATCCACCCCCATTTCTCTGCCAACCAGCTCACGGCCAGAG
AAGGTAAATTTGGGGATCTTCATTTTAGGGAATGTTACTTTTCCAGATCCACTTTCCAAGTGACCTTGAGGCCCAGAC
ACACTCAGCCCAGGAGCCTGGAGTCCAATCTGACCTCCTTTCACACCTCCTTCCACCTTTGGTCCTGAGAAATGAAG
GCCCCAGCAAACTT 
 
PZF187PBIND+T7 
  
GCTGAGCAGCCTCCTGAAAGATGAAGCTACTGTCTTCTATCGAACAAGCATGCGATATTTGCCGACTTAAAAAGCTCA
AGTGCTCCAAAGAAAAACCGAAGTGCGCCAAGTGTCTGAAGAACAACTGGGAGTGTCGCTACTCTCCCAAAACCAAA
AGGTCTCCGCTGACTAGGGCACATCTGACAGAAGTGGAATCAAGGCTAGAAAGACTGGAACAGCTATTTCTACTGAT
TTTTCCTCGAGAAGACCTTGACATGATTTTGAAAATGGATTCTTTACAGGATATAAAAGCATTGTTAACAGGATTATTTG
TACAAGATAATGTGAATAAAGATGCCGTCACAGATAGATTGGCTTCAGTGGAGACTGATATGCCTCTAACATTGAGAC
AGCATAGAATAAGTGCGACATCATCATCGGAAGAGAGTAGTAACAAAGGTCAAAGACAGTTGACTGTATCGCCGGAA
TTCCCGGGGATCCGTCGACTTGACGCGTTGATATCGAATTCCTGCAGGTCGACCGGGGGCAGAAGGGCGAGTCGG
CGGCGGCGAGGGCAAGCTCTTTCTTGCGGCACGATGCCGTCTCTGCTGGTGCTCACTTTCTCCCCGTGCGTACTAC
TCGGCTGGGCGTTGCTGGCCGGCGGCACCGGTGGCGGTGGCGTTGGCGGCGGCGGCGGTGGCGCGGGCATAGG
CGGCGGACGCCAGGAGAGAGAGGCGCTGCCGCCACAGAAGATCGAGGTGCTGGTGTTACTGCCCCAGGATGACTC
GTACTTGTTTTCACTCACCCGGGTGCGGCCGGCCATCGAGTATGCTCTGCGCAGCGTGGAGGGCAACGGGACTGG
GAGGCGGCTTCTGCCGCCGGGCACTCGCTTCCAGGTGGCTTACGAGGATTCAGACTGTGGGAACCGTGCGCTCTTC
AGCTTGGTGGACCGCGTGGCGGCGGCGCGGGGCGCCAAGCCAGACCTTATCCTGGGGCCAGTGTGCGAGT 
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Appendix E:  reverse and forward sequence for AHNAK1 construct 2 
 
 
PZ21+M13FORWARD 
AATTGGGTACCGGGCCCCCCCTCGAGGTCGACGGTATCGATAAGCTTGATATCGAATTCCGTGCAAGTCCACATCAG
GCATGGAGATCTTGGGGGCCTTGATATTCATCTCTGGCATCTTGAACTTGGGGCCCTTCAGCTTTCCTTCAGGTCCTT
CAATATTCACATCTGGAACTTCAACACCCACCTTGGGTCCTGAGATGTCCACATCAGCCTTGGGCAGGTTCACATCCA
CTTCTGGGCCCTCTGCTTTGAAGCCAGGCATGCTGAACTTGGGCATTTTCATCTTGGGCATCTTCAGGTGCCAGTCT
GGGCCTTGAACCTCCACATCTGGGACATCAATGTCCATTTTGGCACTTTTAAGTTCAACATCAGGAACTTTAATCTCAC
TTTCAACCTTTGGCATTGTGACATCATATTCTCCCTTTACGTTAGGGCCTTTCAGATGTAAGTCCACATCAGGCATGGA
GATCTTGGGGACTTTGATGTTCATCTCAGGCATCTTAAACTTGGGCCCTTTCAATTTCCCTTCTGGTTCCTCAATGCTC
ACATCAGGAGCAGTAACATCTATCTTGGGCCCGGAAATGTCCACATCAGCCTTGGGCAGGTTCACATCCACTTCTGG
GCCCTCTGCTTTGAACCCTGGCACACTGAATTTGGGCATTTTCATCTTGGGCATCTTCAAGTGCCAGTCTGGGCCATG
AACATCCACATCTGGGGCATCAATGTCCACTTTTGGGCCTTTGAGTTCTCCTTCCAGCTTTGGTACAGTTACATCATAC
TCTCCCTTCACCTTTGTACCTTTCACGTGCAAATCTACATCAGGCATGGAGATCTTTGGTGTCTTGACACTCATATCAG
GCAGCTTAACATCGGGGCCTTTAAGTTTTCCCCCCAGACCCTCCAAGTTGACATCTGGGGCTTCCACATTGACCTTG
GGCCCTGAAATACTGATATCTCCTTTGGGTAGAGTCATATGAACATCTGGACCTTCCCCTTTGGCTCCTGGAGTGCTG
AACGTGGGCATTTTCATCTTGGGCAT 
 
pZ21+M13REVERSE 
AACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCGCTCTAGAACTAGTGGATCCCCCGGGCTGCAGGAATTCCGCT
GAAGTCGGAAGATGGAGTGGAAGGAGACCTCGGGGAGACCCAGAGCCGTACCATCACAGTGACCAGAAGGGTCAC
GGCCTACACTGTGGATGTGACTGGCCGGGAAGGAGCCAAGGACATAGACATCAGTAGCCCTGAATTCAAGATCAAG
ATTCCAAGACATGAACTGACTGAAATCTCCAATGTGGATGTGGAGACCCAGTCTGGGAAGACCGTGATCAGACTGCC
CTCGGGCTCGGGGGCAGCCTCTCCGACAGGCTCTGCTGTGGATATCCGAGCAGGGGCCATTTCTGCTTCAGGACCA
GAGCTCCAAGGTGCTGGCCACTCGAAGCTCCAGGTCACCATGCCTGGGATAAAGGTGGGAGGCTCAGGTGTCAATG
TCAATGCAAAGGGCTTGGACTTGGGTGGCAGAGGAGGGGTCCAAGTTCCAGCAGTGGACATTTCATCTTCTCTTGGG
GGTAGGGCAGTAGAGGTACAGGGCCCATCTCTGGAGAGTGGTGATCATGGCAAAATTAAATTTCCCACCATGAAAGT
GCCGAAATTTGGTGTCTCAACAGGGCGTGAGGGCCAGACACCAAAGGCAGGGCTGAGGGTTTCTGCACCTGAAGTC
TCTGTGGGGCACAAGGGCGGCAAGCCAGGCTTGACTATCCAAGCCCCTCAGCTGGAAGTCAGTGTGCCCTCTGCCA
ATATTGAGGGCCTTGAGGGGAAGCTGAAGGGCCCCCAAATCACTGGGCCATCACTTGAGGGTGACCTAGGCCTGAA
AGGTGCCAAGCCACAGGGGCACATTGGGGTGGATGCCTCTGCTCCCCAAATTGGGGGTAGCATCACTGGCCCCAGT
GTGGAAGTTCAGGCCCCTGACATTGATGTTCAGGGGCCTGGGAGCAAACTGAATGTGCCCAAGATGAAAGTCCCCA
AGTTCTCTGTATCAGGTGCAAAGGGAGAGGAAACTGGGATTGATGTGACACTGCCTACAGGTG 
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Appendix F: Construction of pACT and pBIND AHNAK1 fusion proteins 
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Appendix G:  Construction of pGEX4T3NPRC     
 
 
Appendix H:  Sequence for rat GST-NPRC 
 
RNPR-C+PGEX-3 
ATCGTCAGTCAGTCACGATGCGGCCGCTCGAGTCGACCCGGGAATTCTCCAAGAACACCCTTTCTGTTCCATTGATG
TCTGTCCTTCAACTATCTCTTTAAGGAATCTCAAGCAGACAAAGCAAGGGGGGCATTTCTTTTAAGCCACCGAAAAAT
GTGATCTGATGGAATCTTCCCGCAGCTCTCGATGTTTCCCAATGTTGCTTTCTTCTTGGTGATTTCGCCTCTCAATGGT
TATTCTGTATTTCTTCCTGAAAAAGTAGAAGGCCATTAGCAAACCAGCACCTAGTAGGGCCCCCACAACAATTCCTGT
CACTGCTGATTCTTCTAGGCCACATGATTTGCAAGGAGAGCTGTTGGTGTGCTCCACAATTCTGGTTTCATCTATTCT
CAATTTCAAAGAGCCCCAAGGATATTTGACATTGGATCGCATTTTGAACCGGCCTTCTTTTCCAAAGTAATCACCAATG
ACCTCCTGGGTACCTGCTTCTGTATCAGTCATGGCAACCACAGAGAAGTCTCCATACCGATCCCCATTAGCATCTATG
GACACCTGCCCGGCGATACCTTCAAATGTCCTGTTCCAAGTCTGCTGGATGATTTTCCCCCCATCCTTCTTGCTGTAG
CCAGCTCTGAGCACTTCATGCAAAGCCAGAACGTAGAGGAGGATGGCATCATGGAAGCCTTCAACGAACATGTTCAC
GTAATCCTCCTCATTGAGCCCTTGTTTCTCAACAGAACTTTTCACCTCCATGGAAAACTTCTCAAACTCAGGCTTCGCG
GTCCTCAGCAGGGTGACTGTTTGGAGGGATGAGTAAGCTTGCTTAGCTTCAAAGTCGTGTTTGTCCCCTCTCTTCCAC
GAGCCATCTCCGTAAGAAGAACTGTTGAAGAGTTCAATGTTGAAGAAAGCATAGTCTCCACTGGTCATGCCGTGTCT
GTGCACCGCCAACATGATTCTCCGAATGGTGTCACCAC 
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Appendix I.  Primers used with the QuikChange site-directed mutagenesis kit 
 
CGG GCT GCA GGA ATT CCG CTT GCT GGC AAC AGG ATG CGG TCC 
 
5’- GGC TGC AGG AGA CGC GTT GGC TGG CAA CAG GAT GCG -3’ 
5’- CGC ATC CTG TTG CCA GCC AAC GCG TCT CCT GCA GCC -3’ 
 
 
 
 
 
 
Appendix J:  Site-directed mutagenesis reaction 
 
Volume (μL) Reagent 
39.5 μL  Water 
5 μL 10X reaction buffer 
1.25 μL Diluted primer #1 
1.25 μL Diluted primer #2 
1 μL Diluted DNA 
1 μL dNPT mix 
50 μL  
Reagents were added sequentially in the order listed.   
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Appendix K:   Cycling parameters for site-directed mutagenesis reaction 
 
# of Cycles Temperature Time 
1 95 °C 30 sec 
16 95 °C 
55 °C 
68 °C 
30 sec 
1 min 
14 min 
 4 °C Hold 
 
 
Appendix L:  Ligation reaction for construction of pACT and pBIND AHNAK1 
 
Vector DEPC H20 T4 DNA ligase 
10X buffer 
Insert Ligase 
5 μL 
pACTAHNAK1 
2 μL 2 μL 10 μL pzdouble 1 μL 
5 μL 
pBINDAHNAK1 
2 μL 2 μL 10 μL pzdouble 1 μL 
 
 
Appendix M:  Restriction digest reaction for verification of pACT and pBIND AHNAK1 
 
Sample 10X reaction 
buffer 
100X BSA DEPC H20 Enzyme 
5 μL 
pACTAHNAK1 
2.5 μL 0.3 μL 15.2 μL 0.75 μL NOT1 
0.75 μL Mlu1 
5 μL 
pBINDAHNAK1 
2.5 μL 0.3 μL 15.2 μL 0.75 μL NOT1 
0.75 μL Mlu1 
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Appendix N:  Reactions and parameters for the subcloning of rat NPRC into pGEX4T3 
Restriction Digestion of rNPRC: 
Sample   10X Buffer H 100X BSA DEPC H2O Enzyme 
5 µL rNPRC (5µg/µL)  10 µL  1 µL  79 µL  5 µL 
EcoR1  
30 µL pGEX4T3 (0.54 µg/µL)  10 µL  1 µL  54 µL  5 µL 
EcoR1 
 
 
 
Gel Electrophoresis 
Sample   TBE   LB 
1 µL rNPRC (0.5 µg/µL) 9 µL   2 µL 
2.5 µL rNPRC digest  7.5 µL   2 µL 
1 µL pGEX4T3  9 µL   2 µL 
2.5 µL pGEX4T3 digest 7.5 µL   2 µL 
5 µL ladder   5 µL   2 µL 
Samples were heated for 15 minutes for 65 °C before load the gel for electrophoresis 
 
 
 
Dephosphorylation of pGEX4T3 vector digest: 
A 100 µL reaction was set up as follows: 
10 µL 10X NEB3 
49 µL DEPC H2O 
1 µL CIP 
The reaction incubated for 1hr at 37 °C in a thermocycler 
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Ligation Reaction: 
Vector   H20  10X Buffer  Ligase  Insert 
2 µL pGEX4T2  15 µL  2 µL   1 µL  none 
2µL pGEX4T2  14 µL  2 µL   1 µL  1 µL 
rNPRC 
3 µL pGEX4T2  13µL  2 µL   1 µL  1 µL 
rNPRC 
Samples were ligated overnight at 16 °C in a thermocycler 
The purity and concentration of the ligation was estimated by gel electrophoresis 
1-5 µL the ligation was transformed into competent cells  
 
 
 
 
 
 
Appendix O:  Transfection reagents used for delivery of plasmid DNA or siRNA 
 
Transfection Reagent  Application  Cell type 
Lipofectamine™ Transfection of plasmid 
DNA 
Adherent/suspension cell 
lines 
Lipofectamine™ 2000 Transfection of plasmid 
DNA 
Adherent/suspension cell 
lines 
FuGENE®  Transfection of plasmid 
DNA 
Adherent/suspension cell 
lines 
FuGENE® HD Transfection of plasmid 
DNA 
Adherent/suspension cell 
lines 
Dharmafect1 Transfection of siRNA Adherent 
Dharmafect3 Transfection of siRNA Adherent 
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